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 To defend against pathogen challenge, multi-cellular organisms mount an immune 
response that recognizes, sequesters and eradicates invading infectious agents. Critical to this 
safeguard is the receptor-mediated detection of pathogens. Pathogen recognition then initiates a 
variety of signaling cascades that lead to the modulation of genes orchestrating an immune 
response. Toll-like receptor 3 (TLR3), a transmembrane receptor found in endosomes, is vital to 
the innate immune response against viruses. Double-stranded RNA (dsRNA) stimulation of 
TLR3 initiates a signaling cascade that leads to the production of type-I interferons and pro-
inflammatory cytokines necessary to trigger the protective defenses of the immune system. 
Critical to this pathway is the activation of a kinase, TANK binding kinase 1 (TBK1), which 
phosphorylates the downstream transcription factors, IRF3 and IRF7, and leads to the production 
of IFN. Interestingly, TBK1 function has been implicated in a number of other signaling 
cascades ranging from the insulin response and vesicle transport to xenophagy and anti-viral 
immunity. Increasingly, however, TBK1 dysregulation has been linked to autoimmune disorders 
and cancers, heightening the need to understand regulatory controls of TBK1. As a result, this 
dissertation investigates three components of the TLR3 signaling cascade in an attempt to further 
advance our understanding of the innate immune response. First, investigations into the adjuvant 
potential of dsRNA reveal that a 139bp dsRNA molecule is a viable candidate for vaccine 
adjuvant studies. Next, structural and functional studies of TLR3 with neutralizing antibodies 
provide evidence for a new TLR-signaling model in which dsRNA:TLR3 signaling units 
laterally cluster to achieve efficient signaling. Finally, cell-based assays, biophysical experiments 
and kinetic investigations into the mechanism by which an endogenous regulator of the TLR3 
response, SIKE, functions, reveal that SIKE not only inhibits TBK1-mediated IRF3 
phosphorylation, but is also a high affinity substrate. Findings from this study further suggest 
that SIKE regulates a critical catalytic hub not by direct repression of activity, but by redirection 
of catalysis through substrate affinity. Taken together, the results presented in this dissertation 
establish a foundation for building long-term studies on the function, regulation and viral 
subversion of the innate immune response. 
 
  
1 
 
 
 
 
 
 
CHAPTER I 
INTRODUCTION 
 
 
1.1 Immunology and the Immune Response 
Immunology is widely known as a branch of biomedical science that investigates the ability 
of an organism to respond to antigenic challenge while also differentiating between “self” and 
“non-self [1].” Its origin is attributed to Edward Jenner who, in 1796, made the observation that 
his patients, who worked with cattle and had come in contact with a relatively mild disease 
called cowpox, never became infected with the deadly smallpox disease that had reached 
epidemic proportions at the time [1, 2]. By taking pus from a cowpox pustule and inserting it into 
an incision on the arm of an 8-year old boy, Jenner proved that having been inoculated with 
cowpox, the boy, who was subsequently inoculated with “variolous matter (Small-pox matter),” 
was immune to smallpox [1-3].  
Interestingly, however, the prevailing theory of Jenner’s era was that chemical toxins were 
carried from an ill patient to others, causing them to contract the same disease [3]. The bacteria 
that were present were considered to be a symptom of the disease and not its cause. It was not 
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until the late 19
th
 century, when Louis Pasteur, who was working on a wine souring problem in 
which wine fermentations were producing a sour taste and very little alcohol, realized that the 
solution to the sour wine problem, a contaminating microbe that was generating lactic acid 
instead of alcohol from sugar, may be related to infectious diseases [4, 5]. In his work entitled, 
“Germ Theory of Disease,” Pasteur postulated that infections and disease were caused by 
invading microorganisms [5-7]. In 1876, Robert Koch proved Pasteur’s “Germ Theory of 
Disease,” when he successfully isolated infectious bacillus, a bacteria which he showed was the 
cause of both anthrax and cholera [8, 9]. Koch then defined a set of postulates which are still 
used today to demonstrate microbial pathogenicity amongst the four categories of disease-
causing microorganisms; viruses, bacteria, pathogenic fungi, and parasites [1, 8, 9]. 
After it was established that microbes were the cause of disease, researchers went on to 
investigate how a host was able to defend against these pathogens. In 1890, using a non-lethal 
form of the diphtheria toxin (remnants of diphtheria with the active bacilli filtered out), Emil von 
Behring and Kitasato Shibasaburo injected guinea pigs and discovered that their tissues were 
able to acclimate to the toxin, producing a substance capable of neutralizing the diphtheria toxin 
itself [1, 10]. Using this antitoxin in humans, the mortality rate from diphtheria was reduced to 
negligible levels. This was the first demonstration of antibody activity and the first signs of the 
humoral theory of immunity. 
While Behring and Shibasaburo were reporting their instrumental work on antibodies, 
another theory on the cellular basis of immunity began to take shape. Elie Metchnikoff, a 
Russian born biologist and zoologist, was making interesting observations in starfish larvae. By 
inserting thorns from garden plants into these transparent larvae and observing what he called 
“wandering cells,” he noted that these cells no longer moved around aimlessly but instead 
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aggregated around the foreign bodies as if to drive them out [1, 11]. Further experiments by 
Metchnikoff involved the insertion of spores from an infectious fungus into Daphnia, a type of 
water flea [1, 11, 12]. He observed mobile cells in the fleas surrounding and engulfing the 
infectious spores [1, 11]. From these findings, Metchnikoff laid a foundation for the theory of 
phagocytosis as he theorized that, under appropriate conditions, protector cells within an 
organism mount an immune response by attacking and ingesting foreign matter [1, 11].  
At the time, an intense debate erupted as to which theory on the cellular basis of immunity 
was correct; the antibody theory of Behring and Shibasaburo or the theory of phagocytosis by 
Metchnikoff [1, 10, 11]. As we now know today, both theories were correct and are fundamental 
to the body’s ability to oppose microbial infection.      
A specific immune response, such as the production of antibodies against a particular 
pathogen seen by Behring and Shibasaburo, is now known as an acquired or adaptive immune 
response. This response is highly adaptable due to V(D)J recombination of antibody heavy and 
light chains to create a unique immunoglobulin gene per B-cell [1, 13]. This is followed by 
somatic hyper-mutations that introduce variability into a clonal B-cell population [1, 13]. The 
end result is a small number of genes that are able to generate a vast number of different, specific 
antigen receptors. Of great significance to the host is the fact that this adaptability requires 
several (three to five) days to develop after the initial infection, but can confer lifelong resistance 
to infection by a pathogen exhibiting the same antigen [1].  
On the other hand, a non-specific, immediate (minutes to hours), but short-lived response 
also exists. It is known as the innate immune response and is limited to germ-line encoded 
sensors that recognize a danger signal [1, 14, 15]. This response can be facilitated by phagocytic 
cells, such as those proposed by Metchnikoff, which engulf and destroy microorganisms, but is 
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also characterized by its many other roles including recognition of pathogens, recruitment of 
immune cells to sites of infection and communication with the adaptive immune response [1, 16, 
17]. Because our lab focuses on the role of the innate immune response as part of the host 
defense system, the remainder of this document will focus on innate immunity. 
 
1.2 Innate Immunity  
The innate immune system is a host’s first line of defense against invading infectious agents. 
It is found, in some form, in all multicellular organisms and is thought to constitute an 
evolutionarily older defense strategy [18]. While it does not recognize pathogen specific 
antigens, it employs a number of other strategies in an attempt to protect the host from invading 
microorganisms.  
Anatomical barriers, inherent to organisomal development, provide the first, and arguably, 
most important defense system of innate immunity [1, 19, 20]. In humans, epithelial cells are 
held together by tight junctions, forming a physical barrier that is impermeable to many 
infectious agents [1, 20, 21]. These epithelia comprise the skin and linings of the body’s tubular 
structures including the gastrointestinal, respiratory and urogenital tracts [1,20,21]. On the skin, 
desquamation, or skin peeling, helps remove bacteria and other infectious agents that may have 
adhered to the surface. Commensal microbes, known as normal flora, also live on the skin and 
compete with pathogenic microorganisms for nutrients and attachment sites on epithelial cells 
[1,20,21]. These nonpathogenic bacteria produce antimicrobial substances such as bacteriocidins, 
cationic proteins and lactoferrin, which work to destroy pathogenic organisms [21]. Internally, 
pathogens are expelled from the gastrointestinal and respiratory tracts by the peristalsis or ciliary 
action of tiny hairs [1,20,21]. Mucosal epithelia in the respiratory and gastrointestinal tracts also 
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secrete a viscous liquid called mucus which traps microorganisms and expels them in the flow of 
mucus driven by the beating of epithelial cilia [20]. Other epithelia in the respiratory and 
urogenital tracts produce antimicrobial peptides, such as -defensins, that kill bacteria by 
damaging the bacterial cell membranes [20,21]. Saliva, tears, nasal secretions and perspiration 
also contain enzymes such as phospholipase A and lysozyme, which destroy gram positive 
bacteria [21]. Taken together, these barriers produce a strong defense against invading 
pathogens.      
 However, infections can occur when pathogens colonize or cross these anatomical barriers 
through cuts or scratches. These microorganisms can also invade by binding to molecules on the 
epithelial planes of internal organs while adhering to or colonizing the surfaces [21]. In most 
cases, when this happens, the pathogen is immediately recognized by mononuclear phagocytes, 
or macrophages, which are located in sub-mucosal tissues. Macrophages mature continuously 
from monocytes that leave the blood circulation and migrate into tissues throughout the body in a 
process called diapedesis [1,20,21]. These macrophages are soon reinforced by neutrophils, 
which are short-lived phagocytic cells that are abundant in the blood [21]. Phagocytic 
macrophages and neutrophils recognize, ingest and destroy many invading organisms. Their 
ability to recognize pathogens is mediated by cell-surface receptors, known as PRRs (pattern 
recognition receptors), which are found on each of the cells that mediate the innate immune 
response [1, 14]. These receptors have evolved to recognize evolutionarily conserved 
characteristics in broad classes of infectious microorganisms [14]. As these receptors are critical 
to the innate immune response, they will be discussed at great length in Chapter 1.3.           
Upon recognition of a pathogen, cells of the innate immune response, through activation of a 
multitude of signaling cascades, are able to up-regulate co-stimulatory molecules on their surface 
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to communicate with the adaptive immune system and are able to produce proteins, such as 
cytokines, chemokines, and cell-adhesion molecules, that guide the migration of effector cells to 
the site of an infection [1,14,20,21]. Activation of these elements has several ramifications for 
the host. Up-regulation of co-stimulatory molecules invokes the adaptive immune system’s 
defenses, including the subsequent activation of T-cells and B-cells for antigenic specific 
immune responses such as production of cytotoxic killer T-cells or antibodies [14,21]. 
Production of cytokines and chemokines mediates an immediate inflammatory response which 
provides a physical barrier, in the form of microvascular coagulation, to prevent the spread of 
infection in the blood stream [14,21]. Subsequently, this response mediates the delivery of 
phagocytic macrophages and neutrophils to the site of infection effectively aiding in the 
destruction of invading pathogen [1,20]. As the invading pathogen is contained, the innate 
immune system signals to the adaptive immune system to help eradicate the remaining pathogen 
and program an inflammatory response for future invasions by the same microorganism (Figure 
1.1). While the innate immune response may be short-lived and non-specific, its initial reaction 
to a pathogen is critical to host survival. 
 
1.3 Pattern Recognition Receptors: Evolution, Redundancy and Cross-talk 
As mentioned in Chapter 1.2, the innate immune system does not recognize pathogen-
specific antigens. Instead, it identifies evolutionarily conserved repeating patterns of molecular 
structure found on the surfaces of or in the nucleic acid sequences of related pathogenic microbes 
(PAMPs (pathogen-associated molecular patterns)), as well as endogenous molecules released 
from stressed, injured, infected or transformed human cells (DAMPs (damage-associated 
molecular patterns)) [1,14,21]. Recognition of these molecules is mediated through PRRs. These 
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Figure 1.1 Progression of the Immune Response 
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receptors reside on various immune cells (macrophages, neutrophils, dendritic cells, etc.), cells 
lining surfaces that may be exposed to pathogen (epithelial, endothelial, keratinocytes, etc.) or 
are secreted to act as sentinels in the blood stream and lymph nodes [14]. Currently, three 
functionally distinct classes of PRRs have been identified; endocytic, secreted, and signaling 
PRRs (Table 1.1) [1,14]. 
Endocytic PRRs are found on the surface of phagocytes and promote the attachment, 
engulfment and destruction of microorganisms without relaying an intracellular signal [14, 22]. 
These PRRs recognize carbohydrates and range from the mannose receptors, which bind 
terminal mannose and fucose groups on microbial glycoproteins and glycolipids, to the 
scavenger receptors, which bind to bacterial cell wall components such as LPS, peptidoglycan 
and teichoic acid [1,20,21].   
 Secreted PRRs, on the other hand, bind to microbial cell walls and facilitate their 
recognition by phagocytes or the complement pathways [1,20]. These pathways, once activated, 
then mediate the regulation of antibody responses and promote the clearance of immune 
complexes and apoptotic cells. A primary example of these secreted PRRs is the mannose-
binding protein [23], a lectin that is synthesized by the liver and released into the bloodstream. 
Once there, it can bind to carbohydrates on bacteria, yeast, viruses and parasites leading to the 
activation of the lectin- complement pathway [21,23]. This triggering effect results in the 
activation of C3b, a molecule that promotes opsonization [23].  
 Finally, signaling PRRs bind a number of microbial molecules which consequently 
promote the synthesis and secretion of intracellular regulatory molecules such as pro-  
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Table 1.1 Representative members of the three functionally distinct classes of PRRs. 
ENDOCYTIC PRRs     
Receptor Recognition Activation 
C-type mannose receptor 1 Glycoprotein/glycolipid Endocytosis by phagocytic cells 
C-type mannose receptor 2 Glycoprotein/glycolipid Endocytosis by phagocytic cells 
SCARA1 LDL, Bacterial cell walls Endocytosis, platelets 
SCARA2 acLDL, oxLDL Endocytosis, platelets 
SCARB1 HDL, LDL, oxLDL Endocytosis, eNOS 
SCARB2 HDL Endocytosis, eNOS 
      
SECRETED PRRs     
Receptor  Recognition Activation 
C-reactive protein Phosphocholine C1Q complex 
Mannose-binding lectin Glycoconjugates Lectin complement pathway 
Serum amyloid protein HDL, oxLDL, acLDL C1Q complex 
      
SIGNALING PRRs     
Receptor  Recognition Activation 
TLRs     
TLR1-TLR2 Triacylated lipopeptide NF-B (MyD88-dependent) 
TLR2-TLR6 Diacylated lipopeptide NF-B (MyD88) 
TLR3 dsRNA NF-B and IRF3 (TRIF) 
TLR4 LPS NF-B and IRF3 (TRIF and MyD88) 
TLR5 Bacterial flagellin NF-B (MyD88) 
TLR7 ssRNA NF-B and IRF3 (MyD88) 
TLR8 ssRNA NF-B and IRF7 (MyD88) 
TLR9 CpG-DNA NF-B and IRF3 (MyD88) 
TLR10 Unknown Unknown 
RLRs     
RIG-I Short, blunt dsRNA NF-B and IRF3 (IPS-1), 
Inflammasome 
MDA5 Long dsRNA NF-B and IRF3 (IPS-1) 
LGP2 dsRNA Positively regulates RLR signaling 
DDX1-DDX21-DHX36 dsRNA NF-B and IRF3 (TRIF) 
NLRs 
 
  
NOD2 Muramyl dipeptide NF-B (RIP2) 
NALP3 Uric acid crystal, silica Inflammasome 
IPAF Flagellin Inflammasome 
AIM2 dsDNA Inflammasome 
CLRs 
 
  
Mincle SAP130 nuclear protein Syk-dependent signaling 
Clec9a/DNGR-1 Necrotic cells Syk-dependent signaling 
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inflammatory cytokines, type I interferons, chemokines, antimicrobial proteins and other co-
stimulatory factors [1,14,20,21]. Currently, signaling PRRs have been organized into four 
distinct families; the RLRs (RIG-I (Retinoic acid-inducible gene)-like receptors) [1, 24], the 
NLRs (NOD-like receptors) [1, 25], the CLRs (C-type lectin receptors) [1, 26] and the TLRs 
(Toll-like receptors) [1, 16]. While the RLRs and NLRs are cytoplasmic protein receptors, the 
CLRs and TLRs are transmembrane protein receptors [16].  
   RLRs, consisting of RIG-I, MDA5 (melanoma differentiation associated gene 1), LGP2 
(laboratory of genetics and physiology 2), and a complex of three RNA helicases, DDX1-
DDX21-DHX36, are intracellular PRRs that act as viral sensors through direct interaction with 
dsRNA, the replicative intermediate of RNA viruses [24]. RIG-I and MDA5 are each comprised 
of two N-terminal CARD domains (caspase recruitment domains), which induce a cellular 
response through interactions with the adaptor protein, IPS-1 (interferon promoter-stimulating 
factor 1), and a DExD/H-box helicase domain, which mediates the recognition and binding of 
dsRNA to the central cavity of the protein [24]. The complex of RNA helicases, DDX1-DDX21-
DHX36, also contains a DExD/H-box helicase domain but differs from RIG-I and MDA5 in that 
a Helicase A domain in DDX1 recognizes and binds dsRNA while an HA2-DUF and a PRK 
domain in DDX21-DHX36 recruit an adaptor protein, TRIF (Toll/interleukin 1 receptor (TIR)-
domain-containing adaptor protein inducing interferon-), the consequences of which will be 
discussed in more detail in Chapter 1.5 [27]. The final member of the group, LGP2, lacks the 
ability to induce signaling alone due to the absence of a CARD domain, but it can recognize 
dsRNA through interactions with its DExD/H-box helicase domain [28]. Upon recognition of 
viral dsRNA, all RLRs activate downstream transcription factors (NF-B and IRF3/7) that 
mediate production of pro-inflammatory cytokines and type-I interferons [16].  
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To recognize cytoplasmic PAMPs as well as endogenous danger signals, NLRs use a 
tripartite-domain organization, consisting of a carboxy-terminal leucine-rich-repeat motif, which 
senses the presence of invading microorganisms (ligand sensing is the focus of these receptors as 
there is only weak evidence supporting a direct interaction of the NLRs and their cognate 
ligands), a central NACHT domain (nucleotide binding domain) with ATPase activity that 
promotes ATP-dependent self-oligomerization, and a variable N-terminal domain that is 
responsible for homotypic protein-protein interactions [16, 25]. NLRs are subdivided into four 
families based on the type of N-terminal domain they use to mediate protein-protein interactions; 
NLRA members have an acidic N-terminal transactivating domain, NLRB members have a BIR 
domain (baculovirus inhibitor of apoptosis protein repeat N-terminal domain), NLRC members 
have an N-terminal CARD domain, and NLRP members have a PYR domain (pyrin domain) 
[1,16,25]. While recognition of pathogen-derived ligands by the NLRC family leads to activation 
of NF-B and subsequent production of pro-inflammatory cytokines, NLRA, NLRB, and NLRP 
recognition of pathogen-derived ligands leads to the formation of an inflammasome that 
mediates the activation of Caspase-1, an enzyme important in the proteolytic processing and 
activation of the  pro-inflammatory cytokines IL-1 and IL-8 [25]. 
CLRs are transmembrane proteins broadly expressed on a myriad of innate immune cells 
ranging from those as complex as immature dendritic cells to those as small as platelets [16, 26]. 
When expressed, they interact with pathogens through the recognition of carbohydrate moieties 
[26]. CLRs have at least one carbohydrate recognition domain, which determines carbohydrate 
specificity, and are broadly classified into two distinct groups [16,26]. Group I CLRs are 
members of the mannose receptor family with an N-terminal cysteine rich domain, a single 
fibronectin type II domain and eight to ten C-type lectin-like domains [16,26]. These receptors, 
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such as CMR1 and CMR2 (C-type mannose receptor 1 and 2), are primarily present on the 
surface of macrophages and dendritic cells where they recognize and bind to repeated 
carbohydrate moieties on the surface of infectious agents [26]. Group II CLRs belong to the 
asialoglycoprotein receptor family and contain one C-type lectin-like domain [26]. These 
receptors, such as the Dectin-1 receptor (DC-associated C-type lectin 1), are expressed on a 
variety of immune cells and recognize pathogens ranging from M. tuberculosis to HIV-1 [16,26]. 
Together, CLRs are able to recognize most classes of human pathogens [16]. This recognition, in 
turn, leads to pathogen internalization, degradation and antigen presentation [16]. CLR activation 
can also lead to the induction of specific cytokines that determine T-cell polarization fate [16]. 
Finally, TLRs, which will be discussed at length in Chapter 1.5, are membrane-spanning, 
non-catalytic receptors found in sentinel cells [1, 16, 29]. They are comprised of an ECD 
(ectodomain), which contains LRRs (leucine-rich repeats) that mediate the recognition of 
PAMPs, a single transmembrane region, and a TIR (cytosolic Toll-IL-1 receptor) domain that 
activates downstream signaling pathways [29, 30]. TLRs recognize a wide variety of PAMPs 
spanning bacterial cell-surface LPS (lipopolysaccharides) and bacterial flagella to viral dsRNA 
and the unmethylated CpG islands of bacterial/viral DNA [16]. TLR-mediated recognition of a 
pathogen leads to the activation of intracellular signaling cascades that induce the production of 
inflammatory cytokines as well as type-I interferons [16].  
While a multitude of defense systems exist to recognize the ever expanding list of invading 
pathogens, questions have been raised as to the redundant nature of signaling PRRs and their 
activation of similar signaling cascades (Figure 1.2).  Microbes harbor a variety of PAMPs that 
induce signaling pathways leading to an amplified host response. These responses, as was 
detailed in Chapter 1.2, are essential for eradicating the invading microorganism. However, over-
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activated responses can be dangerous to the host. In the case of sepsis, also known as systemic 
inflammatory response syndrome, effector proteins induced by an immune response are over 
produced leading to a state of sustained inflammation, a drop in blood pressure and a lack of 
perfusion of vital tissues and organs [31]. The deadly nature of these over-activated responses 
has led to research focused on the cross-talk between PRRs and their signaling pathways [16, 
32]. The redundant nature of both entities seems to induce cooperative activation that is critical 
to an effective immune response, but may contribute to detrimental effects on the host if not 
tightly regulated [32].  
Examples of cross-talk have been shown between similar PRRs such as the TLRs [16,32]. 
Experiments indicate that stimulation of TLR3 and TLR4 can up-regulate TLR2, TLR7 and 
TLR9 expression based on the adaptor proteins that are recruited to the cytoplasmic domain of 
each TLR [32, 33]. Other investigations have shown that TLR3 and TLR4 can also interact, 
synergistically, with TLR7, TLR8 and TLR9 to increase the production of a Th1-polarizing 
cytokine known as IL-12p70 [33]. This TLR synergy can be further boosted by IFN and 
CD40L, products of activated NK- and T-cells, suggesting that cross-talk between innate and 
adaptive immune responses can also occur to control optimal immune cell activation [32,33]. 
 In addition to cross-talk within one class of PRRs, researchers have shown that cross-talk 
also exists amongst different PRRs [32]. While the RLRs, RIG-I and MDA5, are IFN inducible, 
specific TLRs, TLR3, TLR4, TLR7, TLR8 and TLR9 are known to induce IFN production. 
Experiments done on human melanoma cells were able to show that the stimulation of TLRs led 
to a RIG-I/MDA5 response that caused these cells to terminally differentiate and irreversibly 
lose proliferative capacity suggesting that the activation of the TLRs can potentiate an RLR 
response [34]. Further experiments done on the NLRs and TLRs have shown that NOD1 and  
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Figure 1.2 The redundant nature of PRRs. Depicted is a small representation of PRRs that 
recognize pathogenic dsRNA. Upon recognition, each PRR activates a distinct signaling cascade. 
Detrimental effects will occur if a coordinated response is not regulated by the host. 
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NOD2 act synergistically with TLR3, TLR4 and TLR9 in human dendritic cells to induce IL-
12p70 production and promote Th1 cell differentiation [35]. Additional experiments done on the 
TLRs and the CLRs have shown that Dectin-1, a CLR, and TLR2 collaborate synergistically to 
produce pro-inflammatory cytokines such as TNF in bone-marrow derived dendritic cells and 
IL-10, an anti-inflammatory cytokine, in splenic dendritic cells [36]. 
While numerous other PRR cross-talk examples exist, researchers are just beginning to 
understand how the immune response is so tightly regulated with the number of seemingly 
redundant structures and pathways found in many hosts. Recent studies, attempting to investigate 
the coordinated activity of large networks of intracellular signaling pathways in one specific cell, 
used RAW 264.7 macrophages to look at 22 receptor-specific ligands and their ability to induce 
calcium mobilization, cAMP synthesis, phosphorylation of numerous signaling proteins and 
cytokine production [37]. Using a combination of computational clustering methods and 
experimental cAMP, calcium and cytokine assays, the investigators found a large network of 
complex non-linear signaling cascade interactions that generated both known and unexpected 
novel interactions amongst different pathways [37]. The authors were able to conclude that while 
many PRRs and signaling pathways do exist, only a small number of interaction mechanisms and 
signaling cascades coordinate a response towards many stimuli to provide for context-dependent 
signaling and prevent a chronic or sustained immune response [37].  
The cross-talk examples provided here focused on the TLRs as their ability to recognize a 
diverse set of pathogens has led to mechanistic studies both on their structures and signaling 
cascades. As will be discussed in Chapter 1.4, the TLRs use their diverse set of recognition 
capabilities and cross-talk mechanisms to not only initiate immediate inflammatory responses, 
but also to shape the adaptive immune response. 
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1.4 Toll-like Receptors: Evolution and Structure  
The first Toll family member, Drosophila Toll, was discovered in 1985 by the Nusslein-
Volhard group [38]. Identified as a maternal effect gene, mutations caused a fruit-fly phenotype 
that surprised German researchers to the point of exclaiming, “Das ist ja toll,” which translates to 
“That’s great,” and subsequently gave the Toll-like receptor family its name [1,38]. Further 
research has since shown that, in the fly, the Toll receptor recognizes a cleaved protein product 
known as Spatzle [39]. In the fly embryo, this recognition induces formation of the dorso-ventral 
axis, while in the adult fly, recognition triggers an intracellular cascade that leads to the 
activation of a transcription factor termed Dorsal, a fly homologue of the transcription factor NF-
B [39]. In 1996, Jules A. Hoffman and coworkers made the ground-breaking discovery that 
Toll was critical to a fly’s antifungal innate immune response [40]. They showed that mutations 
to the Toll receptor dramatically reduced survival of the host after fungal infection [40].       
It was not until 1997 that Charles Janeway, the scientist who, a decade earlier, had 
hypothesized that a set of factors, which he termed PRRs, were capable of detecting PAMPs in 
the immune response [41], discovered the first human Toll receptor [42]. Through cloning 
experiments in which Janeway’s group transfected into human cell lines a constitutively active 
construct of human Toll, they were able to show an induced activation of NF-B and the 
expression of NF-B controlled genes for the inflammatory cytokines IL-1, IL-6 and IL-8 [42]. 
Further studies with the constitutively active human Toll showed an induced expression of the 
co-stimulatory molecule B7.1, required for activation of naïve T-cells, and suggested an essential 
role for this receptor in the human immune response [42]. A year later, building off of Janeway’s 
results, Bruce Beutler, investigating what he called the most powerful microbial stimulant of the 
innate immune response, LPS, discovered TLR4 to be the sole LPS receptor and the gateway to 
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the endotoxin response [43]. Through missense mutations in the TLR4 gene of C3H/HeJ LPS 
response locus mice, Beutler was able to show that the mammalian TLR4 protein had been 
adapted to primarily recognize LPS and, as he postulated, transduce the LPS signal across the 
plasma membrane [43]. Knockout mutations of the TLR4 gene further corroborated Beutler’s 
work as these mice were resistant to the development of Gram-negative sepsis but susceptible to 
infection [44]. Subsequent studies by several groups [45] found additional Toll-like receptors 
that could similarly activate a transcriptional based response.  
To date, 10 human Toll-like receptors (13 Toll-like receptors in mice) have been 
characterized (Figure 1.3), each recognizing a variety of evolutionarily conserved PAMPs 
including lipopeptides (TLR2 associated with TLR1 or TLR6) [46, 47], viral dsRNA (TLR3) 
[48], LPS (TLR4) [43], bacterial flagellin (TLR5) [49] , viral or bacterial ssRNA (TLR7 and 
TLR8) [50, 51] and CpG-rich unmethylated DNA (TLR9) [52], among others [16](Table 1.2). 
While these receptors seem to diverge in the ligands they recognize, clustering studies have 
found that human TLR1, TLR2, TLR6 and TLR10 converge into a TLR subgroup (TLR1/2/6/10) 
based on sequence homology as do TLR7, TLR8 and TLR9 (TLR7/8/9) [53, 54].  
Further, structural studies have determined that a high degree of homology also exists in the 
framework of each of these receptors. Each TLR is now known to be an evolutionarily conserved 
type-I integral membrane glycoprotein that consists of an N-terminal ligand recognition domain 
(TLR-ECD), a single transmembrane helix that contains approximately 20 uncharged, mostly 
hydrophobic residues, and a C-terminal cytoplasmic signaling domain, known as the TIR domain 
[29]. So named for its homology with the signaling domains of IL-1R family members, TIR 
domains are also found in many adaptor proteins that interact with the TIR domain of TLRs and 
in plant proteins that confer resistance to pathogens [55]. This has suggested to numerous 
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Figure 1.3 The 10 human Toll-like receptors and the pathogens they recognize. 
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Table 1.2 TLRs and their specific ligands. 
 
TLRs Localization Exogenous Ligands Source of Exogneous Ligands Endogenous Ligands
TLR1 Plasma Membrane Lipopeptides Bacteria and Mycobacteria
TLR2 Plasma Membrane Lipoprotein/lipopeptides Gram-positive bacteria, 
Mycoplasma, Mycobacteria, 
Spirochetes
HSP60, HSP70, HSP96, HMGB1,              
Hyaluronic acid
Peptidoglycan Gram-positive bacteria
Lipoteichoic Acid Gram-positive bacteria
Glycolipids Treponema maltophilia
Outer membrane protein A Klebsiella pneumonia
Glycoinositolphospholipids Trypanosoma cruzi
Phospholipomannan Candida albicans
Hemagglutinin Measles virus
Lipoarabinomannan Mycobacteria
Zymosan Saccharomyces
TLR3 Endolysosome Double-stranded RNA (dsRNA) RNA Viruses mRNA
TLR4 Plasma Membrane Lipopolysaccharide Gram-negative bacteria HSP22, HSP60, HSP70, HSP96, HMGB1, 
Heparin sulfate, Fibrinogen
HSP60 Chlamydia pneumonia
Glycoinositolphospholipids Trypanosoma cruzi
TLR5 Plasma Membrane Flagellin Gram-positive or Gram-negative 
bacteria
TLR6 Plasma Membrane Diacyl lipopeptides Mycoplasma
Lipoteichoic Acid Gram-positive bacteria
Zymosan Saccharomyces
TLR7 Endolysosome Single-stranded RNA (ssRNA) RNA Viruses Endogenous RNA
TLR8 Endolysosome Single-stranded RNA (ssRNA) RNA Viruses Endogenous RNA
TLR9 Endolysosome Unmethylated CpG motifs Bacteria and viruses Endogenous DNA
TLR10 Extracellular Unknown, may interact with TLR1 and TLR2
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researchers that the TIR domain actually represents an evolutionarily conserved motif that may 
have had an immune function prior to the divergence of plants and animals.    
         In observing the extracellular domain of each crystallized TLR, it has been noted that all 
are constructed of 19-25 tandem copies of a motif known as the LRR (leucine-rich repeat) motif 
(Figure 1.4) [53, 56]. A single LRR motif is typically 22-29 residues in length and contains 
hydrophobic residues spaced at distinct intervals [57]. In three dimensions, all LRRs adopt a loop 
structure that begins with three residues in a -strand configuration [58]. When assembled 
consecutively in the TLR-ECDs, the LRR motifs form a solenoid structure with all consensus 
hydrophobic residues pointing to the interior, to form a stable core, and all -strands aligning to 
form a hydrogen-bonded parallel -sheet [57,58]. Because the -strands in the LRR motif are 
packed more closely than the rest of the structure, the solenoid is forced into a curved 
configuration in which a concave surface is formed by the -sheets [57,58]. This effectively 
creates a structure with a concave surface, a convex surface, an ascending lateral surface, and a 
descending lateral surface on the opposite side [57,58]. To date, the structures of the ECDs of 
TLR1[59], TLR2[59], TLR3[30], TLR4[60], TLR5[61], TLR6[62], and TLR8[63] have been 
reported. In common with all of these structures is the fact that the solenoid motif is the basis for 
ligand recognition as ligand binding occurs on the ascending lateral face, the only portion of the 
molecule that completely lacks N-linked glycan and is free to interact with ligand (Figure 1.4). 
Interestingly, however, while all of the TLR-ECDs assume a typical horseshoe-shape, attempts 
to predict these structures in modeling studies have been unsuccessful due to variations in the 
curvature of the structure.  
  
21 
 
Figure 1.4 hTLR3-ECD consisting of 23 leucine-rich repeats. hTLR3 contains 23 leucine-rich 
repeats, each of which follows the typical 24-residue repeat pattern of the LRR motif [57,58]; 
xL
2
xxL
5
xL
7
xxN
10
xL
12
xxL
15
xxxxF
20
xxL
23
x where L represents conserved hydrophobic residues, 
N represents a conserved asparagine and F represents a conserved phenylalanine. Also depicted 
is the glycan-free side (ascending side) of the TLR3-ECD, involved in ligand binding in all TLRs 
[58]. 
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As specific ligands of each receptor were identified, focus shifted to the mechanistic 
understanding of the resulting activated signaling pathways. As will be discussed at great length 
in Chapter 1.5, the identification of players in the activated TLR signaling cascades and the 
elucidation of products from each of these pathways led to the scientific community’s re-
evaluation of the importance for these receptors in immunity. The culmination of this recognition 
came in 2011 with the awarding of the Nobel Prize in Physiology or Medicine to Bruce Beutler, 
Jules Hoffman and Ralph Steinman for revolutionizing our understanding of the immune system 
by discovering key principles for its activation. 
 
1.5 Toll-like Receptors: Pathogen Recognition and Signaling  
Classifying specific TLRs with the pathogens they recognize was a critical first step in 
understanding how TLRs aid in the innate immune response. In addition, detailing the 
mechanism by which TLRs recognized specific pathogens and understanding how subsequent 
signal transduction events translated pathogen recognition into a host response were essential in 
understanding the important role TLRs have in protecting a host from microorganism invasion. 
This is because each TLR and TLR:pathgogenic-ligand complex elicits distinct downstream gene 
expression patterns that lead to innate immune responses tailored towards specific pathogens and 
to the development of antigen-specific adaptive immune responses.  
Long established was the fact that signal transduction by type I transmembrane receptors 
required ECD dimerization events [64]. Originally observed with the full-length Drosophila Toll 
ECD, unstable dimers were able to form in solution and thought to exist in pre-assembled, low 
affinity complexes before ligand binding [65]. However, it was not until 2003, when Nicholas 
Gay’s group investigated the mechanism by which a protein, Spatzle, activated the Toll-receptor 
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in adult Drosophila flies, that researchers were able to propose a mechanism by which microbes 
induced TLR activation. Using analytical ultracentrifugation in combination with chemical 
cross-linking and isothermal titration calorimetry experiments, Gay’s group was able to show 
that the Toll-receptor-activating ligand, Spatzle, formed a heterotrimeric complex containing two 
molecules of Toll-receptor ECD for every one molecule of ligand [66]. From these results, Gay’s 
group proposed that Toll-receptor activation required ligand-induced dimerization events which 
caused secondary receptor-receptor interactions effectively stabilizing and producing an active 
signaling complex [66]. Subsequent structural studies have found that in common with most 
TLR subfamilies, PAMP binding occurs when two TLR extracellular domains form an “m-
shaped” dimer and effectively trap the ligand molecule (Figure 1.5) [29]. This “sandwiching” 
effect brings the TLR transmembrane and cytoplasmic domains in close proximity and triggers a 
downstream signaling cascade. However, while the ligand-induced dimerization events of all 
TLRs have many common features, the recognition events leading to TLR-ECD dimerization are 
markedly different between TLR paralogs as individual TLRs use unique subsets of LRRs for 
ligand recognition. This effectively suggests a means by which a limited number of TLRs are 
able to recognize a diverse array of ligands.  
Best understood due to the elucidation of crystal structures for three of the four family 
members (TLR10 is the only member without a known structure), the TLR1/2/6/10 subfamily 
differentiates between different PAMPs based on specific dimerization events. Structural studies 
have shown that TLR2 is able to dimerize with either TLR1 or TLR6 (Figure 1.5A and 1.5B, 
respectively)[59, 62] and that the specific heterodimeric complex that is formed determines 
whether these TLRs bind PAMPs containing di-acylated cysteine-rich lipopeptides (TLR2/6) or 
tri-acylated cysteine-rich lipopeptides (TLR1/2). Further experiments have revealed the reason  
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Figure 1.5 Representative examples of the ligand-induced “M-shaped” dimer complex 
formed by the TLR-ECDs. A. TLR1 (green) -TLR2 (blue) heterodimer induced by the binding 
of tri-acylated lipopeptide (purple) (PDB ID: 2Z7X)[59]. B. TLR2 (blue) -TLR6 (red) 
heterodimer induced by the binding of di-acylated lipopeptide mimetic (black) (PDB ID: 
3A79)[62]. C. TLR4 (raspberry) – MD-2 (yellow) complex induced by the binding of LPS (PDB 
ID: 3FXI)[67].
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for this difference as crystallographic analysis has shown that three distinct subdomains exist in 
each ECD of the subfamily; N-terminal, central, and C-terminal [59,62]. The border between the 
central subdomain and C-terminal subdomain (LRRs 9 to 12) contains a group of hydrophobic 
residues which form a ligand binding pocket on the convex side of the ECD [59,62]. This pocket 
can increase or decrease in size depending upon the formation of distinct TLR complexes. 
Complexes between TLR1 and TLR2 form a pocket that is large enough to accommodate tri-
acylated cysteine containing lipoproteins [59] while complexes between TLR2 and TLR6 form a 
pocket that is much smaller, due to constraints placed on the structure by phenylalanine residues, 
effectively binding only di-acylated lipopeptides [62]. While the fourth member of the family, 
TLR10, has not been structurally characterized, homology models refined through molecular 
dynamic simulations suggest that TLR2/10 heterodimeric complexes form a ligand binding 
pocket similar to the TLR1/2 complexes, effectively recognizing tri-acylated cysteine-containing 
lipopeptides, while TLR1/10 heterodimeric complexes and TLR10 homdimeric complexes form 
ligand binding pockets similar to those of the TLR2/6 complex, effectively recognizing di-
acylated cysteine-containing lipopeptides [68].   
In the TLR3 subfamily, ligand recognition and binding are dependent upon two interactions 
between dsRNA and the TLR3-ECD, one near the N-terminus, encompassing LRR-NT and 
LRRs1-3, and one near the C-terminus, involving LRRs 19-23 [30]. These interactions correctly 
position four ligand binding sites in a TLR3 homodimeric complex with dsRNA [30]. As TLR3 
is the focus of much of the work presented in this thesis, these associations and subsequent 
signaling events will be discussed in more detail in Chapter 1.6. 
For the TLR4 subfamily, advances on Beutler’s work [43], discussed earlier, have led to a 
crystallographic analysis of the receptor structure which depicts similarities to the TLR2 
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heterodimeric structures previously elucidated [67]. The TLR4-ECD is composed of three 
subdomains located in similar regions to that of the TLR2-ECD (LRR-NT to LRR5 and LRR8-
10); an N-terminal, central, and C-terminal subdomain [67]. However, the -sheet present in the 
central subdomain of the receptor contains unusually small radii and large twist angles that 
prevent a ligand binding pocket, seen in TLR2 heterodimeric complexes, from forming [67]. 
Instead, it has been found that a co-receptor, MD-2, binds to TLR4 on the concave surface of the 
N-terminal and central subdomains [67]. LPS is then extracted from the bacterial membrane and 
transferred to TLR4-MD-2 heterodimers by two accessory proteins, LPS-binding protein and 
CD14 [67]. LPS interacts with a large hydrophobic pocket in MD-2 and induces the formation of 
a receptor multimer, composed of two copies of the TLR4-MD-2-LPS complex, by forming 
hydrophobic interactions with conserved residues on TLR4 [67]. While it has been determined 
that PAMPs are not directly recognized by TLR4, LPS binding to MD-2 and subsequent 
interaction with TLR4 induces the formation of the classical “m-shaped” dimeric receptor 
complex (Figure 1.5C) which is then able to transduce a signal through membranes to the 
cytosol.  
The TLR5 subfamily is the only protein-binding (Flagellin) TLR that is conserved in 
vertebrates from fish to mammals. However, even with its vast evolutionary background, the 
human TLR5 structure has not been determined due to technical challenges in expression of the 
protein in a functionally active, soluble form. Recent crystallographic studies, however, have 
elucidated a TLR5 structure in zebrafish using a baculovirus system and C-terminal deletion 
variants that, along with computer based prediction algorithms, have led to an understanding of 
how TLR5 interacts with bacterial flagellin [61]. This PAMP is composed of three specific 
domains, D1/D2/D3, which are responsible for the ability of flagellin to polymerize into a 
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filament in bacterial flagellum, and effectively provide motility to the pathogen [69]. From 
crystallographic analysis of the zebrafish structure, TLR5 is shown to primarily interact on its 
lateral side (LRR-CT and LRRs12-13) with three helices that make up the D1 domain of 
flagellin [61]. This interaction forms an extensive primary binding interface that defines a 1:1 
heterodimer [61]. Upon formation of this complex, further ligand-induced oligomerization events 
lead to the formation of a symmetric 2:2 complex where TLR5 from the first heterodimer creates 
additional, weaker interactions with flagellin and TLR5 from the second heterodimer [61]. 
Ligand-induced assembly of two TLR5 receptors juxtaposes the C-terminal tail regions of TLR5-
ECD for signaling in a similar manner to all other agonist-bound TLRs [61].  
Similar to TLR3, members of the TLR7/8/9 subfamily are all located in the endosome. 
However, distinct amino-acid sequence differences and the recent elucidation of the TLR8-ECD 
structure [63] indicate that the ligand binding mechanisms of TLR7/8/9 are different from their 
endosomal dsRNA receptor counterpart. The recent elucidation of the TLR8-ECD has revealed 
that similar to all other TLRs, ligand recognition is mediated by a dimerization interface formed 
by two protomers [63]. However, three-dimensional structures, based on homology modeling 
studies of the LRR motifs in the TLR7/8/9 subfamily[70], and the recently reported TLR8-ECD 
structure[63], have shown that all members contain large insertions in LRR2, LRR5 and LRR8 
which give rise to distinct structures that loop out from the dimerization surface of the ECDs. 
These extensions were postulated, and have been confirmed for TLR8, to provide additional 
support to the receptors upon ligand binding [63,70]. These studies also report that all members 
of this subfamily contain a 40-amino-acid stretch of residues between LRR14 and LRR15 that 
have a high degree of species variability amongst the paralogs and are implicated in signal 
transduction events which will be discussed in the next paragraph [63,70]. Finally, studies have 
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also suggested that residues in the insertion face of the ECD (LRR17) for TLR8 (Asp543) and 
TLR9 (Asp535 and Tyr537) are essential for ligand binding [70]. While recent structural studies 
of TLR8 have confirmed the importance of Asp543 in ligand binding, a more detailed structural 
analysis of the entire subfamily is still required for a complete understanding of the ligand 
recognition mechanism used by these compartmentalized TLRs.  
Interestingly, investigations have revealed that specific proteolytic cleavage events are 
required for effective downstream signaling in the TLR7/8/9 subfamily [63]. Studies report that 
lysosomal proteolysis is required for TLR7/8/9 signaling and that this processing occurs in the 
undefined regions between LRR14 and LRR15 of the ECDs (proteolytic processing events have 
also been implicated in TLR3 signaling [71, 72] but these will be discussed in more detail in 
Chapter 1.6) [63]. Experimental data shows that TLR7/8/9 are escorted from the endoplasmic 
reticulum, by a chaperone molecule, Unc93b1, to the endolysosome where they are cleaved in a 
multistep process that has created much controversy in the scientific community [63, 73, 74]. 
Researchers agree that primary cleavage events, performed by asparagine endopeptidase and 
other undefined cathepsin family members [75], remove the majority of the ECD domain from 
the TLRs. However, following this initial proteolytic processing event of TLR7/8/9, researchers 
diverge on the reasons for these events as experimental data leads to two different conclusions. 
Further studies done on the cleaved fragments of TLR7/8/9 have suggested that subsequent 
proteolytic trimming events process the C-terminal fragments of the TLR-ECDs so that only the 
processed forms are capable of recruiting adaptor molecules, effectively activating a signaling 
cascade and inducing an immune response [76]. However, other studies mutated various residues 
in the N-terminal fragment of the cleaved TLR-ECDs and showed that these TLRs were inactive, 
suggesting that the N-terminal fragments were just as important as the C-terminal fragments for 
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signal transduction [77]. To this point, no conclusions have been made regarding the nature of 
these cleaved fragments, but researchers agree that the initial proteolytic processing event is 
required for effective TLR7/8/9 signaling and the induction of an immune response.    
Taken together, the events above suggest that TLR ligand recognition and activation is a 
specific, concerted and sequential process that is critical for transmission of signal to the 
cytoplasm. Upon ligand-induced dimerization of the TLR-ECDs, TLRs signal a response to 
pathogen by dimerization of their cytoplasmic TIR domains. This event creates a new platform 
on which signaling complexes can be built as TIR-domain containing adaptor proteins (MyD88, 
MAL, TRIF and TRAM) recognize the dimerization event [16]. Subsequent activation of a 
MyD88 (myeloid differentiation primary-response protein 88)-dependent or TRIF-dependent 
pathway is dependent upon which receptors are involved in the recognition process and which 
TIR-domain containing adaptor molecules are recruited to the TIR domain platform.   
The first pathway, the MyD88-dependent pathway, is so named for the MyD88 protein which 
functions as an adaptor molecule linking the TIR domains of every TLR (except for TLR3 and, 
at times, TLR4) with downstream signaling molecules so as to induce the activation of the 
transcription factor NF-B [78]. MyD88 is directly recruited to the TIR domain of TLR5, TLR7, 
TLR8 and TLR9, or recruited by an adaptor, the MyD88-adapter-like (MAL) protein, and 
functions to recruit IL-1R-associated kinase 4 (IRAK4), a kinase which is essential in signaling 
for NF-B [78]. This recruitment then leads to a pathway which involves the activation of 
IRAK1, TRAF6 (tumor-necrosis-factor-receptor-associated factor 6) and TAK1 (transforming-
growth-factor--activated kinase) through their modification by ubiquitylating factors UEV1A 
(ubiquitin-conjugating enzyme E2 variant 1) and UBC13 (ubiquitin-conjugating enzyme 13) 
[79]. Subsequent activation of the IB kinase complex (IKK/) and phosphorylation of an 
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inhibitor protein, IB (Inhibitor of kappa light chain gene enhancer in B-cells alpha) leads to 
the activation of the transcription factor, NF-B [80]. Release from IB allows NF-B to 
translocate to the nucleus where it is able to induce the expression of inflammatory cytokines, 
various anti-viral and anti-microbial proteins and initiate the adaptive immune response (Figure 
1.6) [81]. 
A second signaling pathway, defined by the recruitment of TRIF to the TIR domain of TLR3 
or to the bridging adaptor, TRAM (TRIF-related adaptor molecule), and subsequent recruitment 
to the TIR domain of TLR4, leads to the activation of the transcription factors NF-B or IRF3/7 
[82]. These transcription factors then translocate to the nucleus where they induce the production 
of immune response genes, or the induction of apoptosis through the activation of the FAS-
Associated with Death Domain protein (FADD)/Caspase 8 pathway [82]. As much of my 
research and part of this thesis focuses on the induction and regulation of the interferon response 
through the TLR3 signaling cascade, the TRIF dependent pathway, which is used partially by 
TLR4 and entirely by TLR3, will be discussed in greater detail in Chapter 1.6. 
 
1.6 Toll-like Receptor 3: Structure and Function  
As was mentioned in Chapter 1.4 and 1.5, the TLRs are a family of innate-immune 
recognition receptors that are able to recognize a variety of PAMPs and induce the activation of a 
number of host defenses. Similar to the rest of the TLR family, TLR3 is a type I integral 
membrane glycoprotein with an N-terminal ligand recognition domain, a single transmembrane 
domain and a C-terminal cytoplasmic signaling domain [30, 83]. Shown to recognize dsRNA, a 
molecular pattern associated with viral infection, TLR3 is known to induce the activation of NF- 
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Figure 1.6 Representation of the NF-B response following ligand-induced pathway 
activation. 
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B and the production of type I interferons [84-86]. Structurally, while all three domains of 
TLR3 have not been crystallized together, the TLR3-ECD has been characterized, independently, 
by two groups [30, 83]. Both groups showed that the TLR3-ECD displayed a heavily 
glycosylated horseshoe-shaped solenoid structure that consisted of 23 leucine-rich repeat motifs. 
The structure was further shown to be capped on the N- and C-terminals by leucine-rich repeat 
domains (LRR-NT and LRR-CT) (Figure 1.7). Interestingly, while both groups had elucidated 
similar ECD structures, they disagreed on the predicted location of the ligand binding site as well 
as the mechanism by which TLR3 was able to recognize viral dsRNA and initiate signaling. 
Choe et al. postulated that dsRNA would bind to the convex, glycan-free surface of the TLR3-
ECD [83]. This, they hypothesized, would enable dsRNA to bind to the positively charged 
residues of the TLR3-ECD surface. Bell et al., however, proposed three dsRNA binding sites 
[30]. In their crystal structure, two sulfate molecules from the crystallization medium had bound 
to the concave surface of the TLR3-ECD. Since the sulfate ions shared a similar atomic 
arrangement with phosphate groups, the researchers reasoned that the sulfate sites could 
represent two potential dsRNA binding sites. The third predicted site was proposed to be a 
binding site on the glycan free face of the receptor. These discrepancies were not resolved until 
2008 when the crystal structure of mouse TLR3-ECD (mTLR3), bound to a 46 base-pair dsRNA 
molecule, was published (Figure 1.8) [87]. As was detailed in Chapter 1.5, the TLR3-ECD exists 
as a monomer in solution and upon ligand binding, dimerization occurs. The mTLR3-dsRNA 
structure showed that dsRNA interacted with basic residues at both the N- and C-terminal sites 
on the lateral, glycan-free side of the TLR3-ECD [87]. When bound to dsRNA, TLR3-TLR3 
direct interactions at the C-terminal were also observed effectively defining three points of  
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Figure 1.7 Structures of the TLR3-ECD solved independently by two groups. A. TLR3-ECD 
solved by Choe et al. in 2005 (PDB ID: 1ZIW) [83]. B. TLR3-ECD solved by Bell et al. in 2005 
(PDB ID: 2A0Z) [30]. The two sulfate groups, which were found to have crystallized with the 
ECD, are depicted in red spheres.  
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interaction in the dsRNA:TLR3 complex; N-terminal with dsRNA, C-terminal with dsRNA, and 
C-terminal receptor interactions (this terminus could contribute to the formation of a TLR3 
signaling unit) [87]. Interestingly, while the N and C-terminal sites were separated by 55-60 
Angstroms in each ECD, the two N-terminal sites in the complex were separated by 110 
Angstroms. The latter distance was equivalent to that of the length of a 45 base pair dsRNA 
molecule, effectively preventing shorter molecules of dsRNA from binding and suggesting to 
investigators that this was a mechanism for preventing auto-reactive responses against self 
dsRNA (endogenous siRNA consists of 25 base-pairs or less) [87]. 
        Further analysis of the mTLR3:dsRNA complex revealed that dsRNA retains a typical A-
DNA like structure in which the ribose phosphate backbone and the position of the grooves are 
the determinants in binding [87]. The TLR3-ECD interacts not with the individual bases of 
dsRNA, but rather through electrostatic interactions between the phosphate groups of the dsRNA 
backbone and the imidazole rings of four histidine residues (three in the N-terminal site and one 
in the C-terminal site) in the TLR3-ECD. These features have been postulated to effectively 
prevent viruses from escaping detection by dsRNA [29].  
         Further experiments done in 2008 focused on dsRNA, its requirements for binding to the 
TLR3-ECD and the minimal signaling unit required for effective TLR3 signal transduction [88]. 
Using a multitude of biophysical techniques, Leonard et al. were able to show that TLR3 ligand 
recognition was specific for dsRNA and that this event was dependent upon pH and dsRNA 
length [88]. Using SPR (surface plasmon resonance), SEC (size exclusion chromatography) and 
AUC (analytical ultracentrifugation) experiments, Leonard et al. defined the length of dsRNA 
that would accommodate a TLR3 dimer, the proposed TLR3 signaling unit, as 48 base-pairs  
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Figure 1.8 mTLR3 bound to 46bp dsRNA. Crystal structure solved in 2008 by Liu, et al. (PDB 
ID: 3CIY) [87].
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[88]. However, further experiments showed that multiple TLR3-ECD dimers bound to long 
dsRNA strands (dsRNA that was 90 base-pairs in length bound two TLR3-ECD dimers while 
dsRNA that was 139 base-pairs in length bound to three TLR3-ECD dimers) suggesting a more 
detailed analysis was necessary [88]. Using a GFP-reporter gene assay, Leonard et al. were able 
to show that when TLR3 was located in an environment where the pH was approximately 6.0-
6.5, such as the early endosome, dsRNA ligands had to be greater than 90-basepairs in length to 
activate TLR3 complexes (2-3 TLR3-ECD dimers) [88]. However, TLR3 proteins that were 
located in environments where the pH was below 5.5, such as that of the late endosomes, could 
bind dsRNA ligands of greater than 48-basepairs to activate TLR3 complexes (1-2 TLR3-ECD 
dimers) [88]. The mouse TLR3-dsRNA crystal structure confirmed these findings as the ligand 
interaction sites on the TLR3-ECD (two TLR3-ECD N-terminal regions) were shown to be 
separated by 120 angstroms, the perfect length for stable binding of a TLR3-ECD dimer to 40-50 
base-pairs of dsRNA [87]. However, given the observation that dsRNA length, location and pH 
could influence the nature of TLR3:dsRNA complexes, the minimum signaling unit for TLR3 
remained ambiguous. 
While previous reports suggested that ligand-induced dimerization was the only necessary 
event for transmission of signal to the cytoplasm and activation of an immune response, recent 
reports have suggested that proteolytic processing of TLR3 may also be required prior to 
recognition of viral ligand and TLR3’s subsequent competent signaling to downstream effector 
molecules [71, 72]. Newly synthesized TLR3 in the ER (endoplasmic reticulum) is associated 
with the chaperone protein Unc93b1 [73, 74]. This association has been shown to be required 
and retained through TLR3’s trafficking from the ER, to the Golgi, and then to the endosomal 
compartments [73,74]. Once in the endosome, several groups have now shown that the TLR3-
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ECD can be cleaved by Cathepsins B and H [73,74]. This cleavage event was localized to amino 
acids 323 to 343, encompassing LRR12 and its unique loop structure [73,74]. Yet, just as with 
the proteolytic processing events in TLR7/8/9, researchers have yet to agree on the importance of 
this event. Some groups suggest that cleavage does not, in fact, dissociate the receptor into two 
fragments. Rather, they postulate that this event acts to induce stability and create a required, 
“cleaved/associated” TLR3 that results in a functional receptor which is able to detect and react 
to viral dsRNA [73]. However, other groups have shown that un-cleaved TLR3 can still induce 
signal transduction events and postulate that this cleavage event has other, yet undefined, roles in 
the cell [74].   
Whether proteolytic processing is required for ligand recognition of TLR3 or is involved in 
other facets of TLR3-ECD function is not yet known. However, what researchers do agree upon 
is the fact that ligand-induced dimerization of TLR3-ECDs is required for TLR3 signal 
transduction [89]. The dimeric orientation of receptor ECDs is proposed to bring the cytoplasmic 
TIR domains of the TLR3 homodimer complex into close proximity with one another [90]. This 
non-enzymatic event is then thought to create a signaling platform upon which the organization 
of downstream signaling cascades can occur [90, 91]. At this point, TLR3 diverges from 
classical TLR signaling as it does not induce a MyD88-dependent signaling cascade. Instead, the 
TLR3 TIR-based signaling platform acts to recruit an adaptor protein known as TRIF. This 712 
amino acid adaptor protein has distinct protein-interaction motifs that allow it to recruit effector 
proteins, which result in the activation of, at least, three possible signaling cascades (Figure 1.9) 
[82].  
 The first two cascades, mediated by the recruitment of TRIF to the TIR domain of TLR3, 
involve the subsequent recruitment of RIP1 kinase (receptor-interacting protein 1), a kinase that 
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associates with the RIP homotypic interaction motif in the TRIF domain [82]. From this point, 
one of two downstream signaling cascades is activated depending upon the ubiquitination state 
of RIP1. Lysine residue 377 of RIP1 has been shown to be an acceptor site for K63-linked 
polyubiquitination [92]. Ubiquitination of this site in RIP1 results in the activation of the IB 
kinase complex (IKK) composed of a heterodimer of the catalytic IKK and IKK subunits and 
a master regulatory protein termed NEMO (NF-B essential modulator) [92]. Once activated, 
this complex phosphorylates two serine residues on the downstream protein IB (inhibitor of 
B). IB maintains the NF-B protein complex, consisting of two subunits, RelA (p65) and 
NF-B1, from a five subunit family (RelB, c-Rel, NF-B2 (p52 and its precursor p100) are the 
other members), in a dormant state until this phosphorylation event occurs [91, 92]. Upon 
phosphorylation, IB is further modified through ubiquitination events that lead to its 
degradation by the proteasome [91]. Upon dissociation from IB, NF-B is then able to 
translocate to the nucleus where it can mediate the induction of genes involved in the immune 
response, the cell survival response or cellular proliferation, as well as up-regulate the expression 
of its own repressor, IB, which forms an inhibitory feedback loop and results in oscillating 
levels of NF-B activity [82].         
 On the other hand, if ubiquitination does not occur on lysine 377 of the RIP1 kinase, 
RIP1 complexes with the cell death-associated protein FADD (FAS-Associated with Death 
Domain protein) and Caspase 8 in a complex which initiates downstream Caspase 8 activation 
[93]. Caspase 8 activation subsequently promotes cell death by triggering the receptor-mediated 
extrinsic apoptotic pathway [93].   
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Figure 1.9 Three possible TRIF-dependent signaling cascades
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 A third signaling cascade, mediated by the recruitment of TRIF to the TIR domain of 
TLR3, requires the recruitment of effector molecules that have been shown to include molecular 
bridge proteins such as TRAF1 (tumour necrosis factor receptor-associated factor), TRAF2, 
TRAF3 and TRAF6 [94]. These proteins mediate signal transduction pathways by interacting 
with downstream protein kinases, acting as components of ubiquitin ligase machinery and other 
adaptor proteins. In the TLR3 signaling cascade, once recruited to the cell surface receptor 
domain, these bridging proteins are able to mediate the activation of TBK1 (TANK-binding 
kinase 1), a kinase that will be discussed at great length in Chapter 1.7 for its critical roles in 
phosphorylating substrates involved in cell proliferation, vesicle transport, xenophagy and the 
anti-viral response [94]. Currently, two competing theories exist regarding the molecular 
interactions of TBK1 and its surrounding proteins. Originally, a proposed kinase complex was 
believed to exist that consisted of three adaptor proteins, TANK (TRAF-associated NF-B 
inhibitor), NAP1 (NF-B activating kinase (NAK)-associated protein 1 ) and SINTBAD (Similar 
to NAP1 TBK1 adaptor) and two kinases, TBK1 and IKK (IB kinase epsilon) [94-97]. Recent 
systematic affinity purification-mass spectrometry experiments have shown a mutually exclusive 
interaction may exist between the adaptors and the kinases, suggesting distinct alternative 
complexes rather than one large signalosome (Figure 1.10) [98]. Yet, with either a large 
signalosome or distinct mutually exclusive complexes, activation of TBK1 leads to the 
phosphorylation of an important downstream transcription factor, IRF3 (interferon regulatory 
factor 3) [94-97]. IRF3, a 427 amino acid protein, is an important transcriptional regulator of the 
antiviral immune response [94-97]. Upon phosphorylation (phosphorylated by TBK1 on residues 
385 and 386 for dimerization and 396-405 to alleviate autoinhibition and allow for interaction 
with co-activators), IRF3 dimerizes and translocates to the nucleus where it regulates the 
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expression of numerous host defense genes including type I interferons [94-97]. These 
interferons, including IFN- and IFN-, are able to stimulate both macrophages and NK cells to 
elicit an anti-viral response or bind to the IFN-/ receptor (IFNAR1/2) in either an autocrine or 
paracrine manner to initiate a positive feedback loop that results in the activation of the 
JAK/STAT pathway and the production of further anti-viral genes [99, 100]. 
 These three defined pathways initiate pro-inflammatory responses that recruit additional 
immune cells to the site of infection, inhibit bacterial and viral replication, communicate danger 
signals to the surrounding cells, and induce apoptosis in cells with overwhelming infection. 
Because of this critical response, our work has focused on the activation of type I interferons, the 
critical effector molecules which were discussed for their production by the pro-inflammatory 
response of the TLR3 signaling cascade. In particular, we have examined the activation and 
regulation of the key kinase in this pathway, TBK1. As will be detailed in Chapter 1.7, TBK1 
has become demarcated as a centralized catalytic hub and an essential modulator of the host 
responses mentioned above. As such, understanding the mechanisms by which the function of 
TBK1 is both activated and regulated provides insight into how this kinase dictates the shape of a 
multitude of downstream innate immune responses.       
1.7 TANK-Binding Kinase 1 (TBK1): Structure, Function and Regulation 
Several signaling pathways converge to activate TBK1 (Figure 1.11) [94, 95, 101]. 
Originally discovered as a kinase that interacted with the effector proteins, TANK and TRAF2, 
in a ternary complex that could activate NF-B [102], TBK1 has since been characterized as a 
key regulator of substrates ranging from cell proliferation [103] and vesicle transport [104] to the 
xenophagic elimination of bacteria [105, 106] and the antiviral immune response [94-97].   
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Figure 1.10 Possible configurations of the proposed TBK1 kinase complex. 
43 
 
TBK1 [102], also known as NAK (NF-B-activating kinase) [107] or T2K (TRAF2-associated 
kinase) [108], is a 729 amino-acid serine/threonine kinase that is a ubiquitously expressed non-
canonical IB kinase family member. The canonical IB kinases, IKK and IKK, 
phosphorylate IB in the NF-B signaling pathway [109], while TBK1 targets the transcription 
factors IRF3 and IRF7 in the type I interferon response [94]. TBK1 is composed of an N-
terminal KD (kinase domain), which contains an activation loop between subdomains VII and 
VIII that controls its catalytic activity, and three C-terminal regulatory domains; a ULD 
(ubiquitin-like domain), which does not interact with known ubiquitin-binding proteins, but 
rather with the KD and appears to be necessary for the full activation of the kinase along with 
substrate presentation, a leucine-zipper containing DD (dimerization domain), and finally a small 
helix-loop-helix protein interaction module that has been termed the AB (adaptor-binding) motif 
(Figure 1.12) [110-112]. From TBK1 structural studies, the kinase has been shown to be a 
dimeric entity in which the KD, ULD and DD form a three-way interface that positions the 
kinase active sites, consisting of the critical activation loops, away from one another (Figure 
1.13) [112]. This configuration, as is postulated by numerous researchers, prevents productive 
autophosphorylation events, which, as will be discussed in the next paragraph, are required for 
TBK1 activation.  
 Upon recognition of an upstream signal, TBK1 is recruited to signaling complexes via its 
AB motif [111]. Once there, TBK1 requires phosphorylation of serine residue 172 within its 
kinase domain activation loop to form a productive active site center (Figure 1.14) [113]. This 
event has been shown to be achieved through the kinase activity of IKK. Recent crystal 
structures of the KD and ULD of TBK1 have also shown that this post-translational modification  
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Figure 1.11 Multiple signaling pathways converge to activate TBK1. 
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Figure 1.12 Structure of TBK1. A. Structure of the kinase domain of dimeric TBK1 with a 
potent small molecule inhibitor, BX795 (depicted in red spheres), bound to the active site (PDB 
ID: 4EUT). B. Structure of the asymmetric unit of TBK1. The KD is depicted in red spheres, the 
ULD in yellow spheres and the DD in green spheres (PDB ID: 4IM0). C. Ribbon diagram of the 
domain structure of TBK1 highlighting the KD, ULD and SDD of the kinase (PDB ID: 4IM0).    
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Figure 1.13 Structural organization of the inactive TBK1 molecule. A. Structural 
configuration of the KD and ULD of inactive TBK1. The activation loop of each monomer is 
depicted in sphere representation with the critical, S172 residue, highlighted in red (PDB ID: 
4EUT). B. Detailed view of a single chain of TBK1 in the inactive state. The activation loop is 
again represented in green spheres with the critical, S172 residue, in red (PDB ID: 4EUT).      
47 
 
can occur through a trans-phosphorylation event mediated by the local clustering of TBK1 
molecules upon recognition of a signal [112]. In this case, neighboring TBK1 molecules interact 
via an activation loop-swapped conformation. These interactions help to supply critical structural 
contacts required to achieve an active kinase conformation, as well as to place the activation loop 
within the catalytic cleft of the adjacent TBK1 KD for phosphotransfer to S172.  While kinetic 
analysis suggests that the initial loop-swapped phosphorylation mechanism is slow, once 
activated, TBK1 is able to readily phosphorylate activation loop sequences of the remaining 
unphosphorylated TBK1 molecules leading to activation of any dormant TBK1 constructs [112]. 
Upon autophosphorylation of S172, the TBK1 activation loop folds back onto the C-terminal 
lobe of its KD to complete an apparent binding site for polypeptide substrates [111]. 
Investigations into the composition of this site along with TBK1 substrate sequence alignments 
have suggested that a consensus sequence for TBK1 phosphorylation exists [112]. This sequence 
reveals that the kinase favors a hydrophobic residue immediately proceeding the modified serine 
(P0) which is then mirrored by several hydrophobic residues lining the P+1 position. Indeed, the 
TBK1 activation loop sequence which is phosphorylated by activated TBK1, contains a leucine 
at the P+1 position. Similarly, a more detailed sequence analysis found that hydrophobic residues 
comprise the P+1 position in approximately 70% of TBK1 substrates [112, 115]. Other attempts 
to derive a TBK1 phosphorylation consensus sequence have suggested that polar amino acids are 
also a requirement at the P+3, P+5 and P+8 positions, or that specific amino acids, defined in 
each study, are a requirement at the P+1, P+3 and P-2 positions, but analysis of a large panel of 
natural TBK1 substrates suggests that the most prominent requirement is that of the hydrophobic 
residue at the P+1 position (Figure 1.15) [112.115]. 
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Figure 1.14 Active conformation of TBK1 kinase domain. A. Structural configuration of 
the KD for active TBK1 with a phosphorylated S172 residue (PDB ID: 4EUU). The activation 
loop of each monomer is depicted in sphere representation with the critical, S172 residue, 
highlighted in red (PDB ID: 4EUU). B. Detailed view of a single chain of TBK1 in an active 
confirmation with phosphorylated S172. The activation loop is again represented in green 
spheres with the critical, S172 residue, in red (PDB ID: 4EUU).       
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While the composition of the kinase active site appears to be critical to substrate specificity, 
researchers were also interested in elucidating the enzymatic mechanism by which TBK1 
functions. Using an IB peptide (amino acids 19-41), that is known to be phosphorylated by 
TBK1 at serine residue 36, in conjunction with ATP as a varied substrate, researchers observed 
almost parallel lines in double reciprocal plots, suggesting that the kinase acted through a ping-
pong mechanism [116]. However, additional kinetic experiments soon revealed that TBK1 could 
not function through a ping-pong mechanism as product inhibition studies showed that ADP was 
a non-competitive inhibitor of TBK1 with respect to the IB peptide [116]. If the enzyme 
functioned through a ping-pong mechanism, ADP would have functioned as a competitive 
inhibitor with respect to IB as both substrates would have to access the same form of TBK1 
during the reaction. Excluding a ping-pong mechanism, sequential versus ordered mechanisms 
were evaluated [116]. The non-competitive inhibition by ADP with respect to the IB peptide 
also excluded an ordered sequential mechanism with IB peptide binding first as ADP would 
then have functioned as an uncompetitive inhibitor [116]. To determine if the TBK1 mechanism 
was therefore random sequential or ordered sequential with ATP binding first, the pattern of 
inhibition with an IB peptide inhibitor was examined [116]. With respect to ATP as the varied 
substrate, the double reciprocal plots intersected at the 1/ATP axis and to the left of the 1/rate 
axis, indicating the presence of a non-competitive inhibitor [116]. This inhibition pattern, as with 
all IKK family members, was consistent with a random sequential mechanism for TBK1 [116-
118]. Interestingly, further kinetic experiments found that ATP decreased the affinity of IB for 
TBK1 and that the dissociation constant of IB for TBK1 was significantly higher than that of 
the IKK/IKK heterodimer (also known to phosphorylate IB subsequently leading to the  
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Figure 1.15 Postulated optimal TBK1 phosphorylation motif. Highlighted in red is the 
modified serine residue (S172) of TBK1 which is required for kinase activation.   
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activation of NF-B) suggesting to researchers, at the time, that other substrates for TBK1 may 
exist [116-118].  
Since that initial characterization, activated TBK1 has now been shown to phosphorylate 
several substrates involved in a multitude of molecular events.  Best understood today for its role 
in the induction of type I interferons [101], activated TBK1 has been shown to target two sites 
(seven serine/threonine residues) near the C-terminus of the transcription factor IRF3 [94, 109, 
119]. Phosphorylation of residues at the first site (Ser385 and Ser386) promotes the dimerization 
of IRF3 [119], required for its translocation to the nucleus, while phosphorylation of residues at 
the second site (Ser396-Ser405) permits IRF3 interaction with its co-activators p300/CBP 
(CREB-binding-protein) [120]. These events, in turn, mediate the formation of a nuclear IRF3 
nucleoprotein complex, at the promoter region of the IFN- gene, which induces the production 
of type I interferons and facilitates an immediate inflammatory response.   
While primarily studied in the antiviral response, TBK1 has also been shown to play a role in 
endosomal sorting and trafficking [104]. VPS37C, another protein defined as a TBK1 substrate, 
is a subunit of ESCRT-1 (endosomal sorting complex required for transport 1), a complex in the 
class E-VPS (vacuolar protein sorting) pathway required for sorting ubiquitinated 
transmembrane proteins into internal vesicles of multivesicular bodies [114]. Unfortunately, this 
pathway is subverted by retroviruses to mediate budding from host cells and facilitate the spread 
of infection [22]. TBK1’s phosphorylation of VPS37C negatively regulates PTAP-dependent (an 
HIV-1 motif) viral budding as this post-translational modification prevents the competent 
assembly of viral budding complexes [114].   
In addition to the antiviral response and vesicle budding, TBK1 has also been shown to 
mediate the sequestration of intracellular bacteria through a number of roles in xenophagy. 
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Infection or invasion by a bacterial pathogen tends to result in compartmentalization of the 
invading organism within PCVs (pathogen containing vacuoles) [105]. This restriction event 
limits nutrient intake by the invading microorganism and prevents collateral host damage. In 
2007, using TBK1-/- cells, a group reported that TBK1 kinase activity was required for the 
restriction of bacterial infection as TBK1 was able to regulate the integrity of PCVs [106]. 
Further experiments, done by the same group, showed that AQP-1 (Aquaporin-1), a water 
channel that regulates the swelling of secretory vesicles, associated with PCVs [104]. In TBK1 
deficient mice, AQP-1 levels were elevated causing PCV destabilization. This suggested to 
researchers that TBK1 may control AQP-1 expression, a critical regulatory point in host cell 
protection [104]. 
Further investigations into TBK1’s role in xenophagy focused on ubiquitination and the 
tendency of polyubiquitinated proteins to accumulate around cytosolic invaders. While it is not 
known whether invading bacteria are ubiquitinated while in the cell or if polyubiquitinated 
proteins surround the invading microorgansims, these studies revealed two roles for TBK1 in 
mediating the selective autophagy of bacteria displaying a polyubiquitinated-coat [105, 106]. 
First, TBK1 has been shown to mediate the activity of a ubiquitin binding protein, NDP52, 
through recruitment of adaptor molecules that recognize bacterial ubiquitin coats [105]. This 
event signals cells to activate autophagy against the bacteria attempting to colonize the host 
cytosol [105].  Second, TBK1 has also been shown to enhance the affinity of an autophagy 
receptor, Optineurin, for ubiquitinated proteins, through its phosphorylation of a residue (serine-
177) known to enhance the autophagic clearance of cytosolic Salmonella [106]. This, in turn, is 
known to promote the selective autophagy of invading intracellular bacteria through interactions 
with xenophagosomes.           
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Interestingly, however, for all of its positive attributes, aberrant activation of TBK1 has been 
shown to contribute to human disease. For example, in oncogenic transformation studies, TBK1 
activation has been shown to support the suppression of a programmed cell-death response to 
oncogene activation [103]. In these investigations, biophysical studies revealed that RalB, a key 
component of the oncogenic Ras signaling network, once activated, promoted a direct interaction 
between Sec5, a critical Ral effector protein, and TBK1 which resulted in kinase activation 
[103]. Using TBK1-/- cells, researchers then showed that TBK1 directly interacted with and 
activated AKT, which, in turn, is associated with tumor cell survival, oncogenic proliferation and 
invasiveness [103].      
Similarly, in the insulin response, TBK1 has been implicated in genetic models of diabetes 
[103, 121]. In co-immunoprecipitation assays with the insulin receptor, researchers have found 
that TBK1 and the insulin receptor interact in obese Zucker rat (OZR) models [121]. Through 
further investigations, researchers showed that TBK1 was able to phosphorylate serine residue 
994 in the insulin receptor, a post-translational modification that has been shown to cause 
reduced insulin sensitivity in genetic models of diabetes [121]. 
As is evident from the experiments above, while TBK1 activation can promote host survival 
during infection, an unchecked TBK1 response can lead to detrimental effects ranging from 
cellular proliferation in transformed cells and insulin resistance, as were detailed above, to 
numerous autoimmune disorders, obesity and glaucoma. For this reason, effector molecules have 
been sought and identified that control TBK1 activation and prevent its rampant activation from 
negating its beneficial effects.  
In searching for regulators of the TBK1 response, two independent groups discovered K63-
linked ubiquitination of TBK1 (one group showed ubiquitination on residues K69, K154, and 
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K372 [122] while the other group showed ubiquitination on residues K30 and K401 [110]) in 
response to RNA virus infection (Figure 1.16). While the E3 ligase responsible for the addition 
of modifications on residues K30 and K401 has not been elucidated, the ubiquitination 
modifications on residues K69, K154 and K372 have been shown to be induced by the E3 ligases 
Mind Bomb 1 and Mind Bomb 2 [122], in response to RNA virus infection, or NRDP1, in 
response to LPS [123]. From this post translational modification, subsequent recruitment of the 
downstream adaptor NEMO, through ubiquitin binding domains, has been shown to lead to the 
assembly of a NEMO/TBK1 complex [122]. This complex, in turn, is known to be able to 
activate TBK1 kinase activity, leading to the phosphorylation of the downstream transcription 
factor, IRF3. While ubiquitination events have not been shown to be required for the activation 
of TBK1, the presence of this post-translational modification has been shown to upregulate the 
type I interferon response and promote host cell defenses. 
 Further investigations into the regulation of TBK1 activity have identified endogenous 
inhibitors that have been shown to prevent the TBK1-mediated downstream phosphorylation of 
numerous substrates. One such inhibitor, A20, a ubiquitin-editing enzyme, has been shown to 
disrupt the K63-linked ubiquitination events discussed previously [124]. Another such inhibitor, 
SHP-2, a tyrosine phosphatase has been shown to negatively regulate TBK1-mediated signal 
transduction [125]. Since tyrosine phosphorylation of recombinant active TBK1 has not been 
detected, researchers postulate that this protein binds to the KD of the kinase and prevents the 
autophosphorylation of S172 in the active loop of the KD [125]. In addition, a yeast two-hybrid 
screen for interaction partners of the closely related, non-canonical, IB kinase, IKK, identified 
the protein SIKE (Suppressor of IKK) as a physiological inhibitor of TBK1 that acts through an 
undefined mechanism [126]. As investigations into the mechanism by which SIKE inhibits  
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Figure 1.16 K63-linked ubiquitination of TBK1. A. Ribbon diagram of a single TBK1 
molecule. Residues in TBK1 found to be ubiquitinated by Wang et al. (K69, K154, and K372) 
are highlighted in red spheres. Residues found to be ubiquitinated by Tu et al. (K30 and K401) 
are highlighted in blue spheres (PDB ID: 4IM3). B. Sphere representation of dimeric TBK1 with 
ubiquitination residues discovered by Wang et al. displayed in red spheres and ubiquitination 
residues discovered by Tu et al. displayed in blue spheres.    
 
 
 
 
56 
 
TBK1 function are a major component of this work, characteristic SIKE structure and function 
details will be explained at length in Chapter 1.8. 
 
1.8 SIKE: Discovery, Structure, and Function 
As was discussed in Chapter 1.7, over-activation of TBK1 can negate the positive attributes 
associated with its induction of critical substrates and downstream signaling cascades. To 
prevent aberrant kinase activity, endogenous inhibitors have been discovered that regulate TBK1 
function. Of interest to our lab was a 207 amino acid protein, SIKE, which was first discovered 
in 2005 by Huang et al. and characterized as a physiological suppressor of the kinases, IKK and 
TBK1 [126]. 
With hopes of identifying IKK interacting proteins, Huang et al. used a yeast two-hybrid 
system that screened a human B-cell cDNA library, consisting of approximately 8x10
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independent clones, with full-length IKK as bait [126]. The group was able to obtain 123 
positive hits, of which, four belonged to a previously uncharacterized protein which they termed 
SIKE [126]. Studies into this ubiquitously expressed protein revealed that SIKE was encoded by 
a gene that mapped to human chromosome 1p13.2 [126]. Interestingly, human chromosome 1 
spans 260 million base pairs, contains over 3000 genes, comprises approximately 8% of the 
human genome, and encodes a large number of disease-associated genes, including those that are 
involved in Parkinson’s disease, Usher syndrome and schizophrenia [127]. Blast searches of the 
GenBank databases revealed that SIKE was an evolutionarily conserved protein (from Xenopus 
to human) that belonged to an uncharacterized family consisting of proteins such as FGF 
receptor 1 oncogene partner 2 (FGFR1OP2) [126]. While SIKE and FGFR1OP2 differed by 40 
amino acids and were shown to be approximately 50% homologous (Figure 1.17), studies 
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revealed that FGFR1OP2 was encoded by a gene that mapped to chromosome 12p12.1 [128]. 
Further investigations revealed that FGFR1OP2 was a protein found in tissues ranging from the 
spleen and thymus to bone marrow [129]. Additionally, studies indicated that FGFR1OP2 had 
the ability to dimerize, associate with coiled-coil structures, and interact with cytoskeleton 
networks of oral wound fibroblasts to enhance wound healing [129].    
      Analysis of the SIKE sequence revealed that this protein had three predicted coiled-coil 
domains; a low probability predicted domain from amino acids 5-42, and two high probability 
predicted domains from amino acids 72-102 and 163-197 [126] (Figure 1.18). Since coiled-coil 
motifs were known to mediate protein-protein interactions and multimerization events, 
researchers questioned whether SIKE had the ability to dimerize or oligomerize. Using co-
immunoprecipitation experiments, investigators were able to show that a FLAG-tagged SIKE 
construct was able to interact with an HA-tagged SIKE construct indicating that SIKE could 
form homodimers or even oligomers [126]. 
Taking interaction studies one step further, researchers knew that, while SIKE interacted with 
IKK, this kinase was undetectable under physiological conditions (inducible in lymphoid and 
other cell types). Scientists wondered whether SIKE, therefore, could interact with TBK1, the 
kinase which was constitutively expressed in most cell types. In co-immunoprecipitation 
experiments, endogenous SIKE did, in fact, interact with endogenous TBK1 under physiological 
conditions [126]. In an attempt to map the interaction sites between TBK1 and SIKE, researchers 
postulated that the coiled-coil motifs of each protein would be the basis for association events. 
Using further co-immunoprecipitation experiments, investigators were able to reveal that the  
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Figure 1.17 Sequence similarity of SIKE and its homologue, FGFR1OP2. Basic Local 
Alignment Search Tool (BLAST) sequence alignment of the two isoforms of FGFR1OP2 and the 
two isoforms of SIKE. Conserved residues are highlighted in yellow. Amino acid inserts in the 
FGFR1OP2 sequence are highlighted in blue. Amino acid inserts in the SIKE sequence are 
highlighted in red.      
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Figure 1.18 Predicted domain organization of SIKE and the kinase TBK1. 
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high probability predicted coiled-coil domains of SIKE, amino acids 72-207, interacted with the 
two coiled-coil domains of TBK1, amino acids 601-729 [126] (Figure 1.18), suggesting that 
coiled-coil motifs did, in fact, mediate the interactions between these two proteins and that the 
first 72 amino acids of SIKE were not necessary for interactions with TBK1. Interestingly, 
however, this study did not detect an interaction between the TBK1-KD and SIKE.   
As TBK1 had been shown to play a significant role in the TLR3 signaling cascade, 
researchers next questioned whether SIKE also associated with the kinase upon pathway 
activation. Upon stimulation with either poly(I:C) (polyinosinic:polycytidylic acid), a dsRNA 
mimetic, or VSV (vesicular stomatitis virus), SIKE dissociated from TBK1 effectively 
terminating the interaction [126]. Huang et al. questioned the functional basis of this dissociation 
event and were able to show that SIKE acted in a more influential manner in the TLR3 signaling 
cascade. Using transient transfections and co-immunoprecipitation experiments, Huang et al. 
showed that SIKE was able to disrupt TBK1 interactions with the upstream adaptor molecule, 
TRIF, and the downstream substrate, IRF3, effectively sequestering TBK1 in an inactive 
complex in the TLR3 signaling cascade [126]. Understanding that TLR3 was able to activate 
both NF-B and IRF3, Huang and colleagues examined whether SIKE disrupted both pathways. 
Interestingly, the use of a SIKE RNAi plasmid in reporter gene assays potentiated poly(I:C)- and 
VSV-triggered activation of the IFN promoter, but had no effect on NF-B [126]. Further 
studies showed that SIKE did not disrupt interactions between TRIF and TRAF6 or RIP1, 
associations required for TLR3-mediated NF-B activation [126]. SIKE also did not inhibit NF-
B activation triggered by TNF, poly(I:C), and VSV suggesting that SIKE specifically inhibited 
the IKK- and TBK1-mediated IFN activation pathways [126]. Subsequent studies by Andrei 
Medvedev’s group showed that LPS-induced pathway activation led to an increase in SIKE 
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mRNA levels [130]. This suggested to researchers that TLR3-pathway activation induced the 
expression of pro-inflammatory cytokines and chemokines as well as the expression of SIKE 
which could return to the TLR3 pathway to negatively regulate TBK1 activity. The production of 
SIKE would, therefore, effectively form a negative feedback inhibition loop in the TLR3 
signaling cascade (Figure 1.19). 
SIKE based studies seemingly terminated following its characterization as a physiological 
inhibitor of IKK- and TBK1-mediated antiviral responses. Intriguing to our lab, however, was 
the unknown mechanism by which SIKE inhibited TBK1 prior to pathway stimulation and the 
unknown role SIKE had in the cell following its dissociation from TBK1. Further confounding 
our thoughts was the fact that SIKE and its homologue, FGFR1OP2, were 50% similar in 
sequence identity yet their defined physiological roles, one as an inhibitor of the innate immune 
response and one as a cytoskeleton protein mediator in wound healing, varied greatly. As will be 
conveyed in Chapter 4, our investigations have defined SIKE as much more than an endogenous 
inhibitor of the TLR3 signaling cascade.   
 
1.9 Current Study 
To defend against pathogens, decades of research have shown that multi-cellular organisms 
mount an immune response that recognizes, sequesters and eradicates invading infectious agents. 
Essential to this safeguard is the innate anti-viral response mediated by PRRs such as TLR3. 
Given the important nature of the TLR3 signaling cascade in antiviral immunity, the current 
study examines three aspects of a TLR3-mediated immune response. First, this study investigates 
the potential for TLR3 ligands to act as adjuvants, pharmacological agents that are included in  
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Figure 1.19 Postulated mechanism of SIKE inhibition.
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vaccines to enhance an antigenic response. This study continues by exploring the role of receptor 
clustering, a key spatial feature that influences effective and proper physical and biochemical 
cellular responses, in the TLR3:dsRNA signaling complex. Finally, the current study concludes 
by exploring the role of endogenous regulation, a critical control to aberrant immune activity, on 
downstream TLR3 signaling pathways. While these studies cover both extracellular and 
intracellular events in innate immunity, the findings as a whole establish a previously undefined 
clustering mechanism as well as a novel substrate that will enhance the scientific community’s 
understanding of TLR3 and add to its already established function in the immune response.  
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Chapter II 
The Adjuvant Potential of dsRNA 
 
 
2.1 Introduction 
 Investigators have established that mature, immunologically competent dendritic cells 
(DCs) are one of the most potent antigen presenting cells (APCs) uniquely able to initiate 
primary immune responses [1, 21]. DC precursors, immature DCs (iDCs), derived from 
hematopoietic bone marrow progenitor cells, migrate from the bone marrow to the blood 
performing sentinel-like functions, internalizing and processing antigens from surrounding 
microenvironments in the cell [1,21]. These iDCs can also be recruited to sites of inflammation 
in peripheral tissues following pathogen invasion through receptor expression on their cell 
surfaces (iDCs may express chemokine receptors, such as CCR1, CCR2, CCR5, CCR6 and 
CXCR1, or receptors from the CD1 family of molecules such as CD1a, CD1b and CD1c) [1, 21, 
131]. Upon recognition of inflammatory mediators, microbial products and other pathogens, 
iDCs phagocytose these danger signals and degrade their proteins into small peptides [1,21]. 
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iDCs then migrate to the draining lymph nodes simultaneously undergoing maturation into 
mature DCs which effectively induces the expression of co-stimulatory molecules and cytokines 
on their cell surface (up-regulation of chemokine receptors CCR6 and CCR7 is observed along 
with the enhanced expression of cell-surface receptors that act as co-receptors in T-cell 
activation such as CD80 (B7.1), CD86 (B7.2) and CD40) [1, 21]. Once migration into these T-
cell rich areas has occurred, DCs act as APCs, using MHC molecules on their cell surface to 
present danger signals and effectively induce cognate T-cells to differentiate into antigen specific 
CTL and Th cells [1, 21]. As these cells are a requirement for long-term protection against 
infection and the generation of acquired immunity, researchers have long investigated the 
adaptability of this process as it pertains to vaccination.   
 A major goal of vaccination is the generation of a strong immune response to an 
administered antigen that can provide long-term protection against infection. To achieve this 
objective in the past, medical professionals used either inactivated vaccines [132], which 
consisted of virus particles that cannot replicate but are stable enough to be recognized by the 
immune system and evoke a response, or attenuated vaccines [133], which consisted of live virus 
particles with low virulence. However, with the ever expanding list of pathogens and the 
growing infection rate from these invading microorganisms, vaccines today tend to be developed 
through pure recombinant or synthetic antigens and are less immunogenic than their predecessors 
[134]. Therefore, in addition to the initial vaccination, doctors also administer adjuvants which 
are pharmacological or immunological agents that modify effects of the vaccine. Adjuvants are 
used for various purposes; to enhance the immunogenicity of highly purified or recombinant 
antigens; to reduce the amount of antigen necessary to elicit a response or the number of 
immunizations needed for protective immunity; to improve the efficacy of vaccines in newborns, 
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the elderly or other immune-compromised persons; or as antigen delivery systems for the uptake 
of antigens by the mucosa. While these pharmacological agents are co-administered with a 
multitude of vaccines today, adjuvants are not a recent concept.  
 In the 1920s, Ramon et al. noted that horses that developed an abscess at the inoculation 
site of diphtheria toxoid generated higher specific antibody titres [135]. They subsequently found 
that an abscess generated by the injection of unrelated substances along with the diphtheria 
toxoid increased the immune response against the toxoid. In 1926, further research was able to 
elucidate the adjuvant activity of aluminum compounds when Glenny et al. demonstrated that the 
diphtheria toxoid absorbed to alum, a specific chemical compound defined as hydrated 
potassium aluminum sulfate [136]. Interestingly, to this day, aluminum-based compounds 
(specifically aluminum phosphate or hydroxide) remain the predominant adjuvants with alum 
being the sole adjuvant approved for human use in the majority of countries worldwide. 
 While alum is able to induce a good antibody (Th2) response, it does not have the 
capacity to stimulate cellular (Th1) immune responses which are important for protection against 
many pathogens [137]. In addition, alum has been shown to cause severe local and systemic 
side-effects including sterile abscesses, eosinophilia and myofascitis [138]. Concerns have also 
been raised regarding the possible role of aluminum in neurodegenerative diseases such as 
Alzheimer’s disease [137, 138]. For these reasons, a demand for safer and more effective 
adjuvants, suitable for human use, has been brought to the attention of the scientific community 
and researchers world-wide.                
 To develop an alternative to alum that effectively enhances both an antibody and cellular 
immune response, research has begun to focus on pathogen and microbially-derived ligands. 
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These ligands, recognized by PRRs, are known to strongly activate an inflammatory response 
and corresponding release of cytokines. This barrage of immune activators signals immune cells 
to sequester and eradicate invading infectious agents. At the forefront of PRR-ligand adjuvant 
studies are the TLRs, the receptors that, as discussed in Chapters 1.4 and 1.5, recognize a 
multitude of PAMPs.  Initial research has shown that synthetic TLR2 ligands, MALP-2 and 
Pam3, were effective in the induction of CTL [139] while synthetic TLR7, TLR8 and TLR9 
ligands, R-848 and CpG ODN, were able to augment both T-cell mediated immune responses 
[140]. Of interest to our lab was the potential adjuvancy of dsRNA with resepct to its activation 
of multiple PRRs, including TLR3. Once activated, TLR3 triggers signaling cascades, discussed 
in Chapter 1.6, that lead to both an immediate inflammatory response and a subsequent adaptive 
immune response. Unfortunately, the widely used, synthetic dsRNA analogue, pI:pC, the 
obvious choice for dsRNA adjuvant development, has toxic side effects that require doses for 
systemic therapeutic applications to be below effective concentrations [141]. The chemical 
structure and biological function of pI:pC has also been shown to vary leading to the 
promiscuous activation of non-TLR3 dependent pathways with unpredictable consequences 
[141]. Recent studies have investigated different delivery methods for this potential adjuvant, but 
results have been inconclusive [142]. Therefore, attention has turned to defined dsRNA 
oligonucleotides.          
 Previous studies had shown that TLR3 activation is dependent upon dsRNA length [88]. 
The minimal length for efficient in vitro binding was shown to be ~48bp, while in vivo, a robust 
response was not observed until dsRNA of ≥90bp was used for stimulation [88]. The objective of 
this study was to determine the adjuvant potential of a 139bp dsRNA molecule as assessed 
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through the maturation of iDCs to DCs. Our goal from this work was to develop a specific PRR 
ligand that would act as a safe agonist of TLR3. 
 
2.2 Materials and Methods 
2.2.1 Reagents 
 Chemicals were purchased from Sigma-Aldrich unless otherwise specified. The T7 
RiboMAX Express Large Scale RNA Production System kit was purchased from Promega. GM-
CSF (granulocyte macrophage-colony stimulating factor) and IL-4 (interleukin-4) were 
purchased from R&D Systems. Hank’s Buffered Saline Solution was purchased from GIBCO. 
Anti-hIgG antibody was purchased from Sigma-Aldrich. FITC-mouse and human CD86 was 
purchased from BD Biosciences (SSS687). PE-mouse-Anti-hCD80 (305207), PE-mouse-Anti-
hCD1a (300105), PE-mouse-Anti-hCD54 (322707), FITC-mouse-hCD14 (301803), and FITC-
mouse-Anti-hHLA-DR (307603) antibodies were purchased from BioLegend. 
2.2.2 Synthesis of dsRNA 
 The enzymatic synthesis of dsRNA requires a dsDNA template. As TLR3 recognizes 
dsRNA molecules of any sequences, any PCR template is suitable, but dsRNA length (>48bp) is 
required to accommodate recognition by a TLR3 dimer. Templates in this study consisted of 
48bp, 139bp and 540bp sections of a WNV (West Nile Virus) sequence. The sequences were 
PCR amplified and included a 5’SacII restriction enzyme site and a 3’SpeI restriction enzyme 
site. PCR products were ligated into a pGEM-T Easy vector containing a T7 RNA polymerase 
promoter upstream. DNA templates in the pGEM-T Easy vector were completed for the forward 
(sense) and reverse (antisense) orientation of the WNV sequence. Prior to the RNA polymerase 
reaction, sense and antisense DNA templates (100 g) were treated with Proteinase K 
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(100g/mL) in Tris-HCl (50mM, pH 7.5) and CaCl2 (5mM) containing 0.5% SDS for 30 minutes 
at 37
o
C to digest any protein present, especially RNases. Following the 30 minute incubation 
period, a Phenol:Chloroform extraction was performed to separate digested proteins and 
Proteinase K from the DNA templates. This was followed by an ethanol precipitation 
(Sambrook/Russell Molecular Cloning: A Laboratory Manual 3
rd
 edition (Appendix A8.9)) to 
purify and concentrate the DNA templates. Sense and antisense DNA templates (50g each) 
were then linearized by digestion with NdeI restriction enzyme (75units) (the NdeI site in 
pGEM-T Easy is 26bp downstream of the target DNA template allowing RNA polymerase to 
“run off” after completing synthesis of the target sequence) through incubation overnight at 
37
o
C. Two micrograms of each solution were then run on a 2% agarose gel to confirm linearized 
product (Figure 2.1B). Sense and antisense ssRNA were then synthesized simultaneously by 
combining, in a single tube, sense (6g) and antisense (6g) DNA templates with the remaining 
reagents at levels detailed in the manufacturer’s protocol for “Synthesizing Large Quantities of 
RNA” reaction. Following synthesis, RNA strands were annealed by heating the reaction tube to 
70
o
C for 10 minutes and allowing it to cool slowly to room temperature (~1 hour) to anneal RNA 
complimentary sense/antisense strands. To remove the DNA template and ssRNA (overhangs of 
annealed strands and unpaired RNA strands), RNAse A (80pg/L) and RQ1 DNase (4L, 
RiboMax kit) were added to the reaction tube and incubated at 37
o
C for 30 minutes. The target 
dsRNA was isolated via a second Phenol:Chloroform extraction and concentrated using an 
ethanol precipitation reaction. Purity and quality of the resulting dsRNA products was assessed 
by separation on a 6% TBE-Urea gel and visualized by silver stain.  
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Figure 2.1 Synthesis of 48bp, 139bp and 540bp dsRNA ligands. A. Protocol for the synthesis 
of dsRNA ligands from DNA. B. 2% agarose gels containing sense (S) and antisense (AS) DNA 
templates either exposed (NdeI) or unexposed (blank) to the restriction enzyme NdeI. C. 6% 
TBE-Urea gels depicting purified 48bp, 139bp and 540bp dsRNA ligands.           
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2.2.3 Cell Culture 
 Peripheral blood mononuclear cells (PBMCs) were prepared in the Segal Lab, NIH. 
Briefly, Buffy coats (~20mL) were received from the NIH Blood Bank. To ~10mL Buffy coat, 
PBS was added to a total volume of 30mL in a 50mL tube. Buffy coat was dispersed by slow 
pipetting (1mL). Ficoll reagent (13mL) was added to the bottom of the tube. Lymphocytes were 
separated by Ficoll gradient (400xg, 20 minutes, RT, no brake) and transferred to a new tube. 
Lymphocytes were washed three times with PBS (~40mL) (1500rpm, 10 minutes, RT). The final 
pellet was resuspended in complete RPMI (10% FBS, 2mM L-glutamine, 1mM NaPyruvate, 1X 
non-essential amino acids, 50g/mL Pen/Strep) and counted by trypan blue exclusion. Purified 
PBMCs were stored at 1x10
7
 cells/mL in 90% serum and 10% DMSO in liquid phase N2. 
Monocytes were selected from PBMC stocks and differentiated into iDCs following the method 
described by Sallusto et al. Briefly, PBMCs were plated in complete RPMI (sans FBS) and 5-
8x10
6
 cells/mL and cultured at 37
o
C and 5% CO2 for two hours. Non-adherent cells were 
removed by gently washing wells with complete RPMI. The remaining adherent population was 
almost exclusively composed of monocytes. To differentiate iDCs from the monocyte 
population, cells were grown in complete RPMI (with 50M Me) supplemented with GM-CSF 
(50ng/mL) and IL-4 (10ng/mL). Cells received 50% fresh complete RPMI (with 50M Me) 
supplemented with GM-CSF and IL-4 on days 1, 3, 5 and 7 following observation (Figure 2.2). 
On day 7, following visual confirmation of monocyte differentiation to iDCs, cells were 
stimulated with LPS (200ng/mL) or pI:pC (20g/mL) or 139bp dsRNA (20g/mL). Following 
24-hours of stimulation, cells were collected and analyzed for cell surface markers by flow 
cytometry.       
2.2.4 Flow Cytometry 
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 Following 24-hour stimulation, cells were harvested by pipetting, counted by trypan blue 
stain and placed in 50mL falcon tubes. Cells (2.5x10
5
) were then aliquoted into 10mL flow 
cytometry tubes and pelleted at 1000rpm for 6 minutes. The supernatant was removed and cells 
were washed with FACS buffer (1X Hank’s buffered saline solution, 0.1% bovine serum 
albumin, and 0.1% sodium azide). Cells were pelleted and then resuspended in blocking solution 
(100LFACS buffer containing 0.1mg Human IgG antibody). Cells were incubated in blocking 
solution for 15 minutes at 4
o
C and then pelleted and washed three times with FACS buffer 
(1000xg, 3 minutes, RT). Cells were resuspended in 200L FACS buffer and tubes were labeled 
as follows; unlabeled, PE-Ctl (PE-mouse-Anti-hCD54), FITC-Ctl (FITC-mouse-Anti-hHLA-
DR), CD80/CD86 (PE-mouse-Anti-hCD80 / FITC-mouse-Anti-hCD86), CD1a/CD14 (PE-
mouse-Anti-hCD1a / FITC-mouse-Anti-hCD14). Antibodies (5L/2.5x105 cells) as indicated by 
tube, were added (manufacturer’s suggested dilutions) and incubated for 45 minutes at 4oC in the 
dark. Following antibody incubation, cells were pelleted and washed three times with FACS 
buffer (1mL) (1000xg, 3 minutes, RT). Cells were resuspended in FACS buffer (100L) and 
analyzed via flow cytometry on an FC500 using CXP v.1 acquisition/analysis software 
(Beckman Coulter). Gates and voltages were optimized using PE and FITC control labeled cells 
prior to analysis. For each sample, a minimum of 10,000 events was recorded. A representative 
figure of 4 separate experiments is recorded in this document.         
 
2.3 Results and Conclusions 
 As a result of work done by Leonard et al. and their findings elucidating the robust 
activation of a TLR3 response following stimulation by a 139bp dsRNA ligand [88], our group 
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set out to synthesize three dsRNA ligands, 48bp, 139bp and 540bp, in an attempt to test a range 
of dsRNA ligands in adjuvant potential studies.   Successful synthesis of all three dsRNA 
constructs provided approximately 1.4mg of pure product for each ligand (Figure 2.1C).  
 After confirming the successful synthesis of dsRNA ligands, monocytes were 
differentiated into iDCs to use in the measurement of dsRNA adjuvant potential studies. iDC 
phenotype was confirmed visually through the transformation of cells from adherent to loosely  
adherent clusters (isolated floating cells or clusters) (Figure 2.2).  Successful loss of receptor 
CD14 expression and gain of receptor CD1a expression, evaluated through flow cytometry 
analysis, also confirmed the successful differentiation of monocytes to iDCs (Figure 2.3). 
 To evaluate the adjuvant potential of synthesized dsRNA, we examined iDCs for 
increased expression of CD80/CD86, cell surface markers of DC maturation. Candidates for 
future development as vaccine adjuvants must successfully mature iDCs to DCs. Untreated iDCs, 
serving as negative controls, showed no surface expression of CD80 or CD86 receptors (Figure 
2.4A). This negative control confirmation was critical as iDCs can undergo some level of 
maturation if roughly handled (i.e. jarring of culture dishes, pelleting of cells during harvest, or 
pipetting to resuspend). LPS treated iDCs, as a positive control, showed that all cells now 
expressed CD80 and CD86 receptors (Figure 2.4B) confirming that our iDC preparation could 
undergo maturation. iDCs, treated with pI:pC, the dsRNA mimetic known to induce TLR3 
activity but shown to have toxic side effects in humans, exhibited an 82.9% gain in expression of 
the CD80 receptor while only a 24.2% gain in the CD86 receptor (Figure 2.4C). Similarly, 139bp 
dsRNA treated iDCs displayed an 82.2% gain in CD80 receptor expression but only a 29% gain 
in CD86 receptor expression (Figure 2.4D). These studies showed that 139bp dsRNA could  
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Figure 2.2 Visual confirmation of monocyte differentiation. Appearance of cells stimulated 
with GM-CSF (50ng/mL) and IL-4 (10ng/mL) over a 7 day period. Notice increased clustering 
and cells losing adherent phenotype. Microscope magnification; Day 1 = 40X, Day 3 = 10X, Day 
5 = 10X and Day 7 = 10X.    
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Figure 2.3 Flow cytometry analysis of monocyte differentiation. Flow cytometry results of 
cells stained with CD14-FITC and CD1a-PE following 7 days of co-culturing with GM-CSF 
(50ng/mL) and IL-4 (10ng/mL).   
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match the maturation of DCs by pI:pC, but neither pI:pC or 139bp dsRNA could increase CD86 
expression to levels observed in LPS treated iDCs.  
 Prior to completing our studies with the 48bp and 540bp dsRNA ligands, a paper was 
published investigating the capacity of dsRNA oligonucleotides of defined sizes to activate DC 
subsets from WT and TLR3-/- mice, to induce antigen specific CTL responses and to serve as 
adjuvants for an experimental influenza vaccine [143]. The authors were able to show that 
dendritic cell activation and adjuvant effectiveness increased with increasing dsRNA length. This 
study confirmed that dsRNA oligonucleotides could effectively serve as vaccine adjuvants. 
 While progress towards the completion of the study proposed in this document included 
the successful synthesis of three dsRNA ligands, the successful differentiation of monocytes to 
iDCs and the successful maturation of iDCs to DCs through stimulation with a 139bp dsRNA 
ligand, the results of the paper published by Jelinek et al. [143] were too similar to the remaining 
objectives for our lab to continue to pursue this project.  Therefore, this study was terminated.  
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Figure 2.4 Assessment of the maturation of iDCs to DCs following stimulation. Flow 
cytometry analysis of cells stained with CD86-FITC or CD80-PE antibodies following A. no 
treatment, B. 24-hour treatment with LPS (200ng/mL), C. 24-hour treatment with pI:pC 
(20g/mL), or D. 24-hour treatment with synthesized 139bp dsRNA (20g/mL).   
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Chapter III 
Elucidating the Role of Receptor 
Clustering in TLR3 Signal 
Transduction 
 
 
3.1 Introduction 
 The events leading to the induction of TLR signaling occur in a sequential process in 
which pathogen recognition induces subsequent ligand binding and simultaneous receptor 
dimerization. TLR3, as was discussed in Chapter 1.6, recognizes viral dsRNA and associates 
with its ligand to form a 2:1 TLR3 to dsRNA complex. This 2TLR3:1dsRNA complex has been 
termed the signaling unit [88]. Previous cell-based studies of the TLR3:dsRNA complex had 
shown that a minimum of two signaling units were required to initiate endosomal TLR3 
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signaling and suggested that competent signaling may also occur through the clustering of 
complexes upon recognition of different length dsRNA ligands [88].  
A multimerization event in which TLR complexes clustered together would not be unusual as 
researchers had shown previously that receptor clustering was required for TLRs that signal 
through the MyD88 adaptor molecule [144]. Upon activation of the MyD88–dependent pathway, 
signaling components interact to form a 14-subunit left-handed helical oligomer [144]. 
Formation of this Myddosome requires multiple, clustered receptor:adaptor complexes that have 
yet to be investigated.  
Further evidence for a TLR3 multimerization event was discovered in cross-linking 
experiments done by the Caux group [145] who, at the time, were investigating both TLR3 and 
the FC-gamma receptor, CD32a. CD32a, a cell surface receptor, was known to have a well-
defined mode of action in which multimeric IgG induced receptor multimerization [145]. This 
led to the activation of a cytosolic ITAM (immunoreceptor tyrosine-based activation motif) 
domain and a subsequent rapid rise in intracellular calcium levels. By generating a TLR3-CD32a 
chimeric molecule in which the TLR3-ECD was fused to the cytosolic ITAM domain of CD32a, 
the investigators were able to show that an intracellular Ca
2+
 flux was only observed upon pI:pC 
stimulation or Anti-IgG crosslinking of Anti-TLR3 antibody suggesting that, in the same manner 
as endogenously expressed CD32a, the TLR3-CD32a chimera required receptor multimerization 
for signaling [145]. 
Although multiple 2TLR3:1dsRNA signaling units appear required for signaling, the 
parameters dictating clustering are unknown. In this study, three TLR3-ECD specific 
monoclonal antibodies (mAbs) were generated. Monoclonal antibody 1068 down-regulated 
dsRNA-induced pro-inflammatory mediators (mAb1068), whereas mAb12 and mAb15 ablated 
80 
 
dsRNA-induced TLR3 activity. Characterization of these antibodies through structural, cell-
based and biophysical methods uncovered a role for lateral receptor clustering in TLR3 signal 
transduction.  
 
3.2 Materials and Methods 
3.2.1 Reagents 
 All chemicals were purchased from Sigma-Aldrich unless otherwise noted. mAb1068, 
Fab1068, mAb12, Fab12, mAb15 and Fab15 were supplied by Janssen Biotech Inc. through a 
Materials Transfer Agreement. Structural determination of the quaternary complex and 
molecular modeling studies were completed by Janssen Biotech Inc. 
3.2.2 TLR3-ECD purification and dsRNA production 
 The coding sequence for the TLR3-ECD (residues 22-702) fused to an N-terminal GP67 
secretion signal sequence and a C-terminal TEV cleavage site followed by FLAG and 6XHis 
tags was inserted into a baculovirus expression system and expressed in High Five cells 
(Invitrogen) by using a multiplicity of infection of 3. Supernatant was harvested at 48 hours post-
infection and passed over Anti-FLAG M2 agarose resin (Sigma) three times. Resin was washed 
with 20-column volumes of 1X TBS. Target protein was eluted with five 10mL volumes of 1X 
TBS plus FLAG peptide (100g/mL). Resin was regenerated and stored as per manufacturer’s 
protocol. Samples from each step were analyzed by SDS-PAGE. Elution fractions containing 
target protein were pooled and stored at 4
o
C. To remove FLAG peptide from target protein, 
samples were separated on a Superdex 200 column (GE Healthcare). 
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 dsRNA production was as described in Chapter 2.2.2    
3.2.3 SEC and gel analysis of TLR3-ECD:dsRNA:Fab complexes 
 TLR3-ECD and/or Fab were mixed with dsRNA in a 2:1 molar ratio. Component or 
complexes were incubated for 1 hour at 4
o
C before separation. Individual components or 
complexes were separated on an Akta FPLC System (GE Healthcare) using a Superose 6 Tricorn 
column (GE Healthcare) equilibrated in 0.02M Pipes, pH 6.0, 150mM NaCl, and 1mM beta-
mercaptoethanol prepared with diethylpyrocarbonate-treated water. Separation was monitored by 
absorbance at 280nm. Samples from each peak fraction were analyzed by SDS-PAGE. Fraction 
(18L) plus loading dye (6L – 4X reducing SDS-loading dye (Life Technologies)) were boiled 
for 10 minutes, briefly spun to sediment condensate and 20L separated onto a 10% Tris-glycine 
SDS-PAGE gel (run at 200V for 35 minutes). Novex Sharp pre-stained molecular weight marker 
(Invitrogen) and/or RNA century marker (Applied Biosystems) were used as molecular weight 
standards. Gels were stained with SimplyBlue SafeStain (Invitrogen) for protein followed by 
silver stain for nucleotides. Gel documentation was completed using an Alpha Innotech gel 
imaging system. Contrast adjustment and cropping of gel images was completed in Adobe 
Photoshop.  
3.2.4 Stimulation Assays 
 Reporter gene assays with luciferase readout were completed as reported by Janssen 
Biotech Inc. TLR3hi cells were a gift from the Segal Lab and stably expressed TLR3 in 
endosomal and cell surface locations along with a GFP-based NF-B reporter. This system 
provides a sensitive readout of TLR3 activation. TLR3hi cells were plated at 1x10
6
 cells/2mL in 
a 6-well plate. Cells were stimulated with dsRNA (25g/mL), or Fab (100g/mL), or control 
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mAb (100g/mL), or dsRNA + Fab/control mAb for 48 hours. Cells were harvested by washing 
wells with PBS + 20mM ethylenediaminetetraacetic acid and counted by trypan blue exclusion 
method. Cells were pelleted, washed three times with FACS buffer (1X Hank’s buffered salt 
solution, 0.1% bovine serum albumin, and 0.1% sodium azide), and resuspended in 200L 
FACS buffer. GFP fluorescence was analyzed via flow cytometry on an FC500 using CXP v.1 
acquisition/analysis software (Beckman Coulter). For each sample, 10,000 events were recorded. 
The mean of three separate experiments ± SEM is reported. The two strands for the 49bp ligand 
were purchased from Dharmacon, mixed 1:1 and annealed. The 540bp dsRNA ligand was 
prepared as previously described in Chapter 2.2.2.  
 
3.3 Results and Conclusions 
3.3.1 A 49bp dsRNA ligand does not induce TLR3 signaling in RGA 
 Initial efforts to investigate receptor multimerization events, as they pertained to the 
induction of TLR3 signaling, utilized an NF-B-driven reporter gene assay (RGA) [88]. In this 
assay, successful ligand-mediated activation of the TLR3 signaling cascade results in luciferase 
production under NF-B promoter control. This luciferase response can be quantified by 
measuring emitted photons in a standard luciferase assay. Similar to the results obtained by 
Leonard et al. [88], pI:pC and long dsRNA (139bp and 540bp) ligands induced robust signaling 
in this assay, mediated through TLR3 in HEK293 cells transiently expressing human TLR3 
(Figure 3.1). In contrast, the 49bp dsRNA ligand, that supports formation of a single signaling 
unit (2TLR3:1dsRNA), did not induce detectable activation in this assay (Figure 3.1). These 
results are consistent with another study that showed increasing pI:pC length proportionally 
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increased the receptor signaling response [146]. Taken together, this data suggests that individual 
signaling units are not sufficient to induce downstream TLR3 signaling, but rather multiple, 
linked signaling units are required for competent transduction of signal. 
3.3.2 Three high-affinity antibodies generated to probe TLR3 function 
 In order to probe the clustering events of multiple signaling units as they pertain to TLR3 
function, three high-affinity anti-TLR3-ECD mAbs (mAb1068, mAb12, and mAb15) were 
developed and their mechanistic inhibitory modes of action were characterized (Janssen Biotech 
Inc.). The affinities of the Fab fragments of each antibody for TLR3-ECD were shown to be in 
the low picomolar range (Table 3.1).All three mAbs dose-dependently inhibited the TLR3-
mediated pI:pC-induced signals in the luciferase RGA (Figure 3.2). MAb1068 only exhibited 
partial neutralization of pI:pC-induced TLR3 signaling as opposed to complete inhibition by 
mAb12 and mAb15 (Figure 3.2). For the latter two antibodies, the potency of inhibition 
suggested the antibodies may block TLR3-ECD binding to dsRNA. Size-exclusion 
chromatography (SEC) experiments were performed to answer this question using the TLR3-
ECD, a 139bp-dsRNA ligand, and the Fab fragments of mAb12 (Fab12) and mAb15 (Fab15) to 
avoid potential complications of the bivalency of mAbs (Figure 3.3). In these studies, the TLR3-
ECD and a 139bp-dsRNA formed an apparent binary complex as shown by the absence of free 
RNA and TLR3-ECD peaks (T+R, Figure 3.3). Fab15 and Fab12 each formed an apparent 
binary complex with the TLR3-ECD (T+F15, T+F12, respectively) while Fab15, Fab12 and the 
TLR3-ECD were able to form a ternary complex (T+F12+F15). When Fab15 was combined with 
the TLR3-ECD and the 139bp dsRNA ligand (T+R+F15), a peak corresponding to T+F15 was 
apparent suggesting that the dsRNA ligand had been excluded. However, in contrast, Fab12 did 
not form a T+F12 peak when combined with the TLR3-ECD and dsRNA (T+R+F12) suggesting  
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Figure 3.1 Length-dependent induction of NF-kB-driven TLR3 signaling RGA. HEK293T, 
cells transiently expressing human TLR3, stimulated with varying concentrations of pI:pC, 49bp 
dsRNA, 139bp dsRNA, or 540bp dsRNA. 
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that Fab12 and Fab15 used different mechanisms to neutralize pI:pC-induced TLR3 signaling. 
When all four components were mixed (T+R+F12+F15), a peak corresponding to T+F12+F15 
was apparent. Taken together, these data indicated that Fab15 prevented the TLR3-ECD from 
binding to dsRNA, while Fab12 could bind the TLR3-ECD that was bound to dsRNA. From this, 
we concluded that Fab15 inhibited TLR3 signaling by blocking TLR3-ECD binding to dsRNA. 
However, Fab12 neutralized TLR3 function even though a TLR3:dsRNA complex formed. 
3.3.3 Structure of TLR3-ECD + Fab1068 + Fab12 + Fab15  
 To further elucidate the mechanisms by which each mAb neutralized ligand-induced 
TLR3 signaling, a structure of the quaternary complex of the TLR3-ECD, Fab1068, Fab12 and 
Fab15 was determined through a collaboration with Janssen Biotech, Inc. (Figure 3.4). The 
asymmetric unit contained one TLR3-ECD and one molecule of each Fab, all retaining their 
respective unbound structures. Interestingly, in the quaternary structure, each Fab bound a 
unique TLR3-ECD surface (Figure 3.4). While Fab12 was found to bind near the N-terminus of 
the TLR3-ECD on the convex surface of the solenoid from LRRs 3-7, Fab1068 was found to 
target the convex surface of the solenoid from LRRs 16-20 and Fab15 was found to bind the 
non-overlapping epitopes spanning LRRs 15-23 near the C-terminus of the TLR3-ECD.  
3.3.4 Fab15 neutralizes by blocking TLR3:dsRNA binding 
 From the structural characterization of the quaternary complex, it was found that the 
Fab15 binding epitope contained amino acid residues N517, H539 and N541 which are part of 
the C-terminal dsRNA binding site of the TLR3-ECD and have been shown to be critical for 
ligand binding [87, 147]. TLR3-ECD binding of Fab15 would therefore prevent the binding of 
dsRNA which was consistent with SEC data (Figure 3.3) showing that Fab15 forms a dsRNA-
free TLR3-ECD:Fab15 complex in the TLR3-ECD:dsRNA:Fab15 mixture. Thus, Fab15  
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Table 3.1 Fab binding affinity and buried surface area (SA) upon TLR3 binding. 
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Figure 3.2 mAbs inhibit NF-kB driven TLR3 activity induced by pI:pC. The ratios of 
luciferase activity induced by pI:pC between HEK293T cells transfected with a TLR3 expressing 
construct and those transfected with a control Renilla vector in the presence of antibodies are 
shown for (A.) mAb1068, (B.) mAb12, (C.) mAb15 and (D.) a control antibody CNTO3161, 
respectively. PIC: pI:pC. 
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Figure 3.3 Fab15 inhibits TLR3-ECD:dsRNA binding. SEC chromatograms of various 
combinations of TLR3-ECD (T), Fab15 (F15), Fab12 (F12), and 139bp dsRNA (R). Fab15 
forms a dsRNA-free TLR3+Fab15 complex (T+R+F15) indicating that it blocks the TLR3-ECD 
from binding to dsRNA. The excess TLR3-ECD was loaded onto dsRNA. Fab12 molecules were 
completely bound by the TLR3-ECD:dsRNA complex (T+R+F12). In the presence of Fab15, 
Fab12 can form a dsRNA-free TLR3-ECD+Fab15+Fab12 ternary complex (T+F12+F15). 
Components in peak fractions of SEC experiments were confirmed by SDS-PAGE separation 
and Coomassie / silver staining as described in Chapter 3.2.2. Individual chromatographs with 
corresponding SDS-PAGE analysis can be found in Appendix 1. 
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competes with dsRNA for TLR3 binding thereby preventing ligand-induced receptor 
dimerization, which is required for the formation of TLR3 signaling units. This finding further 
corroborates the luciferase RGA results in which mAb15 is able to completely neutralize pI:pC-
induced TLR3 activation (Figure 3.2).   
 
3.3.5 Fab12 and Fab1068 are compatible with the TLR3-ECD:dsRNA signaling unit                  
In contrast to Fab15, the Fab1068 and Fab12 binding sites did not overlap any of the amino acid 
residues involved in dsRNA binding to the TLR3-ECD (Figure 3.4). Based upon the structures of 
the TLR3-ECD:3Fabs and the TLR3-ECD:dsRNA, composite molecular models of Fab12 and/or 
Fab1068 bound to the TLR3-ECD:dsRNA dimer (Figure 3.5A) were generated. The bound 
Fab1068 and Fab12 did not sterically clash with the dsRNA ligand or the TLR3-ECD dimer 
partner in the signaling unit. Additionally, both bound Fabs were nearly parallel to the proposed 
cell membrane surface and would therefore be unlikely to disrupt the orientation of the 
TLR3:dsRNA complex with respect to the membrane surface and subsequent TIR domain 
dimerization. Thus, we predicted that Fab1068 and Fab12 would each be able to bind to a 
signaling unit without disrupting its function. SEC data confirmed this hypothesis as both 
Fab1068 (Figure 3.5B) and Fab12 (Figure 3.5C) were able to bind TLR3:dsRNA complexes. 
Taken together, these data indicate that Fab1068, and similarly Fab12, can bind simultaneously 
to two TLR3 molecules of a signaling unit without preventing dsRNA binding or TLR3 
dimerization. This further indicates that Fab12 and Fab1068 are unlikely to neutralize TLR3 
function by direct inhibition of signaling unit formation.  
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Figure 3.4 Molecular structure of the quaternary complex of TLR3-ECD:3Fabs. Overall 
structure of the complex in ribbon (A.) and surface (B.) representations. TLR3 colored in 
rainbow scheme (blue-to-red for N-to-C), Fab12 in yellow-green, Fab15 in light blue, and 
Fab1068 in blue. Carbohydrates are omitted for clarity. (B.) Distinct binding epitopes are 
highlighted on TLR3. The epitopes are colored on the TLR3-ECD as for the Fabs in (A.). The C-
terminal dsRNA binding site is indicated. The overlap of the Fab15 epitope and dsRNA binding 
site is indicated in cyan.   
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3.3.6 Lateral clustering model of TLR3 signaling                  
From SEC (Figure 3.3) and structural data (Figure 3.4), in collaboration with Janssen Biotech 
Inc., we propose a modified model of TLR3 signaling following ligand induced dimerization 
(Figure 3.6). As discussed in the introduction and alluded to by Leonard et al., longer dsRNA 
ligands are not only important for the induction of TLR3 activity, but they also support TLR3 
multimerization events on a single dsRNA molecule. The apparent affinities of the TLR3-ECD 
for longer dsRNA ligands has also been shown to be much higher than for 49bp dsRNA ligands 
[88], potentially indicating the occurrence of lateral signaling unit interactions and avidity effects 
of multiple binding sites on the longer dsRNA ligands. To interpret our results, we will use a 
model of two adjacent signaling units assembled on dsRNA (Figure 3.6). Binding of Fab12 and 
Fab1068 laterally separates, but does not disrupt, individual signaling units along the dsRNA 
molecules. The Fab-induced signaling unit separation likely provides the neutralizing activity of 
these antibodies and indicates that maintaining a short distance between the signaling units, 
termed “lateral clustering,” is required for TLR3 signaling. Fab12 and Fab1068 neutralized 
lateral clustering by separating the signaling units to avoid steric clashes between bound 
antibody and a neighboring signaling unit. This would suggest that increasing neutralization 
effects of antibodies would be dependent upon the distance between signaling units resulting 
from antibody binding. This separation, however, would not inhibit the basal activity of a single 
signaling unit. As shown in Figure 3.6, Fab12 causes a larger signaling unit separation than 
Fab1068. Fab12’s larger signaling unit separation correlates with mAb12’s ability to consistently 
exhibit greater neutralizing activity than mAb1068 (Figure 3.2) even though Fab12 has a slightly 
lower binding affinity (Table 3.1).  
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Figure 3.5 Fab12 and Fab1068 bind the TLR3-ECD in the TLR3-ECD:dsRNA signaling 
unit. A. Model of Fab1068 and Fab12 binding to a single signaling unit. Fab binding does not 
inhibit dsRNA binding, TLR3 dimerization, or membrane association of TLR3. B. SEC of 
various combinations of TLR3-ECD (T), Fab1068 (F), and 49bp dsRNA (R) indicate the 
presence of the R+T+F ternary complex. C. SEC of various combinations of TLR3-ECD (T), 
Fab12 (F12), and 49bp dsRNA (R) indicate formation of R+T+F12 complex. Components in 
peak fractions of SEC experiments were confirmed by SDS-PAGE separation and Coomassie / 
silver staining as described in Chapter 3.2.2. Chromatograms with corresponding SDS-PAGE 
analysis can be found in Appendix 1.  
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Figure 3.6 Lateral signaling unit clustering mediated TLR3 signaling. Model of two 
signaling units clustered on a 76bp dsRNA ligand (top panel) and separation of signaling units 
(bottom panel) on long dsRNA by Fab1068 and Fab12 due to steric clashes between the 
antibodies and neighboring signaling units. The separation distances were calculated using the 
center of gravity of a group of TLR3-ECD C-terminal atoms. 
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 3.3.7 Experimental support for lateral clustering model                  
 To test the validity of a lateral clustering model which depends upon signaling unit 
distance for competent TLR3 signaling, we carried out neutralization assays in TLR3hi cells that 
stably express TLR3 and the GFP reporter gene driven by NF-kB (Figure 3.7). As opposed to the 
transient TLR3 RGA, short dsRNA ligands were able to generate robust TLR3 activation in this 
cell line (Figure 3.7A). Cells were stimulated with a 49bp (single signaling unit) (Figure 3.7A) or 
540bp (multiple signaling unit binding) (Figure 3.7B) dsRNA ligand in the presence of Fab. 
Fab15 completely inhibited GFP fluorescence induced by both ligands consistent with Fab15 
ability to directly block dsRNA binding to TLR3. In contrast, Fab12 did not significantly inhibit 
49bp dsRNA (single signaling unit)-induced fluorescence, as predicted by our structural analysis 
that shows Fab12 does not affect formation of individual signaling units. In contrast, Fab12 did 
partially inhibit 540bp dsRNA-induced fluorescence. This, we postulate, is due to Fab12 altering 
the distance between individual signaling units. These results were further corroborated in an 
NF-B luciferase RGA in HEK293 cells transiently expressing human TLR3, where both Fab15 
and Fab12 strongly inhibited the RGA luciferase activity induced by pI:pC in a dose dependent 
manner (Figure 3.7C). Taken together, these results are consistent with the model in Figure 3.6 
in which Fab12 (and Fab1068 by inference) reduces TLR3 signaling via disruption of signaling 
unit-signaling unit interactions but has little impact on signaling from the single signaling unit. 
3.3.8 Lateral clustering study concluded                  
 Prior to this study, the functional differences observed between short (~48bp) dsRNA 
ligands that form a single signaling unit and longer (>~90bp) dsRNA ligands with multiple  
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Figure 3.7 Antibody inhibition of TLR3 activation induced by dsRNA and pI:pC. Fab15 
completely inhibits fluorescence of TLR3hi cells (A. and B.). Fab12 partially inhibits signal 
induced by 540bp dsRNA (B.) and has no significant impact on that of 49bp dsRNA (A.). 
Percentage of GFP-positive cells after 48h treatment with dsRNA (49bp or 540bp) ± antibody 
treatment as indicated. Error bars indicate mean and SEM from three independent experiments. 
Tests for significant differences were performed by Bonferroni posttests of one-way ANOVA. 
NS, not significant. C. Fab15 and Fab12 nearly completely inhibit pI:pC-induced TLR3 
signaling in NF-kB RGA in HEK293 cells with transient TLR3 expression. 
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signaling units docked to the ligand could not be addressed by a single signaling unit structure. 
Through structural and functional studies of TLR3, utilizing neutralizing antibodies, we provide 
evidence for a new TLR3 signaling model in which dsRNA:TLR3 signaling units laterally 
cluster to achieve efficient signaling. While multimerization events do not contribute to single 
signaling unit signal transduction, we show here that the requirement for multiple signaling units 
on longer (>~90bp) dsRNA ligands is mediated by our novel lateral clustering mechanism. This 
mechanism is critical for competent TLR3 signaling in response to longer dsRNA ligands and 
may be a mechanism by which other TLR proteins mediate downstream signaling cascades.      
 
 
 
 
 
 
 
 
 
 
 
97 
 
 
 
 
 
 
 
 
Chapter IV 
SIKE: A Novel TBK1 Substrate and 
Endogenous Regulator of the Type-I 
Interferon Response 
 
 
4.1 Introduction 
 Inhibitor of B kinases (IKKs) are essential regulators of innate immunity, inflammation, 
cell proliferation and apoptosis [109]. Canonical IKK signaling is mediated by the IKK complex 
consisting of two kinases, IKK and IKK, and the regulatory scaffold, NEMO [148]. As 
discussed in Chapter 1.7, the canonical IKKs activate the transcription factor NF-B by 
phosphorylating the inhibitor of B proteins. This post-translational modification releases NF-
B from an inhibitory complex and permits its translocation to the nucleus where it mediates 
gene transcription.  
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 In addition to the IKK and IKK kinases, the IKK kinase family contains two non-
canonical family members, a constitutively expressed serine/threonine kinase, TBK1, and an 
expression inducible serine/threonine kinase, IKK (largely immune-cell specific) [101]. In 
response to receptor-mediated pathogen detection, these kinases play distinct roles in inducing 
type I interferon production and modulating NF-B signaling. In addition, several substrates 
have been identified that implicate these kinases in functions ranging from insulin response and 
cell growth to xenophagy.  
 Increasingly, however, dysregulation of the non-canonical members of the IKK family 
has been linked to autoimmune disorders and cancers. IKK has been shown to be up-regulated 
in breast, ovarian and prostate cancer cell lines as well as in patient-derived tumors [149]. TBK1 
has been implicated in KRAS-signaling dependent cancers, such as colorectal and lung cancer, 
as RALB-mediated activation of TBK1 has been shown to promote cancer cell survival [150]. 
Furthermore, studies have found that viruses, such as Hepatitis C (HCV), the Vaccinia virus 
(VACV) and certain Hantaviruses have evolved to target these kinases in order to evade immune 
pathway activation and subsequent anti-viral responses [22]. These findings have elevated the 
need to understand regulatory controls of kinase activity in an effort to therapeutically 
manipulate the pathways involved in aberrant kinase activity.  
 To control the activity of TBK1, the study presented herein focuses on the 207 amino-
acid protein termed SIKE, which, as discussed in Chapter 1.8, was previously characterized as an 
endogenous inhibitor of the TLR3 signaling cascade. Using a multitude of biophysical 
techniques and cell-based assays, this document explores the undefined mechanism by which 
SIKE inhibits the type-I interferon response and, the regulatory release mechanism of SIKE from 
99 
 
TBK1 mediated by viral activation of the TLR3 signaling cascade. Additional experiments 
attempt to elucidate the potential role of SIKE following its release from TBK1. Taken together, 
this study not only highlights potential therapeutic targets in the type-I interferon response, but 
also establishes a novel role for a critical member of the TLR3 signaling cascade.          
 
4.2 Materials and Methods 
4.2.1 Reagents 
 Chemicals were purchased from Sigma-Aldrich unless otherwise specified.  -32P-ATP 
was purchased from Perkin Elmer.  Recombinant TBK1 was purchased from Life Technologies.  
Anti-phospho-serine antibody was purchased from Qiagen.  Anti-FLAG-HRP was purchased 
from Sigma-Aldrich.  Anti-HA antibody was purchased from Covance.  Anti-full-length IRF3 
and anti-actin-HRP antibodies were purchased from Santa Cruz.  Anti-phospho-S396 IRF3 
antibody was purchased from Cell Signaling.  Anti-rabbit-IgG-HRP and anti-mouse-IgG-HRP 
antibodies were purchased from Southern Biotechnology Associates, Inc. pFLAG-CMV5a-IRF3 
was a gift from Dr. T. Kordula. 
4.2.2 Cell Culture 
 HEK293 cells were purchased from American Type Culture Collection.  Cells were 
cultured in complete medium (RPMI 1640 supplemented with 10% low-endotoxin FBS, 20mM 
L-glutamine, 100mM HEPES, 10mM Na-pyruvate, and 1X nonessential amino acid solution) at 
37
o
C in 5% CO2. 
4.2.3 Constructs 
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 The human SIKE sequence was cloned from total RNA isolated from the 786O cell line 
using the OneStep RT-PCR kit according to the manufacturer’s protocol (Qiagen).  The primers 
incorporated a 5’ NdeI restriction enzyme site (5’-
ATTATCATATGAGCTGCACCATCGAGAAGATC-3’) and a 3’ BamHI restriction enzyme 
site (5’-TAATAGGATCCTTATTTGATGGCTTGGGAAGC-3’) compatible with insertion into 
the pET15b vector (Novagen).  The SIKE72 construct (residues 72-207) was amplified using 5’- 
TATACATATGCTGCTGTCCCAAGAGAAC-3’ and inserted into the pET15b vector using the 
same strategy.  Full-length SIKE was amplified from FL-SIKE pET15b using standard molecular 
biology techniques with primers including a 5’ EcoRI restriction enzyme site (5’- 
TATAGAATTCAGAGCTGCACCATCGAGAAG-3’) and 3’ SalI restriction enzyme site (5’- 
TATAGTCGACTTATTTGATGGCTTGG-3’) compatible with insertion into the pCMV HA 
vector (Clontech).  SIKE113-207 was amplified from FL-SIKE pET15b using standard 
molecular biology techniques and primers with a 5’ EcoRI restriction enzyme site (5’- 
TATAGAATTCGGTTACAGTTAATGGTTGC-3’) or 5’ NdeI restriction enzyme site (5’- 
TATACATATGTTACAGTTAATGGTTGC-3’) and the 3’ primer used for FL-SIKE pCMV HA 
or pET15b compatible with insertion into the pCMV HA or pET15b vector, respectively.  SIKE 
point mutations (S133A/E, S185A/E, S187A/E, S188A/E, S190A/E, S198A/E) and insertions 
(stop codons after 112 (SIKE 1-112), 184 (SIKE72-184) and N-terminal FLAG sequence into 
pUNO-TBK1 vector (Invivogen) were made using the Quikchange site-directed mutagenesis kit 
following the manufacturer’s protocol (Agilent Technologies).  All constructs and mutations 
were confirmed by DNA sequencing.  GST-IRF3 173-427 pGEX4T1 vector was a kind gift from 
Dr. Katherine Fitzgerald. 
4.2.4 Expression and purification of proteins 
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 For pET15b SIKE72 construct expression, vector was transformed into chemically 
competent BL21-CodonPlus (DE3)-RIPL following the manufacturer’s protocol (Agilent 
Technologies).  A single colony was used to inoculate an overnight culture of Luria broth (LB) 
plus 100 g/ml ampicillin.  The overnight culture was sub-cultured, 1:100, into 2-1L LB/amp 
flasks grown at 37°C until the cell density reached an A600  0.6.  Cultures were induced with 1 
mM isopropyl--D-galactopyranoside (IPTG) and allowed to grow for an additional 4 hours at 
37°C. Cells were harvested by centrifugation at 7,000 xg and the pellet solubilized in guanidine 
hydrochloride (GudHCl) buffer (6 M guanidine hydrochloride, 100 mM sodium phosphate (pH 
8.0), 500 mM NaCl and 1 mM 2-mercaptoethanol) (5ml buffer/g of cell pellet).  Lysate was 
clarified by centrifugation at 14,000 xg.  The supernatant was mixed with 5ml Ni-NTA agarose 
resin (Qiagen), pre-equilibrated in GudHCl buffer. The lysate-resin mixture was loaded into a 
column (BioRad) and washed by gravity with 50 column volumes (CV) of GudHCl buffer.  
Bound protein was refolded on the column using a 40-CV reverse gradient of GudHCl buffer to 
100 mM sodium phosphate (pH 8.0), 500 mM NaCl and 1 mM 2-mercaptoethanol (Buffer 1) and 
eluted with 5-CV of Buffer 1 plus 500 mM imidazole.  Elution fractions were separated on a 
HiLoad 16/60 Superdex 200 column (GE Healthcare) and peak fractions screened for target 
protein by SDS-PAGE analysis.  CD experiments of WT and mutant SIKE72 proteins indicated 
primarily helical secondary structure (Figure 4.1A), consistent with a predicted coiled coil 
domain structure, while a thermal melt denaturation experiment of WT SIKE72 revealed a ≥ 
two-state unfolding curve typical of globular proteins (Figure 4.1B). 
 For GST-IRF3 173-427 expression, pGEX4T1-IRF3 173-427 was transformed into 
chemically competent BL21-CodonPlus (DE3)-RIPL cells following the manufacturer’s protocol 
(Agilent Technologies).  Cell culture was identical to pET15b expression prior to induction.  
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When cell density reached A600  0.6, cultures were incubated on ice for 30 minutes, induced 
with 1 mM IPTG, and allowed to grow at 16°C for an additional 14 hours.  Cells were harvested 
by centrifugation at 7,000 xg and the cell pellet was resuspended in Buffer A (2X PBS, 10mM 
DTT, 1mM EDTA), 5ml buffer/g of cell pellet. Cells were emulsified to lyse (Emulsiflex C3, 
Avestin) and clarified by centrifugation at 12,000 xg.  The supernatant was mixed with 
glutathione Sepharose 4b resin pre-equilibrated in Buffer A (5 mL)(GE Healthcare).  The resin-
supernatant solution was loaded into a column (Biorad) and washed by gravity with 100 CV 
Buffer A, 100 CV 20 mM Tris, pH 7.5, 500 mM NaCl, 1 mM EDTA, 10 mM DTT, 10% 
glycerol (Buffer B) and eluted with 2-5CV fractions of Buffer B plus 10 mM glutathione (pH 
8.0).  The elution fractions were concentrated in an Amicon Ultra-15 centrifugal filter 
(Millipore) to 6 mg/ml.  GST-IRF173-427 was incubated with 20U/ml thrombin (GE Healthcare) 
for 24 h at 4°C.  IRF3 173-427 was separated from GST using a HiLoad 16/60 Superdex 75 
column (GE Healthcare) equilibrated in 20 mM HEPES, pH 7.5, 500 mM NaCl, 1 mM 2-
mercaptoethanol.  Peak fractions were screened for cleaved, pure IRF3 173-427 by SDS-PAGE 
analysis.  Fractions were pooled and stored at 4°C. 
Protein concentrations were determined using the Bradford method (BioRad). 
4.2.5 In vitro kinase assays: TBK1 activation and linear range controls 
 TBK1 (Life Technologies) was pre-activated (S172 phosphorylated) through 
auto/transphosphorylation prior to kinetic assays. To determine the optimal pre-incubation time, 
a time course following 
32
P incorporation into TBK1 was completed. TBK1 (4.93 nM) in 50 mM 
Tris, pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.025% Triton-X 100 (assay buffer) was incubated   
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Figure 4.1 Characterization of WT and mutant SIKE72. Recombinant WT SIKE72, S6A 
SIKE72 and S6E SIKE72 were dialyzed into 5mM NaH/H2PO4, pH 8.0 and 0.15M NaCl and 
diluted to ~1 mg/mL. A. CD sprectra were collected on a Jasco 720 Circular Dichroism 
spectrophotometer. Five scans were accumulated, buffer subtracted and smoothed using the Jasco 
spectra manage software. B. Ellipticity at 222 nm was monitored over the temperature range of 
4-90oC. The thermal melt was completed on the sample used in A. Increases in temperature were 
controlled by a Peltier cell holder set to 1o increase/minute. 
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with 100 μM ATP plus 0.1 mCi γ-32P-ATP at 30°C for 240 minutes (200L total volume). 20L 
aliquots were removed at indicated times and the reaction was terminated by the addition of SDS 
loading dye (Invitrogen) and boiling for 10 minutes at 98°C. Duplicate samples (10L) were 
separated by SDS-PAGE on a 4-12% Bis-Tris polyacrylamide gel (Life Technologies). Gels 
were mounted on filter paper and exposed to a storage phosphor screen (Imaging Screen K, 
BioRad). The screen was read by a Molecular Imager FX system (BioRad). Band densitometry 
was measured and converted to 
32P μM via a γ-32P-ATP standard curve. Incorporation of 32P into 
TBK1 stabilized at 25 minutes (Figure 4.2).  
 Initial rate parameters for TBK1 phosphorylation of IRF3 were also established. 20L 
aliquots from a reaction (250L total volume) containing 20 μM IRF3 173-427, 100 μM ATP, 
0.1 mCi γ-32P-ATP and 4.93 nM TBK1 (preactivated for 30 minutes with 100 mM “cold” ATP) 
in assay buffer were taken at the indicated times and reaction terminated as described above. 
Duplicate samples (10L) were analyzed for 32P-IRF3 as described above. The initial rate 
remained linear between 5-200 minutes (Figure 4.3). 
 
4.2.6 In vitro kinase assays: Experimental  
 Michaelis-Menten kinetic assay reactions (50 l volume) contained 0.1 mCi -32P-ATP, 
100 M ATP and 0.042-20.8 M IRF3 173-427 for IRF3 varied assays; 0.1 mCi -32P-ATP, 20 
M IRF3 173-427 and 0.48-83 M ATP for ATP varied assays; and 0.1 mCi -32P-ATP, 100 M 
ATP and 0.043-8.4 M SIKE72 for SIKE varied assays.  Reactions were initiated by addition of 
29.6 nM TBK1 (10 L, 4.93 nM final concentration, pre-activated for 30 minutes with 100 M 
ATP in assay buffer, Figure 4.2).  For ATP varied reactions, excess cold ATP from pre-  
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Figure 4.2 Control experiment investigating the activation of TBK1. Activation of TBK1 via 
autophosphorylation at S172 is required for in vitro experiments. TBK1 (4.93 nM) was incubated 
with ATP (100 M) for 240 minutes at 30oC. At indicated times, 20 L aliquots were collected 
and the reaction stopped by addition of 4X Loading Dye sample buffer and boiling at 98
o
C for 
10 minutes. Reactions were analyzed as described in Chapter 4.2.5.       
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Figure 4.3 Control experiment investigating initial rate parameters for the TBK1-mediated 
phosphorylation of IRF3. Initial rate kinetic parameters were determined from a reaction 
containing IRF3 (20 M), ATP (100 M), and TBK1 (4.93 nM) and incubated for 720 minutes 
at 30
o
C. At indicated times, 10 L aliquots were collected and the reaction stopped by the 
addition of 4X Loading Dye sample buffer and boiling at 98
o
C for 10 minutes. Reactions were 
analyzed as described in Chapter 4.2.5.  
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activation of TBK1 was removed by desalting column (Zeba spin, 7 MWCO, 2 ml -Pierce) prior 
to initiating reactions.  Reactions were incubated for 120 minutes at 30°C (determined in Figure 
4.3) and terminated by boiling in reducing SDS sample buffer (20 L, Life Technologies).  
Duplicate samples (10 L ea.) were separated by SDS-PAGE on a 4-12% Tris-Bis-Tris 
polyacrylamide gel (Life Technologies).  Gels were mounted on filter paper and exposed to a 
storage phosphor screen (Imaging Screen K, BioRad).  The screen was read by a Molecular 
Imager FX system (BioRad).  Band densitometry was measured and converted to 
32
P M via a -
32
P-ATP standard curve.  Inhibition experiments were carried out using the assay methodology 
described for IRF3 varied and ATP varied assay with the addition of SIKE72 at 20.8 or 83.3 nM 
final concentration.  All reactions were analyzed by SDS-PAGE/autoradiography as described 
above.  A minimum of quadruplicate repeats was completed for each reaction.  Data were plotted 
as a Michaelis-Menten plot or double reciprocal plots and fit to a single rectangular hyperbola or 
linear polynomial equations, respectively, in SigmaPlot (Systat Software, Inc.).  Errors were 
reported as standard deviation.  From the intercepts and slopes derived from the double 
reciprocal plot fit to a linear polynomial, inhibition constants were calculated for the SIKE + 
ATP or IRF3 varied data using: 
         Inh           none   (
[ ]
 i
)   (1) 
 
     Inh       none   (
[ ]
 i
)   (2) 
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To examine inhibition of IRF3 phosphorylation by SIKE72, 4.17 M IRF3 173-427, 100 M 
ATP, 0.1 mCi -32P-ATP and SIKE72 or SIKE72 mutant, at indicated concentrations, were 
prepared in assay buffer (50 L volume).  TBK1 (10 L of 29.6 nM, 4.93 nM final 
concentration) pre-activated as above, was added to initiate the reaction.  Reactions were 
incubated at 30°C for 120 minutes and analyzed as described above to derive initial rates for 
IRF3 173-427 phosphorylation.  Data were plotted as the percentage of uninhibited reaction rate 
versus SIKE72 concentration.  Errors were reported as standard deviation. To derive the Ki,app 
parameter, inhibited reaction rate versus SIKE72 or SIKE72 mutant concentration was fit to a 2-
parameter rectangular hyperbola. 
4.2.7 DNA transfection, immuneprecipitation and immunoblot analysis  
 Approximately 0.5 × 10
6
 cells were plated into 10 cm
2
 wells and transfected with 2.5 μg 
total DNA of the different expression plasmids (1:0.9:0.6 ratio of( pUNO-FLAG-TBK1 or 
mTurq-TBK1 or FLAG-IRF3 or HA-SIKE):pCDNA3.1:pCMV-HA-SIKE) using Lipofectamine 
2000 following the standard procedure (Life Technologies).  After 24 h, cells were stimulated 
with 50 g/ml polyinosinic:polycytidylic acid (pI:pC) for 3 hours, harvested and lysed in a lysis 
buffer (200 l, 0.02 M HEPES, pH 7.4, 0.15 M NaCl, 10 mM NaF, 2 mM DTT, 2 mM EGTA, 
1.5 mM MgCl2, 1 mM Na3VO4, 2.7 mg/ml -glycerophosphate, 1 mg/ml N-ethylmaleimide, 
0.5% Triton-X100, 1X Complete, EDTA-free protease inhibitor cocktail (Roche)).  Lysates were 
cleared by centrifugation (14,000 xg for 30 minutes at 4°C).  Protein concentration was 
quantified by Bradford method (BioRad).  For whole cell lysates, 50 g of total protein per 
sample were boiled in sample buffer (Life Technologies), and separated by SDS-PAGE (10% 
Tris-Glycine) and transferred to nitrocellulose membrane.  The membrane was blocked in 5% 
non-fat dry milk diluted in Tris-buffered saline (TBS) containing 0.1% Tween20 and probed 
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with indicated antibodies.  Blots were developed with chemiluminescent reagents, ECL Plus (GE 
Healthcare).  For immunoprecipitations, cell lysates (500 g) were incubated with 40 L of anti-
FLAG M2 antibody affinity gel (Sigma Aldrich) for 24 hours in TBS at 4°C.  Resin was washed 
with TBS (3x1mL) and bound proteins eluted with 100 L of 125ng/L FLAG peptide (Sigma 
Aldrich).  Eluted proteins were analyzed by immune-blot as described above.  Each experiment 
was repeated in triplicate. 
 
4.2.8 Characterization of phosphorylation by MALDI-TOF  
 Protein (500 nM SIKE72, 5000 nM IRF3 173-427, 714 nM gMDH) was incubated with 
4.93 nM TBK1 and 100 μM ATP for indicated times at 30°C. Reactions were terminated by 
addition of an equal volume of 6 M guanidine hydrochloride and target protein recovered by 
absorbtion onto Ni-NTA resin. Proteins were eluted from Ni-NTA as described above, desalted 
and concentrated using a ZipTipC4 (Millipore). ZipTipC4 eluent was mixed 1:1 with -cyano-4-
hydroxycinnamic-acid and spotted onto a Scout49 target. Data were collected on a Bruker 
OmniFlex MALDI-TOF mass spectrometer. Spectra for time points 0, 24 and 96 hours were 
recorded. 
 
4.2.9 Phospho-peptide mapping 
 Recombinantly expressed SIKE72 (500 ng) was incubated with TBK1 (4.93 nM) and 
ATP (100 M) in assay buffer (100 L volume) for 24 hours at 30°C.  The reaction was 
terminated by diluting the reaction 1:1 with 6M GudHCl buffer.  SIKE72 was isolated from the 
reaction by incubation with 40 L of Ni-NTA resin, washed with GudHCl buffer and bound 
SIKE eluted with 50 L of GudHCl buffer plus 0.5 M imidazole.  Eluent was separated by SDS-
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PAGE (10% Tris-Glycine) and target band excised for analysis. The band was submitted for 
analysis to the Chemical and Proteomic Mass Spectrometry VCU Core (Dr. K.T. Nelson). The 
method for analysis was as follows: The gel slice was washed and de-stained in 200µL 50% 
methanol overnight.  The gel pieces were dehydrated in acetonitrile, rehydrated in 30µL of 
10mM dithiothreitol in 0.1M ammonium bicarbonate and reduced at room temperature for 30 
minutes.  The DTT solution was removed and the samples were alkylated in 30µL 50mM 
iodoacetamide in 0.1M ammonium bicarbonate at room temperature for 30 minutes.  The reagent 
was removed and the gel pieces were dehydrated in 100µL acetonitrile.  The acetonitrile was 
removed and the gel pieces were rehydrated in 100µL 0.1M ammonium bicarbonate.  The pieces 
were dehydrated in 100µL acetonitrile, the acetonitrile removed and the pieces completely dried 
by vacuum centrifugation.  The gel pieces were rehydrated in 1µg trypsin in 50 mM ammonium 
bicarbonate on ice for 10 min.  Any excess trypsin solution was removed and 20µL 50mM 
ammonium bicarbonate added.  The samples were digested overnight at 37
o
C and the peptides 
that were formed were extracted from the polyacrylamide in two 30µL aliquots of 50% 
acetonitrile/5% formic acid.  Extracts, evaporated to 15 L, were separated by C18 reversed-
phase capillary column (Waters NanoAcquity) coupled with nanospray tandem mass 
spectrometry (LTQ-Orbitrap hybrid, Thermo Electron).  The digest was analyzed using the 
double play capability of the instrument acquiring full scan mass spectra to determine peptide 
molecular weights and product ion spectra to determine amino acid sequence in sequential scans.  
The data were analyzed by database searching using the Sequest search algorithm against custom 
databases generated from the SIKE72 sequence.  All potential phosphor-peptides were manually 
examined for correct identification of the modified site. 
4.2.10 Tandem mass spectrometry for identification of SIKE interaction network 
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 Approximately 0.5 × 10
6
 cells were plated into 10 cm
2
 wells and transfected with 4 μg 
pCMV-HA-SIKE using Lipofectamine 2000 following the standard procedure (Life 
Technologies).  After 24 h, cells were stimulated with 50 g/ml polyinosinic:polycytidylic acid 
(pI:pC) for 3 hours, harvested and lysed in a lysis buffer (200 l, 0.02 M HEPES, pH 7.4, 0.15 M 
NaCl, 10 mM NaF, 2 mM DTT, 2 mM EGTA, 1.5 mM MgCl2, 1 mM Na3VO4, 2.7 mg/ml -
glycerophosphate, 1 mg/ml N-ethylmaleimide, 0.5% Triton-X100, 1X Complete, EDTA-free 
protease inhibitor cocktail (Roche)).  Lysates were cleared by centrifugation (14,000 xg for 30 
minutes at 4°C).  Protein concentration was quantified by Bradford method (BioRad). For 
immunoprecipitations, cell lysates (500 g) were incubated with 50 L of monoclonal-Anti-HA 
agarose for 24 hours in PBS at 4°C.  Resin was washed with PBS (3x1mL) and bound proteins 
incubated with 120 L of 0.1M glycine-HCl, pH 2.5 for 8 hours (elution). Following incubation, 
resin was pelleted at 12000xg for 2 minutes and the supernatant was added to 40 L of 1M Tris 
buffer, pH 8.0.  Quality of IP was analyzed via SDS-PAGE gel / silver-stain. Remaining 
solutions (~500 L) were submitted for analysis to the Chemical and Proteomic Mass 
Spectrometry VCU core (Dr. K.T. Nelson). The method for analysis was as follows: Solutions 
were diluted to 150 L with 100mM ammonium bicarbonate to reduce the concentration of salts 
prior to digestion. Samples were reduced with 5 L of 10mM dithiothreitol in 0.1M ammonium 
bicarbonate at room temperature for 30 minutes. Samples were then alkylated with 5 L 50mM 
iodoacetamide in 0.1M ammonium bicarbonate at room temperature for 30 minutes. Samples 
were then digested with 1 g trypsin overnight and then quenched with 5% (v:v) glacial acetic 
acid. Sample analysis was completed on an LC-MS system consisting of a Thermo Electron 
LTQ-Orbitrap hybrid mass spectrometer with a nanospray ion source interfaced to a Waters SCX 
trap column and a Waters NanoAcquity C18 reversed-phase capillary column. Seven L of the 
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final solution was injected onto the trap column, and the peptides were eluted from the column 
by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.4 L/min over 60 minutes. The 
nanospray ion source was operated at 3.5kV. The digests were analyzed using the double play 
capability of the instrument acquiring full scan mass spectra to determine amino acid sequence in 
sequential scans. This mode of analysis produces approximately 10000 CAD spectra of ions 
ranging in abundance over several orders of magnitude. Final data analysis was done by database 
searching using the Sequest search algorithm against the IPI Human database.  
 
4.2.11 Cell lysate separation into nuclear and cytoplasmic fractions  
 HEK293 cells, transiently transfected with S6A SIKE72 or S6E SIKE72, were stimulated 
with 50 g/mL pI:pC. Cells were harvested by washing with ice cold 1X PBS and placed in a 
microcentrifuge tube. Cells were then pelleted via centrifugation at 2000 xg for 3 minutes and the 
supernatant removed. Cells were then gently resuspended in 400 L of cold Solution A (0.01M 
Hepes, pH 7.8, 0.01M KCl, 0.1mM EDTA, 1mM NaVO4, 1mM DTT, and 1X complete protease 
inhibitor). Cells were incubated on ice for 15 minutes. Following the incubation period, Solution 
B (10% IGEPAL) was added to create a final IGEPAL percentage of 0.7% (30 L Solution B to 
400 L Solution A). Cells were immediately vortexed for 10 seconds and pelleted at 14000 xg 
for 30 seconds at 4
o
C. Following this centrifugation step, the supernatant was transferred to a 
new tube as it was the soluble cytosolic fraction (leaving 15L to avoid contamination with 
pelleted nuclear fraction) . The remaining pelleted material was then resuspended in Solution A 
and washed three times (pelleted at 14000xg for 30 seconds at 4
o
C between washes and 
supernatant discarded). Following the final wash, 50 L of ice cold Solution C (0.02M HEPES, 
pH7.8, 0.4M NaCl, 1mM EDTA, 1mM EGTA, 1mM NaVO4, 1mM DTT, and 1X complete 
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protease inhibitor) was added to the pelleted material and the pellet gently resuspended. The 
solution was placed on ice for 15 minutes with gentle agitation every 2-3 minutes. The solution 
was then spun at 14000 xg for 5 minutes and the supernatant transferred to a new tube as it was 
the soluble nuclear extract fraction. Both cytosolic and nuclear fractions were stored at -80
o
C.      
 
4.3 Results and Conclusions 
4.3.1. SIKE acts as a mixed-type inhibitor in the TBK1-mediated phosphorylation of IRF3 
 SIKE was originally classified as a physiological suppressor of TBK1 [126]. In response 
to viral or dsRNA stimulation, overexpression of SIKE disrupted TBK1 interactions within the 
dsRNA receptor pathways, including the upstream adaptor TRIF and the kinase’s downstream 
substrate IRF3 [126]. Although IRF3 phosphorylation is essential for the anti-viral response, the 
mechanism by which SIKE selectively represses the type-I interferon response remains 
undefined. 
 Our studies into the mechanism of SIKE’s inhibitory activity focused on the TBK1-
mediated phosphorylation of IRF3. The IRF3 construct used in these studies included residues 
173-427, encompassing the IRF3 activation domain and TBK1 phosphorylation sites (residues 
385, 386, 396, 398, 402, 404, and 405). The Michaelis-Menten plot of IRF3 as the varied 
substrate gave initial kinetic parameters for KM (Michaelis constant) and VMAX (maximum 
velocity) as 2.69 M and 10.5 nM/min reaction, respectively (Figure 4.4A, Table 4.1). Similarly, 
using ATP as the varied substrate, initial kinetic parameters for the KM and VMAX values of the 
reaction were 35.3 M and 12.3 nM/min reaction respectively (Figure 4.4B, Table4.1). To 
examine the effect of SIKE72 on IRF3 phosphorylation, SIKE72 was added at ~20 nM and ~80 
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nM to the IRF3 varied or ATP varied (Figure 4.4C,D) assays. The primary effect of SIKE72 for 
IRF3 varied reactions occurred on VMAX (~1.8 fold decrease), indicative of a non-competitive 
inhibitor (Table 4.1). Interestingly, the KM and VMAX values calculated from double reciprocal 
plots of the ATP varied reactions indicated a 2.2-3.0 fold change in both KM and VMAX consistent 
with a mixed-type inhibitor (Table 4.1).The Ki,app values were calculated from the double 
reciprocal plot slope and intercept parameters using equations 1 and 2, described in Chapter 4.2.6 
(Table 4.2).  
4.3.2 TBK1 directly phosphorylates SIKE in vitro 
 TBK1-mediated 
32
P incorporation was assessed by phosphor K screen of SDS-PAGE 
separated reactions with saturating ATP (100 M), IRF3 held constant at 5 M (~KM value), and 
increasing SIKE72 concentrations (5-5000 nM). Analysis of the -32P-ATP kinase assays 
revealed two 
32
P-labeled species corresponding to IRF3 and SIKE72 (Figure 4.5A). Inhibition of 
TBK1-mediated phosphorylation of IRF3 was apparent at 500nM SIKE72, 10 fold less than the 
substrate concentration. Moreover, as IRF3 phosphorylation diminished, SIKE72 
phosphorylation increased (Figure 4.5A) suggesting that SIKE had a competitive nature 
associated with its inhibitory mode of action.  
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Figure 4.4 SIKE is a non-competitive inhibitor of TBK1. A.  Michaelis-Menten plot of TBK1-
mediated phosphorylation of IRF3 with saturating ATP (100 μM), pre-activated TBK1 (5.6 nM) and IRF3 
varied from 0.042-20.8 μM. Data were fit to a 2-parameter rectangular hyperbola (SigmaPlot). B. 
Michaelis-Menten plots of TBK1 phosphorylation of IRF3 with increasing SIKE (0-83nM) fit to a single 
rectangular 2-parameter hyperbola curve (SigmaPlot). C. Michaelis-Menten plot of TBK1 mediated-
phosphorylation of IRF3 with saturating IRF3 (20.8 μM), pre-activated TBK1 (5.6 nM) and ATP varied 
from 0-150 μM. Data were fit to a 2-parameter rectangular hyperbola (SigmaPlot). D. Michaelis-Menten 
plots of TBK1 phosphorylation of IRF3 (20.8 μM) with ATP varied (0.08-150 μM) and increasing SIKE 
(0-83 nM) fit to a single rectangular, 2-parameter hyperbola curve (SigmaPlot). Circle, no SIKE; 
Triangle, 20.8 nM SIKE; Square, 83 nM SIKE. E. Lineweaver-Burk plots of TBK1-IRF3 assays with 
ATP IRF3 varied from 0.042-20.8M, 100M ATP. Data for 0.042-0.42M and 1.7-20.8M IRF3 were 
fit to a linear polynomial equation (Sigma Plot). F. Lineweaver-Burk plots of TBK1-IRF3 assays with 
ATP varied from 0.08-150M, 20.8M IRF3. Data were fit to a linear polynomial equation (Sigma Plot).  
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Table 4.1 Michaelis-Menten and LineWeaver-Burk derived kinetic parameters 
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4.3.3 DsRNA stimulates SIKE phosphorylation in vivo and dissociates a TBK1-IRF3-SIKE 
complex 
 With the observation that SIKE is phosphorylated in vitro, but kinetic characterizations 
suggesting that SIKE functioned as a non-competitive inhibitor, we examined whether this post 
translational modification occurred in vivo. In HEK293 cells transiently transfected with HA- 
epitope-tagged WT-FL SIKE, serine phosphorylation of WT-FL SIKE was observed following 
stimulation with pI:pC (Figure 4.5B).  
 From these results, taken together with the in vitro data discussed previously (Figure 
4.5A), we next examined the effect of SIKE on the TBK1:IRF3 interaction required for 
competent TLR3 signaling. In HEK293 cells transiently transfected with mTurq (GFP variant)-
tagged TBK1, FLAG-tagged IRF3 and HA-tagged SIKE72, co-IP/immunoblot analysis revealed 
that prior to pathway stimulation, a TBK1-IRF3-SIKE complex existed (Figure 4.6). Upon 
dsRNA stimulation, however, SIKE was shown to be released from this complex (Figure 4.6) 
meaning that in the absence of over-expressed TBK1, SIKE is excluded from a TBK1:IRF3 
complex. Interestingly, IRF3 remained bound to TBK1 following dsRNA stimulation suggesting 
that a hetero-substrate may be bound to the two active sites of TBK1. While these results cannot 
rule out SIKE as a truly competitive inhibitor, this data raises the possibility that the release of 
SIKE from TBK1, upon pathway stimulation, may be mediated by the post-translation 
modification observed both in vitro (Figure 4.5A) and in vivo (Figure 4.5B). 
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Table 4.2 Parameters for SIKE inhibition of TBK1 mediated IRF3 phosphorylation 
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Figure 4.5 SIKE is directly phosphorylated by TBK1. A. SIKE (5-5000 nM) was added to the 
TBK1 assay containing 5 M IRF3 (~Km concentration), 100 M ATP and 4.93 nM TBK1.  
Reactions were completed and analyzed as described in Chapters 4.2.6 and 4.2.7.  O = p-IRF3; 
= p-SIKE.  B. HEK293 cells were transiently transfected with HA-SIKE.  Cells were 
stimulated for 3 hours with pI:pC (50 g/ml).  HA-SIKE was immunoprecipitated from lysates 
with -HA resin.  Total and phospho-Serine SIKE was assessed via Western blot using -HA or 
-pSer antibody, respectively.  One representative experiment is shown. 
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4.3.4 TBK1 phosphorylates SIKE on six serine residues that mimic the IRF3 
phosphorylation motif 
 TBK1 prefers a hydrophobic residue following the targeted serine/threonine (S/T) residue 
as noted in Chapter 1.7. In SIKE, 23 S/T residues occur in the protein sequence of which 11 
conform to the preferred S/T-hydrophobic residue motif for TBK1 phosphorylation. To 
determine the number of TBK1-mediated SIKE phosphorylation sites, we assessed TBK1-
mediated phosphorylation by MALDI-TOF mass spectrometry. Over a 96 hour time course, we 
observed a mixture of singly to triply phosphorylated SIKE72 (Figure 4.7A). Under the same 
conditions, single to 7 out of 7 known IRF3 phosphorylation sites were modified, whereas 
glyoxosomal malate dehydrogenase, not known to be phosphorylated by TBK1 but containing 16 
preferred S/T motif sites out of 36 total S/T residues, remained unmodified (Figure 4.7B,C). To 
identify the positions of TBK1-mediated phosphorylation in SIKE72, we completed phosphor-
peptide mapping by tandem mass-spectrometry. Six SIKE72 phospho-serine residues (S133, 
S185, S187, S188, S190, S198) were identified (Figure 4.8.1 and Figure 4.8.2). When compared 
to the multiple phosphorylation sites of IRF3, SIKE72 and IRF3 shared a remarkable, conserved 
phosphorylation motif (Figure 4.9).  
4.3.5 SIKE phosphorylation status alters its inhibitory activity 
 To determine the relationship between the multiple SIKE phosphorylation sites and 
SIKE-mediated inhibition of IRF3 phosphorylation by TBK1, we probed these sites via truncated 
mutants or site-directed mutagenesis and assessed the effect of these SIKE mutations on TBK1-
IRF3 assays. The broad effect of SIKE phosphorylation was analyzed by phosphomimetic 
mutant, Ser to Glu mutation at the six identified sites (S6E), and phosphoknockout mutant, Ser to  
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Figure 4.6 TBK1-IRF3-SIKE complex exists prior to TLR3 pathway stimulation. HEK293 
cells were transfected with mTurquoise-TBK1, FLAG-IRF3 and HA-SIKE. Cells were 
(un)stimulated with 50g/mL pI:pC and harvested 3 hours later. Immunoblots were performed 
using -GFP, -FLAG and -HA antibodies from -FLAG co-immunoprecipitation 
experiments. 
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Figure 4.7 MALDI-TOF mass spectra of SIKE, IRF3 and gMDH exposed to TBK1. Protein 
(500nM SIKE72, 500nM IRF3 173-427, 714nM gMDH) was incubated with TBK1 (4.93 nM) 
and ATP (100 M) for indicated times at 30oC. Reactions were terminated by the addition of an 
equal volume of 6M guanidine hydrochloride and target protein recovered by absorption onto 
Ni-NTA resin (SIKE, gMDH). Proteins eluted from Ni-NTA and IRF3 were desalted and 
concentrated using a ZipTipC4 (Millipore). ZipTipC4 eluent was mixed 1:1 with -cyano-
hydroxycinnamic-acid and spotted onto a Scout49 target. Data were collected and analyzed as 
described in Chapter 4.2.8. Spectra for 0, 24 hours and 96 hours are shown. Addition of a 
phosphate moiety (~80 Daltons) is indicated along the top y-axis and vertical dotted lines. A. WT 
SIKE72, B. IRF3 173-427, and C. gMDH.     
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Ala mutations at the six identified sites (S6A). Subsets of phosphoknockout mutants were 
created to further probe sites essential for the inhibitory activity of SIKE: S4A (S185, 187, 188, 
190A), S2A (S133, 198A), and S185A. SIKE’s phosphorylation sites cluster in the C-terminal 
portion of SIKE. To examine the role of the N-terminal sequence in SIKE inhibition, SIKE 
truncation mutants containing one (SIKE72-184) or retaining all phosphorylation sites (SIKE 
113-207) were constructed. The panel of constructs is summarized in Figure 4.10A. 
 Inhibition curves for the phosphomimetic and phosphoknockout mutants showed that the 
negative charge introduced at phosphorylation sites of SIKE72 reduced the ability of SIKE to 
inhibit TBK1-mediated IRF3 phosphorylation, whereas unmodified SIKE72 had greatly 
enhanced inhibitory activity (Figure 4.11). Using four concentrations that defined SIKE’s 
inhibitory effect, kinase assays were completed with the full panel of mutants (Figure 4.10B). 
Apparent inhibition constants (Ki,app) for each mutant were derived (Table 4.3). The Ki for the 
phosphomimetic mutant increased ~3 fold over WT SIKE72, suggesting that the negative charge 
introduced by multiple glutamic acid residues may reduce the interaction between TBK1-SIKE 
and/or enhance release of SIKE from TBK1. The Ki,app for the C-terminal 113-207 construct, 
retaining all of the phosphorylation sites, was similar to WT SIKE72. Surprisingly, the Ki,app for 
the N-terminal 72-184 construct was 196 nM, even though maximal inhibition was only ~25% of 
the reaction. Loss of the two peripheral phosphorylation sites, S133 and S198, in the S2A 
construct also did not alter the Ki,app value, whereas phosphoknockout of the four clustered 
serines, S185, S187, S188, and S190, reduced the Ki,app parameter by 2.5 fold. Within this 
cluster, the Ki,app for the point mutation S185A was similar to the S6A mutant, implying that this 
position regulates the TBK1-SIKE interaction (Table 4.3).  
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Figure 4.8.1 TBK1 phosphorylates SIKE on six serine residues. A. Mass spectrum resulting 
from analysis of indicated phosphopeptide sequence.  Two separate ion series were recorded 
simultaneously; b- and y-ion series, which represent sequencing inward from the N- and C-
termini, respectively. Lower case “s” indicates phosphorylated residue.  B. Summary of 
phosphopeptide sequences identified using a Sequest search algorithm against custom databases 
generated from the 6xHis-SIKE72 sequence.  “?” indicates that a phosphorylation site exists in 
peptide but cannot be uniquely assigned to a single serine residue.    
125 
 
 
Figure 4.8.2 Spectra of SIKE phosphopeptides. Mass spectra resulting from analysis of 
indicated phosphopeptide sequence showing mixture of uniquely phosphorylated peptides. Two 
separate ion series were recorded simultaneously; b- and y- ion series, which represent 
sequencing inward from the N- and C- termini, respectively. Lower case “s” indicates 
phosphorylated residue.  
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Figure 4.9 TBK1-mediated SIKE phosphorylation sites mimic phosphorylated IRF3 
sequence. Sequence alignment of known phosphorylation sites on IRF3, required for 
dimerization and activation, with TBK1 phosphorylation sites on SIKE found through 
phosphopeptide mapping. Gray letters = phosphorylated residues; *, conserved site; :, 
functionally conserved site. 
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Figure 4.10 Phosphorylation status modulates SIKE inhibitory activity.  A. Cartoon diagram 
of SIKE constructs highlighting the six potential sites of serine phosphorylation, mutations used 
to probe phosphorylation sites and truncation mutants.  Serines listed from left to right; 133, 185, 
187, 188, 190, 198.  CC, coiled coil.  B)  WT or mutant SIKE (4-1658 nM) was added to the 
TBK1 assay containing 5 M IRF3 (~Km concentration), 100 M ATP and 4.93 nM TBK1.  
Reactions were completed and analyzed as described in Chapter 4.2.7.  
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Figure 4.11 Effects of SIKE mutants on IRF3 phosphorylation to define inhibitor 
concentration parameters. WT or S6A or S6E SIKE (5-5000nM) was added to the TBK1 assay 
containing 5 M IRF3 (~KM concentration), 100 M ATP and 4.93 nM TBK1. Reactions were 
completed and analyzed as described in Chapter 4.2.6.   
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4.3.6 SIKE phosphorylation status controls TBK1-SIKE interaction in vivo 
 To investigate the effect of SIKE phosphorylation on the TBK1-SIKE interaction, we 
utilized co-immunoprecipitation assays of epitope-tagged TBK1 and WT or mutant FL SIKE. 
Prior to stimulation with pI:pC, all HA-tagged SIKE constructs co-immunoprecipitated with 
FLAG-tagged TBK1 (Figure 4.12A). The S6E, S185E and 1-112 constructs showed limited 
interaction with TBK1 relative to input protein as observed in whole cell lysates. Following 
pI:pC stimulation, WT-FL, 1-112 and 113-207 SIKE constructs were released from TBK1, 
whereas the S6A, S185A, S6E, and S185E SIKE interactions with TBK1 were unchanged from 
unstimulated conditions (Figure 4.12A). These findings suggest that SIKE 1-112, absent TBK1 
phosphorylation sites, has reduced affinity for activated TBK1and that the phosphorylation of 
SIKE does, in fact, regulate the interaction between SIKE and TBK1.   
 Further investigations into the role of phosphorylated  SIKE on downstream cascade 
activation revealed that the release of WT-FL SIKE from TBK1 correlates with increased TBK1- 
mediated phosphorylation of IRF3 (Figure 4.12B). The reduced interaction of S6E or S185E and 
TBK1 had no effect on dsRNA stimulated IRF3 phosphorylation, but the stable interaction of 
S6A SIKE or S185A SIKE with TBK1, irrespective of dsRNA stimulation, negated dsRNA 
stimulated IRF3 phosphorylation.  
4.3.7 SIKE is a TBK1 substrate     
 SIKE is directly phosphorylated by TBK1 (Figure 4.8). To establish kinetic parameters 
for SIKE as a TBK1 substrate, TBK1 assays with saturating ATP (100 M) and SIKE72 varied 
from 0.043-8.3 M were completed. The KM and VMAX parameters were 0.41 M and 7.4 
nM/min reaction, respectively (Figure 4.13A and Table 4.1). Strikingly, the double reciprocal 
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Table 4.3 
a
Kd values for SIKE inhibition of TBK1-mediated IRF3 phosphorylation 
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Figure 4.12 Phosphorylation status modulates TBK1-SIKE interaction and p-IRF3 in vivo.   
A. HEK293 cells were transiently transfected with FLAG-TBK1 and HA-tagged WT or mutant 
SIKE.  Cells were (un)stimulated with pI:pC (50 g/ml) for 3 hours.  FLAG-TBK1 was 
immunoprecipitated from lysates with -FLAG resin, separated by SDS-PAGE, transferred to 
nitrocellulose and immunoblotted with -HA or -FLAG antibody.  Immunoblots of whole cell 
lysates show expression of each construct.  Blots are representative of three independent 
experiments.  B. HEK293 cells were transiently transfected with empty vector (none), or TLR3 
and WT or mutant SIKE.  Cells were (un)stimulated with pI:pC (50 g/ml) for 3 hours. 
Immunoblots of whole cell lysates were probed for -phosphoS396-IRF3, -IRF3, -HA or -
actin antibodies. Blots are representative of two independent experiments.  Densitometry was 
calculated using ImageJ software.  Each band was corrected for background scatter and then the 
phospho-IRF3 and IRF3 bands were normalized to their respective actin bands.  Ratio of 
phospho-IRF3:total IRF3 is reported under corresponding bands. 
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plot revealed a downward, concave curve, similar to the double reciprocal plot of IRF3 varied, 
TBK1 assays (Figure 4.13B).  
4.3.8 SIKE is able to interact with a multitude of proteins 
 Following the discovery that SIKE was a novel substrate of TBK1, experiments were 
then focused on possible roles for SIKE downstream of TBK1. The first approach to identifying 
a SIKE function was to examine SIKE’s interaction network. A co-immunoprecipitation 
experiment of FLAG-SIKE, transiently over-expressed in HEK293 cells, was used to isolate 
SIKE interaction networks +/- dsRNA stimulation for three hours. These samples were subjected 
to tandem MS/MS analysis to identify proteins within the solution. This analysis revealed that 
SIKE formed a network with at least 13 other proteins in the cell (Figure 4.14 and Table 4.4). 
These proteins could be broadly classified as transcription-associated (p15 and CLE), RNA 
transport (ALY), ribosomal (NPM1, Treacle, eEF1A), chaperones (HSP70, HSP80, cyclophilin 
A), cytoskeletal (-actin isoform, keratin), and enzymes (-enolase and glyoxylase I). The 
presence of keratin may be specific or could be due to contamination during sample preparation. 
Surprisingly, the SIKE interaction network did not appear to be altered following dsRNA 
stimulation. Under these conditions, SIKE should become serine phosphorylated by TBK1-
mediated interactions. We hypothesize that the similar interaction map +/- dsRNA was due to 
heterogeneous levels of SIKE phosphorylation.  
 To determine if the post-translational modification state of SIKE altered the SIKE 
interaction network, the experiment was repeated with the S6A (phospho-knockout) and S6E 
(phospho-mimetic) SIKE mutants (Table 4.5). While this analysis identified 27 interaction 
partners, the interaction networks were again nearly identical regardless of SIKE modification  
133 
 
 
Figure 4.13 SIKE is a substrate of TBK1. A. Michaelis-Menten plot of TBK1 mediated 
phosphorylation of SIKE with saturating ATP (100 M), pre-activated TBK1 (4.93 nM) and 
SIKE varied from 0.043-8.4 M.  Data were fit to a 2-parameter rectangular hyperbola 
(SigmaPlot).  B, C.  Lineweaver-Burk plots of (B) TBK1-SIKE assays with SIKE varied from 
0.043-8.4 M, ATP (100 M) and (C) TBK1-IRF3 assays with IRF3 varied from 0.042-20.8 
M, ATP (100 M).  TBK1 was at 4.93 nM in both assays.  Data for 0.042-0.42 M (O) and 
1.7-20.8 M ()  IRF3 and 0.043-0.23 M (O) and 0.43-8.4 M () SIKE were fit to a linear 
polynomial equation (SigmaPlot).  
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Figure 4.14 SIKE interaction partners in vivo. HEK293 cells, transiently transfected with 
FLAG-SIKE, were (un)stimulated with 50 g/mL pI:pC and harvested three hours later. A 
FLAG co-immunoprecipitation experiment removed SIKE and any interaction partners from 
whole cell lysates. Stimulate and un-stimulated SIKE samples were run on a 10% SDS-PAGE 
gel and analyzed via Coomassie/Silver stain. Heavy band at 28 kDa is SIKE. Red arrows indicate 
interaction partners that were pulled-down with SIKE in the co-IP experiment.   
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Table 4.4 Tandem mass spectrometry analysis of WT SIKE immunoprecipitants from 
HEK293 cells 
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state or dsRNA treatment.  Interestingly, while ALY, an eEF protein, NPM1, and -actin were 
again identified, the majority of the remaining proteins, which were found to interact with SIKE, 
were RNA binding proteins (ribosomal and ribonucleoproteins), histones and a mitochondrial 
ATP synthase subunit. These results led us to question whether SIKE had the ability to directly 
bind RNA.      
4.3.9 SIKE does not bind dsRNA but interacts with a variety of proteins  
 As SIKE functions downstream of a dsRNA receptor and may form interactions with 
several RNA binding proteins, we performed preliminary SEC experiments to determine whether 
SIKE associated with RNA. SEC experiments (Figure 4.15) revealed that SIKE did not associate 
with pI:pC, a synthetic RNA analogue composed of double- and single-stranded RNA. 
 In parallel with these experiments, fluorescence microscopy to examine SIKE 
localization with a SIKE YFP construct (JKB unpublished data) had been completed (Figure 
4.16). These studies showed that SIKE was excluded from the nucleus. This data suggested that 
SIKE interactions with nuclear proteins (i.e. p15, CLE, histones, etc.) either occurred in the 
cytosol as these proteins are being translated or these interactions occurred during sample 
preparation when the integrity of the nucleus was compromised. To determine if these nuclear 
protein interactions were an artifact of sample preparation, we isolated the cytosolic fraction and 
then proceeded with the co-immunoprecipitation / tandem MS/MS experiments with the 
S6E/S6A SIKE constructs (Table 4.6). No dsRNA stimulated samples were analyzed by MS for 
this experiment. Under these conditions, we identified 19 interaction partners, again including 
HSP, -actin, eEF proteins, -enolase, and NPM1. Underway are experiments to confirm MS 
identified interaction partners (reciprocal co-immunoprecipitation, immunofluorescence, co-
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localization assays, etc) focusing on the five proteins identified in multiple experiments (Figure 
4.17).   
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Table 4.5 Tandem mass spectrometry analysis of S6A and S6E SIKE immunoprecipitants 
from HEK293 cells. 
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Figure 4.15 SEC experiments reveal that SIKE does not bind dsRNA. A. Chromatograph of 
pI:pC (100 g) separated on a Superdex 200 10/300 GL column. Peak fractions were analyzed 
via SDS-PAGE, Coomassie/silver stain. B. Chromatograph of WT SIKE72 (1mg) separated on a 
Superdex 200 10/300 GL column and analyzed as above. C. Chromatograph of pI:pC (100g) 
and WT SIKE72 (1mg) were incubated together on ice for 30 minutes. Following incubation, the 
solution was separated and analyzed as in A. and B. Red line under peaks indicates fractions 
analyzed by SDS-PAGE.   
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Figure 4.16 Fluorescence microscopy experiments reveal SIKE is localized to the 
cytoplasm. HEK293 cells were transiently transfected with mTurq SIKE72 (A&B) or SIKE72 
sYFP2 (C&D). Cells were viewed under white light (A&C) or Hg source with a 488nm 
excitation, 515 long pass emission cube filter set (B&D) 24 hours post-transfection (JKB 
unpublished data). 
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Table 4.6 Tandem mass spectrometry analysis of S6A and S6E SIKE immunoprecipitants 
from cytosolic fractions of HEK293 cells 
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Figure 4.17 Venn Diagram of MS/MS data from SIKE interaction experiments. Results of 
co-immunoprecipitation experiments are detailed from WT SIKE (Table 4.4), S6A and S6E 
SIKE WCL (whole cell lysates) (Table 4.5) and S6A and S6E SIKE cytoplasmic fractions (Table 
4.6). Shared interactions between all experiments include; γ-actin, eukaryotic elongation factors 
(eEF protiens), heat shock proteins (HSP proteins) and nucelophosmin.   
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CHAPTER V 
DISCUSSION 
 
 The innate immune system is the body’s first line of defense against viral and bacterial 
challenge. Essential to this safeguard is the initial recognition of invading microorganisms. In 
this dissertation, the focus is on the TLRs, a highly conserved subset of PRRs that are known for 
their ability to recognize a variety of PAMPs [14, 29, 151]. Pathogen recognition by the TLRs 
initiates signaling cascades that lead to the modulation of gene expression involved in 
orchestrating an anti-microbial response. Interestingly, while the concept of innate immunity was 
discovered in the late 19
th
 century, much is still unknown regarding this critical defense 
mechanism as is evident by new discoveries made daily in the field. To that end, this dissertation 
focuses on three growing areas in innate immune research: pathogen recognition, through studies 
based on the adjuvant potential of dsRNA (Chapter 2); immune pathway activation, through 
studies based on the effects of receptor clustering in TLR3 signal transduction (Chapter 3); and 
regulation of PRR signal transduction, through studies based on an endogenous inhibitor of the 
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TLR3 response (Chapter 4). While these three topics seem to examine disparate facets in the 
innate immune response, they are tied together by the fact that the coordinated activation and 
regulation of innate immunity is critical to maintaining host viability. Over-activation of an 
immune response is associated with autoimmune disorders, breast and prostate cancer, obesity 
and glaucoma while non-response leads to pathogen control of host and potential death [103, 
152, 153]. By examining the mechanisms that initiate and control the innate immune response, 
this dissertation sought to identify possible regulatory targets as well as novel immune defense 
strategies used by a host to thwart pathogen challenge.  
The adjuvant potential of dsRNA 
 It is a well-established fact that TLR3 is activated by the viral genomic material dsRNA 
leading to a robust innate immune response [88, 89]. From this, we postulated that dsRNA would 
be a viable candidate for adjuvant studies as a major goal of vaccination, and the co-
administration of adjuvants, is the generation of a strong immune response that can provide long-
term protection against infection. The major discovery of this work is that a 139bp dsRNA ligand 
is a viable candidate for future vaccine adjuvant studies. These results were confirmed by a paper 
published shortly after the onset of our preliminary data collection and further revealed that 
dendritic cell activation and adjuvant effectiveness increased with increasing dsRNA length 
[143].    
 Interestingly, however, through the evaluation of a ligand’s ability to successfully mature 
iDCs to DCs based on the gain of CD80/CD86 cell surface receptor expression, we showed that 
while LPS-treated positive control cells exhibited a 100% gain in both receptors, cells treated 
with 139bp dsRNA ligand only exhibited an 80% gain in CD80 expression and a 25% gain in 
CD86 expression (Figure 2.4). While DC maturation was evident, the incompleteness of this 
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event, in response to dsRNA, raises the possibility that other dsRNA ligands, targeted to 
different dsRNA receptors, may also induce potent immune responses and hence be more viable 
vaccine adjuvant candidates. Jelinek et al., authors of the study confirming that dsRNA is a 
viable candidate for adjuvant studies directed at TLR3, also showed data supporting the 
possibility of other dsRNA receptors being potent adjuvant targets. A 540bp dsRNA ligand in 
their investigations, shown previously to induce a robust TLR3 response, did, in fact, induce a 
25-fold increase in CD86 expression in FLT3 ligand-generated DCs (FL-DCs) [143]. However, 
this same ligand was only able to increase CD86 expression by two fold in splenic DCs and 
failed to induce CD86 expression in GM-CSF-generated DCs (GM-DCs). Interestingly however, 
their data showed that pI:pC was able to induce CD86 expression in GM-DCs of TLR3-/- mice 
suggesting that other receptors might be responsible for the GM-DC response to pI:pC [143]. 
Taking these experiments one step further, Jelinek et al. investigated the possibility that MDA5 
may be required for the induction of CD86 expression in response to pI:pC as it had been 
previously shown that MDA5 is able to respond to pI:pC [154]. In their studies, deletion of 
MDA5 abrogated the induction of CD86 expression of GM-DCs in response to pI:pC suggesting 
that pI:pC enters the cytoplasm in GM-DCs where it activates MDA5 [143]. As the authors of 
the paper were focused on the adjuvant potential of dsRNA as it pertained to the TLR3 response, 
they did not investigate the fold increase in CD86 expression upon stimulation by synthetic 
dsRNA ligands directed towards MDA5. However, it would be interesting to investigate whether 
dsRNA directed toward MDA5 (dsRNA > 1-2kb in length [154]) may induce a potent DC 
maturation event as this would suggest that long pieces of dsRNA and pI:pC exert a qualitatively 
different effect on the immune system than shorter dsRNA oligonucleotides (≤ 139bp). 
146 
 
 The preferred strategy for the development of new generation vaccines is to add highly 
purified synthetic adjuvants, which activate only the elements of the immune response required 
for protection and will not trigger a more generalized activation of the immune response [155]. 
This makes dsRNA a perfect candidate for adjuvant studies as a select set of receptors recognize 
and initiate a response from dsRNA. Furthermore, dsRNA has several properties that render it 
advantageous in adjuvant potential studies. First, compared to other potential adjuvants such as 
QS21, a purified plant extract that enhances the ability of the immune system to respond to 
vaccine antigens but is highly unstable due to hydrolyses [156], or ssRNA, which is rapidly 
degraded in many hosts [157], dsRNA is stable as it is resistant to digestion by ubiquitous 
RNases [158, 159]. Second, dsRNA oligonucleotides are soluble, homogenous molecules that 
can be manufactured in a consistent fashion [143]. This is in contrast to many other potential 
adjuvants such as polyI:C12U [134], polyI:CLC [160] or PIKA [161], which are heterogeneous 
(vary between samples in both chemical structure and biological function) and promiscuous in 
their activation of multiple immune response pathways with unpredictable consequences [162]. 
Finally, dsRNA recognition appears to depend upon length, as observed in multiple 
investigations [88, 154], making its recognition more easily adaptable in adjuvant studies. This is 
in contrast to TLR9-based adjuvant studies in which specific nucleotide sequences of CpG 
oligodeoxynucleotides are required for the induction of an immune response [163]. Taken 
together, it may therefore be possible to manipulate the adjuvant properties of dsRNA simply by 
varying the lengths of the oligonucleotides which would effectively direct the ligands towards 
different dsRNA receptors in the cell. This should produce highly specific immune responses 
that will effectively enhance vaccine antigen potency. While experiments are required to validate 
this hypothesis, the ease with which dsRNA length can be manipulated to target different 
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receptors in the cell and thus induce specific pathway activation, makes it an ideal candidate in 
experimental vaccination systems.        
 Through this study, we have shown the ability to produce milligram quantities of 48bp-, 
139bp- and 540bp-dsRNA ligands (Figure 2.1) that can be used to test the adjuvant potential of 
dsRNA as it pertains to the immune response. Furthermore, we have shown the ability to 
generate iDCs (Figure 2.2, Figure 2.3) to be used in the evaluation of dsRNA ligands as 
adjuvants. Finally, we have shown that a 139bp dsRNA ligand does have the ability to partially 
mature iDCs to DCs (Figure 2.4) and is a viable candidate for future adjuvant studies. Through 
this work, we have also raised the possibility that other dsRNA receptors [154], particularly RIG-
I (dsRNA longer than 23 nucleotides with a linear structure and uridine- or adenosine-rich 
ribonucleotide sequences bearing a 5’-triphosphate [164]), MDA-5 (dsRNA greater then 1-2kb 
[154]), or PKR (dsRNA greater then 33bp in length or containing secondary structural 
imperfections [165]) may be viable vaccine adjuvant candidates and should be explored further 
due to the ease with which each dsRNA ligand can be adapted to target each of these receptors.  
Elucidating the Role of Receptor Clustering in TLR3 Signal Transduction     
 Previous cell-based studies of the TLR3:dsRNA complex had shown that a minimum of 
two signaling units were required to initiate endosomal TLR3 signaling [88]. This led us to 
postulate that a clustering of signaling unit complexes, dependent upon the size of the dsRNA 
ligand being recognized, was required for competent TLR3 signaling. Structural and functional 
studies of TLR3 with neutralizing antibodies, in this study, provide evidence for a new TLR3 
signaling model in which dsRNA:TLR3 signaling units laterally cluster to achieve efficient 
signaling (Figure 3.6). Furthermore, in cell lines transiently expressing TLR3 (Figure 3.1) or 
endogenous TLR3 in normal human epithelial cells (Figure 3.5), data indicated that blocking 
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signaling unit lateral clustering (by Fab12/mAb12) is nearly as effective in inhibiting TLR3 
signal transduction as blocking dsRNA-mediated dimerization of TLR3 (by Fab15/mAb15). 
Taken together, this study indicated that signaling unit – signaling unit lateral clustering is 
essential for efficient TLR3 signaling induced by dsRNA. 
 Interestingly, in the studies presented here, TLR3hi cells, stably expressing TLR3, are 
responsive to 49bp dsRNA (Figure 3.7) while HEK293 cells, transiently expressing TLR3, are 
not responsive to the same ligand (Figure 3.1). These differences, I postulate, could be due to 
recently reported TLR3 proteolytic processing events described in Chapter 1.6 [71, 72]. As 
discussed previously, dsRNA binds to the TLR3-ECD in two regions, one near the N-terminus 
(LRR-NT to LRR3) and the other at the C-terminus (LRR19 to LRR21) [30, 87, 88]. The 
location of these binding sites is important as multiple groups have now shown that TLR3 
cleavage, by Cathepsins B and H, into N- and C-terminal fragments, occurs prior to ligand 
recognition and pathway activation [71,72]. While investigators debate whether cleavage events 
are essential for TLR3 signaling, data has shown that proteolytic processing leads to an 
accumulation of cleaved peptides [72], of which, the C-terminal fragments have a longer half-
life, as compared to un-cleaved protein, and are able to signal in response to dsRNA [71, 72]. 
Taken together, I postulate that these cleavage events occur so that smaller, more stable C-
terminal fragments of the TLR3-ECD can more efficiently recognize short dsRNA ligands 
(≤48bp).  As discussed by Luo et al., short dsRNA ligands (~21bp) are long enough to form a 
complex with TLR3 with only the C-terminal binding sites engaged [166]. Accumulation of the 
C-terminal cleaved TLR3-ECD fragments, I postulate, leads to improved recognition of short 
dsRNA. Subsequent formation of cleaved signaling units (2TLR3-ECD-C-terminal-
fragments:1dsRNA), I further hypothesize, leads to lateral signaling unit clustering as detailed 
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for TLR3 signaling unit binding to long dsRNA ligands (Figure 3.6). These lateral clusters of 
cleaved signaling units can then be disrupted with Fab1068 and Fab12 binding which is 
compatible with data shown in Figure 3.7. Interestingly, prior to proteolytic processing, 
investigators have shown a requirement for the presence of a transporter protein, UNC93b1, and 
the addition of complex glycans in the Golgi complex [71]. Taken together, I suggest that the 
ideas postulated here would explain why TLR3hi cells respond to 49bp dsRNA while HEK293 
cells, transiently expressing TLR3, have no response. While TLR3hi cells would undergo normal 
transport and glycan modification followed by processing events that lead to recognition of 49bp 
dsRNA ligands and subsequent response, HEK293 cells, transiently over-expressing the TLR3 
receptor, would not contain the components necessary to fully modify or process an over-
expressed protein. This would in turn prevent the accumulation of C-terminal TLR3-ECD 
fragments necessary for signaling unit formation and competent TLR3 signaling. Furthermore, 
the ideas postulated here would also explain why a controversy exists as to the importance of the 
proteolytic processing of TLR3 as groups have only examined TLR3 processing events in 
response to pI:pC, a long dsRNA ligand. However, while these postulated ideas may address 
many questions, numerous experiments need to be done to validate these assertions. 
 Previous reports have also shown that TLR3:dsRNA signaling unit formation relies on 
stabilization conferred by each individual component (TLR3-ECDs do not efficiently dimerize 
without additional stabilization conferred by dsRNA binding, and dsRNA binding is weak 
without stabilization by homotypic interactions between TLR3-ECDs) [88]. Furthermore, these 
reports postulate that additional stabilization might be conferred by interactions between pairs of 
TLR3-ECDs on long dsRNA molecules as they show that binding affinities increase with 
dsRNA length beyond the 40-50bp required for dimer formation [88]. However, molecular 
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modeling results presented in this study (Figure 3.6) did not identify any additional interactions 
between TLR3-ECDs of multiple signaling units. This data, combined with Fab1068 data 
showing that shorter separations (≤ 125 Angstroms) of lateral signaling units still permit the 
partial induction of TLR3s signaling (Figure 3.2 and Figure 3.6), suggests that intracellular 
factors must play a role in bridging TIR dimers for signaling unit lateral clustering and efficient 
TLR3 signaling. This would not be unusual as investigations into MyD88-dependent TLR 
signaling pathways found that signal transduction was mediated by the formation of an 
intracellular Myddosome, a 14-subunit left-handed helical oligomer consisting of six molecules 
of MyD88, four molecules of IRAK4 and four molecules of IRAK2.  
 We postulate that a likely candidate to facilitate the intracellular assembly of TIR dimers 
in TLR3 signaling unit lateral clustering events is TRIF, the intracellular adaptor protein that 
mediates TLR3 signaling [167]. The TIR dimer of TRIF is known to interact with the TLR3 TIR 
dimer and recent data has suggested that TRIF dimerization is required for TLR3 function [90]. 
If TRIF does play a role in bridging TIR dimers of TLR3-ECDs participating in lateral 
clustering, this would define yet another role for an already important adaptor molecule in TLR3 
signal transduction. 
 Already found to mediate downstream NF-B and IRF3 activation as well as to directly 
interact with caspase 8 to induce apoptosis [168, 169], TRIF is a critical adaptor molecule in 
efficient TLR3 signal transduction. Due to its importance in the TLR3 signaling cascade, 
numerous pathogens, from Vaccinia virus (VACV) and Hepatitis C virus to Salmonella and 
Shigella, have been shown to produce proteins that target the TIR domain of TRIF [170, 171]. 
Researchers have postulated that this viral-mediated interaction prevents downstream activation 
of the NF-B and IRF3 pathways and inhibits caspase 8 interactions. However, if our hypothesis 
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is correct and TRIF does, in fact, mediate the ligand-induced lateral clustering of TLR3 signaling 
units, pathogens may target TRIF for additional reasons than those already postulated. By 
targeting the TIR domain of TRIF, pathogens would prevent TRIF dimerization which, from 
previous studies [90], would seem to be required for efficient lateral clustering of TLR3 
signaling units. By preventing lateral clustering, activation upon pathogen recognition would be 
abolished and a host response would be negligible. Further experiments would certainly be 
required to prove the validity of this hypothesis.  
 In summary, through the characterization of three TLR3-ECD specific monoclonal 
antibodies (Figure 3.2-3.4), we have provided structural and biochemical evidence that lateral 
signaling unit clustering (Figure 3.6) is necessary for productive TLR3 signaling.  Furthermore, I 
postulate that proteolytic processing of the TLR3-ECD could mediate short dsRNA (≤49bp) 
recognition and competent TLR3 signaling. We further postulate that TRIF is required for lateral 
clustering events and competent TLR3 signaling. Taken together, our data suggests that lateral 
clustering seems to be a mechanism that could unify the detection and activation of TLR3 by 
both short and long dsRNA ligands.   
SIKE: A novel TBK1 substrate and endogenous regulator of the type-I interferon response 
 TANK binding kinase 1 (TBK1) serves as a key convergence point in multiple innate 
immune signaling pathways [94, 95, 101].  In response to receptor-mediated pathogen detection, 
TBK1 phosphorylation of downstream substrates promotes production of pro-inflammatory 
cytokines and type I interferons. Although a central player in the innate immune system’s 
defenses that shapes the downstream innate immune response, mechanisms by which the host 
controls TBK1 activity are not well understood. To address this issue, we sought to define, 
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mechanistically, how an endogenous inhibitor of TBK1, SIKE, blocks the TBK1 mediated anti-
viral response. 
 The major discovery of this work is that SIKE is not only an endogenous inhibitor of 
TBK1-mediated phosphorylation of IRF3, but is also a TBK1 substrate.  SIKE has a 6.5 fold 
lower KM (0.41 µM), as compared to IRF3, with a comparable Vmax suggesting that changes in 
SIKE concentration could effectively manipulate TBK1 function through altered substrate 
selection.  Using kinetic analyses and protein interactions assays, we characterized how this 
novel TBK1 substrate effectively inhibits type I interferon production. 
 In our kinetic studies, we examined the effect of SIKE on TBK1-mediated IRF3 
phosphorylation using a macromolecular IRF3 substrate (residues 173-427).  Previous studies on 
TBK1 kinetic mechanism, using an Inhibitor of κBα peptide as substrate [116], showed that the 
enzyme functioned via a rapid equilibrium, random order (RERO) mechanism. Our data obtained 
with macromolecular substrates are consistent with this mechanism, but reveal evidence (non-
linear, downward concave double reciprocal plot (Figure4.4E-F)) suggesting the existence of 
negative cooperativity in substrate binding or the presence of a regulatory site for protein 
substrate.  The equilibria for this mechanism with respect to IRF3 phosphorylation are given in 
Figure 5.1A, and is described by Dalziel’s generalized rate equation [172]: 
     
where e is TBK1 concentration in the  reaction, Vo is the initial velocity of the reaction, and ᵠ are 
Dalziel coefficients that, for an RERO mechanism, pertain to the concentrations of specific 
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complexes in the reaction mechanism (ᵠ1 = TBK1:IRF3, ᵠ2 = TBK1:ATP, ᵠ12 = TBK1 and ᵠ0 = 
TBK1:ATP:IRF3), labeled in Figure 5.1A. 
 We first determined the baseline kinetic parameters for IRF3 and ATP as summarized in 
Table 4.1.  The double reciprocal plot of IRF3 varied substrate was not linear, but a downward 
concave curve (Figure 4.13).  This type of plot is indicative of one of three phenomena: i) 
substrate activation, ii) non-identical active sites or iii) negative cooperativity.  In examining 
these three explanations, we assumed from both the related IKK and TBK1 
crystallographic structure [112] and our own size exclusion chromatography (data not shown) 
that TBK1 functions as a dimeric species (required for ii & iii above).  Substrate activation 
entails a substrate binding site (with lower affinity than the active site) that when bound leads to 
activation of the reaction.  For non-identical active sites, the dimeric TBK1 would have a high 
and low affinity active site for substrate a priori.  Finally, negative cooperativity between TBK1 
active sites would occur if binding of substrate at the first active site lowered the affinity for 
substrate at the second active site by allosteric interactions between the subunits.  Alone, the 
IRF3 varied assay data (Figure 4.4A) does not allow us to discern which mechanism is at play.  
Luckily, SIKE also functioned as a macromolecular TBK1 substrate.  The double reciprocal plot 
of the SIKE varied assays also exhibited this characteristic downward concave curvature (Figure 
4.13).  As SIKE and IRF3 share no sequence homology and are distinct macromolecular 
substrates, the substrate activation or non-identical active site mechanism seem improbable as 
these macromolecular substrates must be similarly recognized by the kinase at a site independent 
of the active site or with equally reduced affinity at a non-identical active site.  Rather, negative 
cooperativity induced by recognition of IRF3’s and SIKE’s shared phosphorylation motif could 
explain the non-linear double reciprocal plots.  Negative cooperativity requires communication  
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Figure 5.1 Models suggesting SIKE and TBK1 function. A. Diagram of rapid equilibrium-
random order (RERO) enzyme mechanism of TBK1 with binding of I (SIKE) to each enzyme 
complex. B. Schematic of mechanisms to interpret non-linear LWB plots of TBK1:IRF3 and 
TBK1:SIKE data and SIKE inhibition of TBK1-mediated phosphorylation of IRF3. Ribbon 
diagram of TBK1 (pdbcode 4IM0) shows overall arrangement of dimeric kinase.
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between active sites.  Interestingly, in IKK, the two active sites appear to be independent of one 
another with dimerization mediated by the SDD (scaffold dimerization domain).  In contrast, the 
TBK1 structure revealed three additional dimerization interfaces between the kinase and 
ubiquitin-like domains of one subunit to the SDD of the contralateral subunit (Figure 5.1B).  
These additional subunit interfaces identified in the TBK1 structures may provide a means of 
communicating substrate binding between active sites.  Cell based and biophysical studies of a 
kinase:substrate complex (mutating residues at the interfaces to block proposed subunit 
communication) to complement the reported kinase:ATP analog inhibitor structures [110-112] 
would directly address this hypothesis. 
Additionally, in a RERO mechanism, the KM value of IRF3 is the Kd for IRF3 binding to the 
E-ATP complex.  From the two linear regions of IRF3’s double reciprocal plot, we calculated the 
KM value at low (0.042-0.42M) versus high (0.42-20.8M) substrate concentrations as 50 nM 
and 3.5 M, respectively.  Similarly, the two linear regions of SIKE’s double reciprocal plot 
were 55.9 nM and 395 nM at low (42-208 nM) and high (208-8,000 nM) substrate 
concentrations, respectively.  This data suggests that binding of substrate, either IRF3 or SIKE, 
to the first active site occurs with near equal affinity.  The ~10 fold difference in KM values at 
high substrate concentration favoring the TBK1:SIKE complex would suggest that SIKE 
functions primarily as a competitive inhibitor of IRF3 phosphorylation. 
For a simple RERO mechanism, an alternative substrate (as we have shown SIKE to be) 
should give competitive inhibition with respect to IRF3 and mixed (or noncompetitive) inhibition 
with respect to ATP [174].  Analysis of SIKE’s inhibitory effects on TBK1-mediated 
phosphorylation of IRF3 revealed a mixed-type inhibitor (Figure 4.4 and Table 4.1) with respect 
to ATP with ~2-3 fold decreases in KM and VMAX (Fig. 4.4D and Table 4.1), as expected for a 
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RERO mechanism.  Surprisingly, SIKE inhibition in IRF3 varied experiments did not exhibit a 
competitive inhibition pattern, but rather displayed primarily as a non-competitive inhibitor, 
reducing VMAX by 3 fold (Fig. 4.4C and Table 4.1).  To further interpret these results, we 
examined SIKE inhibition of the TBK1 reaction in terms of the generalized linear rate equation 
for a RERO mechanism developed by Dalziel [172].  In the RERO mechanism, SIKE could in 
theory interact with any TBK1 complex and would affect the appropriate ᵠ parameter.  The 
rearranged generalized linear rate equation with ATP as the varied substrate is: 
    
In this equation, the slope effects result from SIKE interactions with E and/or E-IRF3, while 
intercept effects result from the interaction of SIKE with E-ATP and/or E-ATP-IRF3.  From the 
Ki,app values determined from the slopes and intercepts of the double reciprocal plots, we 
observed that the Ki,app derived from the intercept is ~56 nM, whereas the Ki,app derived from the 
slopes is ~420 nM.  This suggests that the apparent affinity of the E-ATP or E-ATP-IRF3 
complexes for SIKE is greater than the affinity of E alone or the E-IRF3 complex.  Rearranging 
the generalized equation for IRF3 as the varied substrate gives:  
    
Here, the slope effects can be attributed to the interaction of SIKE with E and/or E-ATP, while 
intercept effects are attributable to SIKE interactions with E-IRF3 and/or E-ATP-IRF3.  The 
Ki,app values determined from slope and intercept were 111 nM and 98 nM, respectively, 
equivalent between the two grouped complexes.  Since we have shown that SIKE is directly 
phosphorylated by TBK1 (Figure 4.7 and Figure 4.8), SIKE would be expected to bind to free 
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enzyme or enzyme-ATP complexes, but not IRF3 containing complexes as no interaction 
between SIKE and IRF3 have been observed (Figure 4.5).  The fact that SIKE alters either or 
both ᵠ0 or ᵠ1 suggests that these effects must arise from either allosteric interactions between 
active sites or the existence of a separate regulatory site for SIKE.  Both of these possibilities are 
consistent with the observed downward curvature of the double reciprocal plots with either SIKE 
(Figure 4.13A) or IRF3 (Figure 4.4C) as the varied substrate. Since IRF3 and SIKE are quite 
different overall structures, these studies suggest that TBK1 substrates bind with negative 
cooperativity between otherwise identical sites rather than the existence of an IRF3/SIKE 
binding site separate from the active sites in the dimer. 
 Interestingly, while also investigating the TBK1-mediated phosphorylation sites of SIKE, 
we noticed that four of the six phosphorylated serines of SIKE align well with the 
phosphorylation sites of IRF3 (Figure 4.9) [119]. The strongest homology was evident at the 
SIKE sequence 
184
L-S-I-S-S-E
189
 comprised of a cluster of three phosphorylation sites.  When 
TBK1 substrates are compared, the phosphorylation pattern of TBK1 substrates has three forms; 
singly as in Akt [103], insulin receptor [175] and optineurin [105], multiple sites but not 
clustered as in DDX3 [115], or multiple clustered sites as in IRF3 [176], IRF7 [82] and, as we 
show here, SIKE.  In IRF3/7, these clustered phosphorylation sites, when modified, alter protein 
function, activating the transcription factor.  We explored the role of these clustered, SIKE 
phosphorylation sites in the context of inhibition of TBK1-mediated IRF3 phosphorylation.  
When replaced with the phosphomimetic mutations, Ser to Glu, SIKE’s inhibitory activity (Ki,app 
~900 nM versus WT Ki,app = 350 nM) and interaction with TBK1 are greatly diminished (Figure 
4.10 and Figure 4.11).  As the introduced negative charge grossly mimics SIKE’s product form, 
these results are consistent with product release from an enzyme.  Initial studies of SIKE held 
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that SIKE maintained TBK1 in an inactive state prior to TBK1 activation at which point SIKE 
was released from the TBK1 complex.  Here, we attribute the TBK1:SIKE interaction to SIKE’s 
high affinity for the enzyme and SIKE’s release to its post-translational modifications. 
 Similar to IRF3 where individual phosphorylation sites have been attributed to specific 
function, we probed the six SIKE phosphorylation sites to determine if a subset of residues was 
essential to TBK1’s preferential binding to SIKE over IRF3.  With a complete phosphoknockout 
mutant (Ser to Ala), SIKE’s inhibitory activity increased 4.5 fold, consistent with retained TBK1 
recognition.  The S2A versus S4A mutants further defined the cluster of phosphorylation sites 
centered at the 
185
SxSSxS
190
 motif as essential to phosphorylation dependent release of SIKE 
from TBK1, whereas the phosphorylation state of the S2A sites did not contribute to SIKE’s 
release from TBK1.  The single mutation, S185A, alone could enhance inhibition of TBK1-
mediated IRF3 phosphorylation.  In fact, the Kiapp values for the S6A (77 nM) and the single, 
S185A (41 nM) mutants are in line with the Michaelis constant at low SIKE concentrations (55.9 
nM, Figure 4.13).  Additional interactions between TBK1 and SIKE or the structural context of 
the phosphorylation motif may also contribute to the high affinity TBK1:SIKE interaction.  This 
is supported by the ability of SIKE 72-184 to inhibit TBK1 function and SIKE 1-112 to form an 
interaction with TBK1 (Figure 4.11 and Figure 4.12).  SIKE72-184 retains a single 
phosphorylation site (S133) that when mutated to Ala (S2A mutant) does not alter SIKE 
inhibitory activity.  Therefore, inhibition by this mutant is attributed to not only S133 docking to 
TBK1’s active site, but also interactions between SIKE and TBK1 outside of the active site.  
Similarly, SIKE 1-112, as it contains no phosphorylation sites, must form a TBK1:SIKE 
interaction exclusive of the active site.  These interactions independent of the active site are 
consistent with the non-competitive/mixed type inhibition mediated by SIKE. 
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Taken together, SIKE’s original characterization as an endogenous inhibitor of the TBK1-
mediated antiviral response only partially explains SIKE function. Comparison of the pseudo Kd 
for the E-ATP complex showed that SIKE is preferred as a TBK1 substrate 6.5 fold over IRF3.  
At equivalent concentrations, SIKE would appear to inhibit IRF3 phosphorylation.  This would 
not be the first time a TBK1 substrate had initially been defined as an inhibitor.  Optineurin 
(OPTN), an autophagy receptor, was classified as an endogenous TBK1 inhibitor.  Subsequent 
studies defined OPTN as a TBK1 substrate [177].  Phospho-OPTN has increased affinity for 
LC3 (microtubule associated protein light chain 3), thereby promoting selective autophagy of 
ubiquitin-coated cytosolic bacteria and providing a mechanism by which TBK1 functions in 
maintaining xenophagosomes [105, 106]. In a similar manner, while SIKE has the ability to 
endogenously regulate TBK1, it appears that TLR3 pathway activation and subsequent release of 
SIKE from the TBK1 kinase complex, leads to its interaction with other binding partners 
effectively promoting other functions in different areas of the cell. 
In fact, co-immunoprecipitation experiments aimed at detecting interaction partners of SIKE 
revealed that this 207 amino acid protein is able to interact with at least 13 other proteins in the 
cell (Figure 4.14 and Table 4.4). Surprisingly, the SIKE interaction network did not appear to be 
altered following dsRNA stimulation (Figure 4.14 and Figure 4.15) which should mediate the 
TBK1 phosphorylation of SIKE (Figure 4.12). Similar results were observed when 
phosphoknockout (S6A) and phosphomimetic (S6E) SIKE constructs were used. Also surprising 
was the fact that neither TBK1 nor any of the scaffold proteins, which interact with TBK1 in the 
TLR3 kinase complex (TANK, SINTBAD, or NAP1) were found to associate with SIKE. While 
the scaffold proteins, which I postulate are, in fact, high affinity substrates of TBK1due to data 
showing that NAP1 can also be phosphorylated by TBK1 (data not shown), have never been 
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shown to associate with SIKE, the TBK1:SIKE interaction is essential in the TLR3 mediated 
innate immune response. Taken together, these results lead me to postulate that in interaction 
experiments, the transient over-expression of SIKE in HEK293 cells is causing us to elucidate 
SIKE interactions with only the most prominently expressed proteins in the cell. While we are 
identifying a number of interaction partners, I postulate that this over-expression is causing us to 
miss a number of other interaction partners that could potentially identify further functions of 
SIKE in vivo. To solve this problem, we will either have to create cell lines stably expressing a 
tagged version of SIKE, or use a SIKE antibody (already developed), and repeat the interaction 
experiments in order to investigate endogenous interactions in the cell. While experiments may 
not have elucidated every interaction partner of SIKE in vivo, multiple interaction experiments 
(Table4.4-4.6) revealed four proteins that were found in each investigation (Figure 4.17).  
The first SIKE interaction partner found in all co-immunoprecipitation experiments was 
nucleophosmin (NPM1), a protein known to be associated with nucleolar ribonuceloprotein 
structures, involved in the biogenesis of ribosomes, and assist small basic proteins in their 
transport to the nucleolus [178]. While SIKE has never been found in the nucleus (Figure 4.16), 
the regulation of NPM1 through SUMOylation suggests another post-translational modification 
that may affect SIKE function and its binding affinity to multiple substrates in the cell.  
The second interaction partner, found in all SIKE interaction experiments, was a class of 
proteins known as the heat shock proteins (HSP). This family of functionally related proteins is 
involved in the folding and unfolding of other proteins and has been shown to be involved in the 
up-regulation of stress as well as in immunity [179]. While its role with SIKE is not yet apparent, 
further microscopy experiments will elucidate the role of this interaction in the cell as it pertains 
to SIKE function. 
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The third interaction partner common in all SIKE binding experiments was again a class of 
proteins, all known as eukaryotic elongation factor proteins (eEF). The members of this family 
are involved in protein synthesis as they facilitate translational elongation, from the formation of 
the first peptide bond to the formation of the last [180]. Interestingly, elongation factors are also 
known to be targets for pathogens which attempt to alter protein function in a host so as to go 
unrecognized and stay alive [180]. While SIKE may interact with this protein in a regulatory 
role, similar to its interaction with TBK1, various kinetic and interaction based experiments will 
be required to identify the fundamental reason for this interaction. 
The final interaction partner, found in all SIKE binding experiments, was-actin. This 
ubiquitously expressed protein is required for reinforcement and long-term stability of 
cytoskeletal structures making it an essential building block of the cytoskeleton in all non-muscle 
cells [181]. Interestingly, FGFR1OP2, discussed in Chapter 1.8 for its 56% sequence homolgy to 
SIKE, associates with actin cytoskeleton networks in oral wound fibroblasts [129]. Taken 
together, we postulate that SIKE also functions as an actin cytoskeleton associated protein 
participating in cytoskeleton rearrangement (cell migration (DCs), phagocytosis (macrophages), 
xenophagy). This function would be in response to pathogen challenge through its 
phosphorylation by TBK1. Further cell based assays and fluorescence microscopy experiments 
are necessary to validate this hypothesis but SIKE does appear to associate with cytoskeleton 
structures (Figure 4.16) and structural rearrangement proteins (Table4.4 – Table 4.6) at a high 
frequency. 
In further examining SIKE function and post-translational modifications, questions were 
raised regarding other potential modifications that could affect SIKE. Investigations revealed that 
the E3 ligases, TRAF2 and TRAF5, are able to poly-ubiquitinate SIKE in the presence of S1P 
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(data not shown). Taken together, from the discovery of multiple SIKE interaction partners along 
with both phosphorylation and ubiquitination events targeting SIKE in the cell, I postulate that 
SIKE has multiple functions in the cell which are mediated by specific post-translational 
modifications targeting the protein at distinct points in time. These modifications, I further 
postulate, affect the affinity of SIKE for specific substrates thereby modifying its interaction 
partners and changing its function. To examine this hypothesis, further post-translational 
modifications affecting SIKE, from acetylation and methylation to glycosylation and 
SUMOylation, would need to be identified and confirmed in vivo. From that point, individual 
interaction assays with SIKE and each of its binding partners would need to be performed to 
elucidate potential roles for the post-translational modifications and their effects on the affinity 
of SIKE for each of its interaction partners. 
Finally, just as the human body needs to regulate the inflammatory response to prevent 
chronic inflammation and degenerative diseases, viruses need to subvert the immune response to 
stay alive in their host. While SIKE interacts with TBK1 to endogenously regulate type-I 
interferon production in the TLR3 response, viruses target TBK1 to prevent TLR3 pathway 
activation. Viruses such as HCV and VACV produce proteins, NS3 and NIL, which associate 
with TBK1 and inhibit its ability to phosphorylate IRF3 [22]. Other viruses, such as 
Hantaviruses, disrupt TBK1 interactions with upstream components, such as the TRAF adaptor 
proteins, which are required for TBK1 to identify TLR3 pathway activation. By defining the 
mechanism by which an apparent endogenous inhibitor of the TLR3 pathway is able to regulate 
the TLR3 response, we postulated that we would identify potential sites of pathway modulation. 
In doing so, we wondered if viruses had also exploited this approach. As discussed previously, 
from our studies into the regulatory mechanism of SIKE, we discovered that TBK1 
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phosphorylated SIKE on six serine residues (Figure 4.8). Of these residues, we found that four, 
present in an 
185
SxSSxS
190
 motif, were critical to the TBK1:SIKE interaction as their mutation to 
a phosphoknockout construct (S4A) decreased the Ki,app of SIKE by more than 3-fold as 
compared to WT (Table 4.3). Interested in examining whether this TBK1 phosphorylation motif 
was conserved in SIKE, we performed a sequence alignment analysis of SIKE constructs from 
human to zebrafish (Figure 5.2) and found significant conservation. Taking this analysis one step 
further, we questioned whether viral proteins, from human parainfluenza virus 2 and 5 to RBP 
and the mumps virus, known to inhibit TLR3 signaling by acting as TBK1 substrates, share this 
TBK1 phosphorylation consensus sequence with SIKE (Figure 5.2). Although the exact site of 
TBK1 phosphorylation is unknown in these viral proteins, we did identify an SxS motif in all 
viral substrates. As a strong conservation was observed, we postulate that this motif may be key 
in targeting substrates to TBK1 and may be critical to viral subversion of the type I interferon 
response. Further phosphopeptide mapping experiments are required to confirm or refute the SxS 
site as a target of TBK1. Additional kinetic experiments, along with the creation of knockout 
constructs, will be required to investigate the importance of this SxS motif in viral substrates if it 
is, in fact, a target of TBK1.  
In summary, this study describes the mechanism by which SIKE inhibits TBK1-mediated 
phosphorylation of IRF3, essential to type I interferon production.  Kinetic analyses showed that 
SIKE not only inhibits IRF3 phosphorylation (Figure 4.4), but is also a high-affinity, TBK1 
substrate (pseudo KD=410nM) (Figure 4.13).  With respect to IRF3 phosphorylation, SIKE is 
shown to function as a mixed-type inhibitor (Kiapp=350nM) rather than, given its status as a 
TBK1 substrate, as a competitive inhibitor (Figure 4.4).  Further analysis revealed that TBK1 
phosphorylation of IRF3 and SIKE displayed negative cooperativity.  Additionally, both  
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Figure 5.2 TBK1 phosphorylation consensus motif is conserved throughout evolution in 
SIKE and is apparent in viral substrates of TBK1. Sequence alignment of known (red) and 
predicted (green) TBK1-mediated phosphorylation sites.  
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substrates are shown to share a similar KM at low substrate concentrations (~50nM), but deviate 
>8 fold at higher substrate concentrations (IRF3=3.5mM; SIKE=0.4mM).  TBK1:SIKE 
interactions are further shown to be modulated by SIKE phosphorylation, clustered in SIKE’s C-
terminal portion (Serine residues 133, 185, 187, 188, 190, 198) (Figure 4.5).  These sites exhibit 
striking homology to IRF3’s phosphorylation motif (Figure 4.9).  Mutagenic probing further 
revealed that phosphorylation of S185 controled TBK1:SIKE interactions (Figure 4.10).  Taken 
together, our studies demonstrate for the first time that SIKE functions as a TBK1 substrate and 
inhibits TBK1-mediated IRF3 phosphorylation by forming a high affinity TBK1:SIKE complex.  
These findings provide key insights into endogenous control of a critical catalytic hub that is 
achieved, not by direct repression of activity, but by redirection of catalysis through substrate 
affinity. Furthermore, in addition to the previously identified preference of S- (= hydrophobic 
residue) for TBK1 substrates, we have found that the SxSS motif is conserved in SIKE, IRF3 and 
many viral protein substrates. From these findings, we postulate the existence of a TBK1 
phosphorylation consensus motif that is a critical regulatory motif in both endogenous regulation 
and viral subversion of the type-I interferon response. 
 
Conclusions 
 In culmination, the chapters in this dissertation provide novel insight into different facets 
of the innate immune response that can be used to understand mechanisms by which a host 
thwarts pathogen challenge. While adjuvant potential studies in Chapter 2 characterized a 139bp 
dsRNA ligand as a viable vaccine adjuvant, further data led us to postulate that by varying 
dsRNA length, we could target different receptors in the cell thereby creating a tailored immune 
response. Similarly, while receptor clustering studies in Chapter 3 characterized a new TLR3 
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signaling model in which dsRNA:TLR3 signaling units laterally cluster to achieve efficient 
signaling, further data led us to postulate the importance of TRIF in pathogen recognition as we 
suggest that this intracellular adaptor protein mediates the receptor clustering events required for 
competent TLR3 signaling. Finally, the studies in Chapter 4 demonstrate, for the first time, that 
SIKE functions as a TBK1 substrate and inhibits TBK1-mediated IRF3 phosphorylation by 
forming a high affinity TBK1:SIKE complex. The data presented also provides key insights into 
the endogenous control of a critical catalytic hub that is achieved, not by direct repression of 
activity, but by redirection of catalysis through substrate affinity. Furthermore, through the 
elucidation of a potential TBK1 phosphorylation consensus motif, these studies also define a 
potential regulatory motif that can be targeted for therapeutic development to modulate TBK1 
activity. Taken together, these studies establish a foundation for building long-term studies on 
the function, regulation and viral subversion of the innate immune response. 
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On the following pages are chromatographs with corresponding SDS-PAGE analysis of 
peak fractions from TLR3-ECD:Fab:dsRNA studies detailed in Chapter 3. Methods are 
described in Chapter 3, section 3.2.3.  
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Figure A1. TLR3-ECD alone in T+R+F12+F15 SEC experiment (Figure 3.3 analysis). 
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Figure A2. 139bp dsRNA ligand alone in T+R+F12+F15 SEC experiment (Figure 3.3 
analysis). 
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Figure A3. Fab12 alone in a T+R+F12+F15 SEC experiment (Figure 3.3 analysis). 
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Figure A4. Fab15 alone in a T+R+F12+F15 SEC experiment (Figure 3.3 analysis). 
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Figure A5. Fab12 + Fab15 run in a T+R+F12+F15 SEC experiment (Figure 3.3 analysis). 
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Figure A6. TLR3-ECD and 139bp dsRNA run in a T+R+F12+F15 SEC experiment (Figure 
3.3 analysis). 
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Figure A7. TLR3-ECD and Fab12 run in a T+R+F12+F15 SEC experiment (Figure 3.3 
analysis).  
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Figure A8. TLR3-ECD and Fab15 run in a T+R+F12+F15 SEC experiment (Figure 3.3 
analysis). 
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Figure A9. TLR3-ECD + Fab12 + Fab15 run in a T+R+F12+F15 SEC experiment (Figure 
3.3 analysis). 
 
 
178 
 
 
 
 
 
 
 
 
Figure A10. TLR3-ECD + 139bp dsRNA + Fab12 run in a T+R+F12+F15 SEC experiment 
(Figure 3.3 analysis). 
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Figure A11. TLR3-ECD + 139bp dsRNA + Fab15 run in a T+R+F12+F15 SEC experiment 
(Figure 3.3 analysis). 
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Figure A12. TLR3-ECD + 139bp dsRNA + Fab12 + Fab15 run in a T+R+F12+F15 SEC 
experiment. (Figure 3.3 analysis). 
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Figure A13. TLR3-ECD alone run in a T+R+F1068 SEC experiment (Figure 3.5B analysis). 
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Figure A14. 49bp dsRNA ligand alone run in a T+R+F1068 SEC run (Figure 3.5B 
analysis). 
 
 
 
 
 
 
183 
 
 
 
Figure A15. Fab1068 alone run in a T+R+F1068 SEC experiment (Figure 3.5B analysis). 
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Figure A16. 49bp dsRNA + Fab1068 run in a T+R+F1068 SEC experiment (Figure 3.5B 
analysis). 
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Figure A17. TLR3-ECD and Fab1068 run in a T+R+F1068 SEC experiment (Figure 3.5B 
analysis). 
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Figure A18. TLR3-ECD and 49bp dsRNA run in a T+R+F1068 SEC experiment (Figure 
3.5B analysis). 
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Figure A19. TLR3-ECD + 49bp dsRNA + Fab1068 run in a T+R+F1068 SEC experiment 
(Figure 3.5B analysis). 
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Figure A20. TLR3-ECD alone run in a T+R+F12 SEC experiment (Figure 3.5C analysis). 
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Figure A21. 49bp dsRNA ligand alone run in a T+R+F12 SEC experiment (Figure 3.5C 
analysis). 
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Figure A22. Fab12 alone run in a T+R+F12 SEC experiment (Figure 3.5C analysis). 
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Figure A23. 49bp dsRNA ligand + Fab12 run in a T+R+F12 SEC experiment (Figure 3.5C 
analysis). 
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Figure A24. TLR3-ECD and Fab12 run in a T+R+F12 SEC experiment (Figure 3.5C 
analysis). 
 
 
 
 
 
 
 
 
 
 
193 
 
 
 
 
Figure A25. TLR3-ECD + 49bp dsRNA ligand run in a T+R+F12 SEC experiment (Figure 
3.5C analysis). 
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Figure A26. TLR3-ECD + 49bp dsRNA + Fab12 run in a T+R+F12 SEC experiment 
(Figure 3.5C analysis). 
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